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ABSTRACT 
  
 The SARS-coronavirus (SARS-CoV) is the etiological agent of the severe acute 
respiratory syndrome (SARS).  The SARS-CoV spike (S) glycoprotein mediates 
membrane fusion events during virus entry and virus-induced cell-to-cell fusion. 
Investigations, described herein, have focused on the genetic manipulation of the SARS-
CoV S glycoprotein in order to delineate functional domains within the protein.  This was 
accomplished by incorporating single point mutations, cluster-to-lysine and cluster-to-
alanine mutations, as well as carboxyl terminal truncations into the protein and 
investigating these mutants in transient expression experiments. Mutagenesis of either the 
coiled-coil domain of the S glycoprotein amino terminal heptad repeat, the predicted 
fusion peptide, or adjacent but distinct regions, severely compromised S-mediated cell-to-
cell fusion, while intracellular transport and cell-surface expression were not adversely 
affected. Surprisingly, a carboxyl terminal truncation of 17 amino acids substantially 
increased S glycoprotein-mediated cell-to-cell fusion suggesting that the terminal 17 
amino acids regulate the S fusogenic properties. In contrast, truncation of 26 or 39 amino 
acids eliminating either one or both of the two endodomain cysteine-rich motifs, 
respectively, inhibited cell fusion in comparison to the wild-type S.  The cysteine rich 
domains were further studied by constructing cysteine cluster to alanine mutants in order 
to ascertain their importance in the function of the protein.  Results showed that the two 
cysteine clusters proximal to the transmembrane region were vital in the functioning of 
the spike protein in mediating cell-to-cell fusion.  Mutagenesis of the acidic amino acid 
xvii 
cluster in the carboxyl terminus of the S glycoprotein as well as modification of a 
predicted phosphorylation site within the acidic cluster revealed that this amino acid 
motif may play a functional role in the retention of S at cell-surfaces. A panel of 
truncations for Bovine Coronavirus (BCoV) S was also constructed and compared to 
truncations made for the SARS-CoV S glycoprotein.  It was found that the two sets of 
truncations had very little comparable effects on protein function when compared to one 
another.  This genetic analysis reveals that the SARS-CoV S glycoprotein contains 
extracellular domains that regulate cell fusion as well as distinct endodomains that 
function in intracellular transport, cell-surface expression and cell fusion. 
 1
CHAPTER I 
INTRODUCTION 
 
STATEMENT OF RESEARCH PROBLEM AND HYPOTHESIS 
 The severe acute respiratory syndrome coronavirus (SARS-CoV) is the most 
recently discovered coronavirus.  It first appeared in the Guangdong Province of southern 
China in November of 2002.  Unlike other human coronaviruses whose infections are 
usually very mild, the SARS-CoV produced mortality rates as high as 15% in some age 
groups (Anand et al., 2003).  Due to this high mortality rate, intense research interest has 
been generated to elucidate certain aspects of the virus life cycle as well as characteristics 
of viral proteins that could possibly allude to why this virus is so lethal when compared to 
the other serotypes of human coronavirus. 
 The SARS-CoV encodes for the typical genes found in all coronaviruses which 
include the nonstructural replicase gene as well as the structural proteins nucleocapsid 
(N), membrane protein (M), envelope protein (E), and spike glycoprotein (S), which are 
assembled into virus particles.  The S glycoprotein is primarily responsible for entry of 
all coronaviruses into susceptible cells through binding to specific receptors on cells and 
mediating subsequent virus-cell fusion (Cavanagh, 1995).  Because of the roles it plays in 
virus attachment, virus entry, and cell-cell fusion, the S glycoprotein seems to potentially 
be the protein most likely responsible for the increase in virulence of the virus.   
Recently the SARS-CoV S glycoprotein has been codon optimized for 
mammalian cells in order to allow for more efficient expression of the protein (Li et al., 
2003).  This optimization of the protein allows the protein to be studied using a transient 
transfection system.  The overall experimental approach was to introduce site specific 
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mutations and truncations into the codon optimized SARS-CoV S glycoprotein in order 
to ascertain the functional impact of certain motifs found in the S glycoprotein.  The 
delineation of functional domains in the endodomain as well as the role of hydrophobic 
amino acids found in and around the heptad repeat regions were the focus of Chapter II.  
A second aspect of the work focused on cysteine rich clusters in the endodomain of the S 
protein that are conserved throughout all coronaviruses.  Cysteine cluster to alanine 
mutations were introduced into the SARS-CoV S glycoprotein in order to determine the 
importance of several conserved cysteines.  These mutants were then tested for their 
ability to mediate cell-cell fusion as compared to the wild-type proteins as well as their 
ability to be properly transported to the cellular surface; this work is described in Chapter 
III.  A codon optimized version of the bovine coronavirus (BCoV) S glycoprotein was 
constructed in order to do a comparison of the motifs found in the endodomain of the 
BCoV S protein versus the SARS-CoV S protein.  Several truncations of the BCoV S 
protein were made in order to compare them with homologous truncations made in the 
SARS-CoV S (described in Chapter IV). 
STATEMENT OF RESEARCH OBJECTIVES 
 The overall goal of this research was to gain a more thorough understanding of 
the functional domains found in the SARS-CoV S glycoprotein.  The specific objectives  
were as follows: 1) To delineate functional domains in the SARS-CoV S glycoprotein; 2) 
To ascertain the importance of the conserved cysteine residues found in the endodomain 
of the SARS-CoV S glycoprotein; 3) To compare the impact on protein function of 
homologous truncations made in both the SARS-CoV and BCoV S glycoproteins.   
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LITERATURE REVIEW 
Taxonomy of Coronaviridae 
 Nidovirales is the taxonomic order in which enveloped, positive-sense RNA 
viruses that synthesize a 3' co-terminal set of subgenomic mRNAs during infection of 
host cells are grouped in (Cavanagh, 1997).  Members of this order include 
coronaviruses, toroviruses, and arteriviruses.  The toroviruses and coronaviruses are 
further grouped into the family Coronaviridae that contain variable length genomes and 
nucleocapsid structure.  
There are three groups of coronaviruses that have little to no cross-reactivity 
among antigens found on virions of the different groups (Table 1.1).  Two of the groups 
are composed of mammalian coronaviruses, while avian coronaviruses such as  the 
Infectious Bronchitis Virus (IBV) and Turkey Coronavirus (TCoV) form a third group 
(Guy et al., 1997; Pedersen, Ward, and Mengeling, 1978).   The model virus for the first 
group of coronaviruses is the HCoV-229E.  Coronaviruses of pigs (transmissible 
gastroenteritis virus [TGEV] and porcine respiratory coronavirus [PRCoV]), cats (feline 
coronavirus [FCoV], and dogs (canine coronavirus [CCoV]) (Pedersen, Ward, and 
Mengeling, 1978) belong to group I.  Murine Hepatitis Virus (MHV) is the prototype of 
group II coronaviruses.  Some viruses found in this group are the coronaviruses of 
humans (HCoV-OC43), rats (rat coronavirus [RCoV]), cattle (bovine coronavirus 
[BCoV]), pigs (hemagglutinating encephalomyelitis virus [HEV]), and other species 
(Pedersen, Ward, and Mengeling, 1978).  Analysis of the severe acute respiratory 
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syndrome associated coronavirus (SARS-CoV) viral genome has demonstrated that it is 
phylogenetically divergent from the three known antigenic groups of coronaviruses 
(Drosten et al., 2003; Ksiazek et al., 2003).  Analysis of the polymerase gene alone, 
however, indicates that the SARS-CoV may be an early off-shoot from the group II 
coronaviruses (Snijder et al., 2003). 
Coronavirus Architecture  
Virion Classification and Morphology 
The basic structure of coronavirus virions is depicted in Figure 1.1.  Coronavirus 
virions are spherical enveloped particles that have a diameter of 100 to 120 nm.  Interior 
to the virion is a single-stranded, positive-sense RNA genome that ranges from 27 to 32 
kb in length, the largest of all known RNA viral genomes (Boursnell et al., 1987; Eleouet 
et al., 1995; Herold et al., 1993; Lai and Cavanagh, 1997; Lee et al., 1991).  The SARS-
CoV genome, specifically, has a length of 29,727 nucleotides (Rota et al., 2003).  The 
RNA genome is associated with the nucleocapsid (N) phosphoprotein which allows it to 
form a long, flexible, helical nucleocapsid (Macneughton and Davies, 1978; Sturman, 
Holmes, and Behnke, 1980).  When not associated with virion particles, the 
nucleocapsids appear as extended tubular strands of 14 to 16 nm in diameter (Risco et al., 
1996; Sturman, Holmes, and Behnke, 1980).  It has been shown that for at least two 
coronaviruses (TGEV and MHV), the helical nucleocapsid is enclosed within a 65 nm in 
diameter, spherical, possibly icosahedral “internal core structure” that can be released 
from the virion particle by NP-40 treatment (Risco et al., 1996).  This virus core is 
encapsidated by a lipoprotein envelope that is formed during virus budding from
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Figure 1.1.  A schematic diagram of a typical coronavirion structure.  S, spike 
glycoprotein; HE hemagglutinin-esterase glycoprotein (found only in a subset of 
coronaviruses); M, membrane glycoprotein; E, small envelope protein; N nucleocapsid 
phosphoprotein. 
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 intracellular membranes (Griffiths and Rottier, 1992; Oshiro, 1973; Tooze and Tooze, 
1985).  The most prominent feature of the coronavirus virion is the “halo of crowns” 
found to line the outside of the virion.  These long proteins (20 nm in length) consist of  
the spike (S) glycoprotein and are present on all coronaviruses.  Some other 
coronaviruses have shorter spike proteins that also line the outside of the virion which 
consist of the hemagglutinin-esterase (HE) glycoprotein.  The matrix (M) glycoprotein, 
because it spans the lipid bilayer three times (Machamer et al., 1993; Machamer et al., 
1990; Machamer and Rose, 1987), is thought to be a component of both the internal core 
structure and the envelope.  The envelope protein (E) also makes up part of the viral 
envelope, although it is present in much smaller quantities than the other viral envelope 
proteins (Godet et al., 1992; Vennema et al., 1996; Yu et al., 1994).   
Structural Proteins 
Nucleocapsid Protein 
The coronavirus nucleocapsid protein, N, is a 50 to 60 kDa highly basic protein 
that interacts with the viral genome in order to form the viral nucleocapsid.  More 
specifically, the SARS-CoV N protein is 422 amino acids that shares only a 20-30% 
homology with other coronaviruses (Marra et al., 2003; Rota et al., 2003).  Translation of 
the protein occurs on free polysomes and is rapidly phosphorylated on serine residues in 
the cytosol (Stern and Sefton, 1982); the extent and physiological relevance of 
phosphorylation, however, remains unclear (Stohlman and Lai, 1979; Wilbur et al., 
1986).  The synthesized protein consists of three highly conserved domains that are 
separated by spacer regions of variable length (Parker and Masters, 1990).   
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The most prominent feature of the N protein is its ability to bind to RNA.  Several 
studies have pinpointed the RNA binding region of the N protein to the second of the 
three conserved domains found in the N protein  (Masters, 1992; Nelson and Stohlman, 
1993; Nelson, Stohlman, and Tahara, 2000; Peng et al., 1995).  The complexes formed 
between the N protein and the viral RNA of coronaviruses and orthomyxoviruses are 
more easily disrupted at high salt concentrations and offer little protection against RNase 
when compared to the complexes formed by N proteins and viral RNA of rhabdoviruses 
and paramyxoviruses (Masters and Sturman, 1990). 
  The second type of interaction is N protein interaction with itself.  Disulfide 
linked multimeric forms of the N protein have been shown to exist (Robbins et al., 1986).  
It has also been shown for the SARS-CoV that the carboxyl terminal conserved domain 
functions as a dimerization domain (He et al., 2004).  The third type of interaction is the 
N protein’s interaction with the matrix glycoprotein (Sturman, Holmes, and Behnke, 
1980) which leads to the formation of virus particles.   
In addition to the structural role of N, it is hypothesized that it may function in 
viral RNA synthesis, transcription, translation, and virus budding (He et al., 2003; Lai 
and Cavanagh, 1997; Tahara et al., 1998).  Specifically, it has been shown that the N 
protein participates in RNA synthesis.  It was found that RNA synthesis was inhibited by 
greater than 90% when antibodies to N were introduced into an in vitro synthesizing 
system prepared from MHV-infected cells (Compton et al., 1987).  This inhibition 
implies a critical role for the N protein in transcription and replication of the viral RNA.  
Although N plays a critical role in RNA synthesis, the relative amounts of free N protein 
in infected cells are quite large and do not appear to be the rate limiting factor for MHV 
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RNA synthesis (Perlman et al., 1986).  Also, some N protein may be complexed with 
cellular membranes (An, Maeda, and Makino, 1998; Stern and Sefton, 1982) where it 
functions in budding of the virus.  The SARS-CoV N protein has not been extensively 
studied, except that the SARS-CoV N protein may selectively activate the AP-1 signal 
transduction pathway (He et al., 2003).   
Membrane Protein  
 The membrane glycoprotein, the most abundant envelope component, is a triple-
membrane spanning protein with a short amino-terminus on the virion exterior surface, 
an α-helical domain, and a large carboxyl terminal domain inside the virion envelope 
(Armstrong et al., 1984; Locker et al., 1992; Machamer et al., 1993; Routledge et al., 
1991).  For some coronaviruses, however such as TGEV, the carboxyl terminus of the M 
protein is exposed on the surface of the virion  (Risco et al., 1995).  The protein is 
inserted into the ER membrane through the action of a signal sequence (Rottier, 
Armstrong, and Meyer, 1985) after being synthesized on membrane bound polysomes.  
After being synthesized, the protein undergoes posttranslational modification in the form 
of glycosylation. Interestingly, for group I and group III coronaviruses, such as TGEV 
and IBV, the matrix protein undergoes N-linked glycosylation (Stern and Sefton, 1982), 
whereas for group II coronaviruses, such as MHV, the matrix protein undergoes O-linked 
glycosylation (Holmes, Doller, and Sturman, 1981; Niemann et al., 1982; Niemann et al., 
1984).  Through the use of a virus like particle system it has been demonstrated that 
neither glycosylation of the M protein nor its interaction with the S glycoprotein is 
necessary for virus assembly (de Haan et al., 1998; de Haan et al., 1999).  These 
observations are consistent with studies using the glycosylation inhibitors tunicamycin 
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(Rossen et al., 1998; Stern and Sefton, 1982) and monensin (Niemann et al., 1982) in 
infected cells.  Mature matrix protein accumulates in the Golgi apparatus and is not 
transported to the plasma membrane (Machamer et al., 1990; Machamer and Rose, 1987; 
Swift and Machamer, 1991).  The nature of the membrane-targeting sequence that causes 
this accumulation in the Golgi varies for each coronavirus (Locker et al., 1992; 
Machamer et al., 1993).   
One of the main functions of the M protein is to direct the incorporation of the S 
glycoprotein (Nguyen and Hogue, 1997; Opstelten et al., 1995) and the N protein 
(Narayanan et al., 2000) into the budding virion particle.  The M protein itself does not, 
however, determine the actual budding site, since when expressed by itself it migrates 
beyond the budding compartment and localizes in the late-Golgi complex (Klumperman 
et al., 1994).  Interactions with other viral proteins have been shown to be mediated 
through the carboxyl terminus of the protein (Corse and Machamer, 2003; de Haan et al., 
1998; Kuo and Masters, 2002).  For several coronaviruses, cells expressing the M and E 
proteins alone have been shown to produce virion like particles which are exported from 
the cell (Baudoux et al., 1998; Bos et al., 1996; Corse and Machamer, 2000; Corse and 
Machamer, 2003; de Haan et al., 1998; Vennema et al., 1996).  For the SARS-CoV, 
however, this is not the case.  Expression of M and E alone is not sufficient for capsid 
formation, however the expression of M and N alone is able to produce virus capsids 
(Huang et al., 2004). 
Envelope Protein 
 The small envelope protein, E, is typically a 9 to 12 kDa protein that is a 
component of the virion envelope (Godet et al., 1992; Liu et al., 1991; Yu et al., 1994).  
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When compared to the other structural proteins, however, the E protein is in much lower 
abundance relative to the M, N, and S proteins (Godet et al., 1992; Liu and Inglis, 1991; 
Yu et al., 1994).  Within the three groups of coronaviruses, the E proteins are well 
conserved, but between the three groups, they show limited homology.  All of the 
proteins do share a general structure: a short hydrophilic region on the amino terminus, 
followed by a large hydrophobic region, preceding  a large hydrophilic carboxyl terminus 
(Liu and Inglis, 1991).  Recent studies of the topology of the protein have found for 
MHV and IBV that the E protein is an integral membrane protein presenting its carboxyl 
terminus on the cytoplasmic face of the endoplasmic reticulum or Golgi which 
corresponds to the interior of the assembled virion (Corse and Machamer, 2000; 
Raamsman et al., 2000; Vennema et al., 1996).  For IBV, this Golgi targeting of the 
molecule has been shown to be associated with the carboxyl tail, in the absence of the 
membrane-bound domain (Corse and Machamer, 2002).  The orientation of the amino 
terminus of the protein has not been well established; one study shows a luminal 
orientation for the IBV E protein (Corse and Machamer, 2000) and another study shows 
the amino terminus being buried within the membrane near the cytoplasmic face for the 
MHV protein (Maeda et al., 2001).  E protein is localized primarily in the perinuclear 
space of infected cells, although it also has been detected on the cell surface (Godet et al., 
1992; Yu et al., 1994).  The main function of the E protein is its role in the formation of 
the coronavirus envelope.  For several coronaviruses, expression of MHV M and E alone 
has been shown to be sufficient for the formation of virion like particles which are 
exported from the cell (Baudoux et al., 1998; Bos et al., 1996; Corse and Machamer, 
2000; Corse and Machamer, 2003; de Haan et al., 1998; Vennema et al., 1996).  For the 
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SARS-CoV, however, expression of M and E alone is not sufficient for capsid formation, 
although expression of M and N is sufficient for capsid formation (Huang et al., 2004).  
Another function of the E protein is its ability to induce apoptosis in the infected cell (An 
et al., 1999).   
 The SARS-CoV envelope protein is approximately 76 amino acids long with an 
approximate molecular weight of 10-15 kDa.  Several studies of the SARS-CoV E 
protein have shown additional properties that may be specific to the SARS-CoV.  The 
SARS-CoV E protein has the ability to form cation-selective ion channels (Wilson et al., 
2004) similar to those of the influenza virus protein, M2 (Duff and Ashley, 1992; Duff et 
al., 1994; Pinto, Holsinger, and Lamb, 1992), the HIV-1 proteins VPu (Ewart et al., 1996) 
and VPr (Piller et al., 1996), and the hepatitis C virus protein, p7 (Griffin et al., 2003; 
Pavlovic et al., 2003; Premkumar et al., 2004).  In addition, a segment of the SARS-CoV 
E protein appears to form three disulfide bonds with another segment of corresponding 
cysteines in the carboxyl-terminus of the S glycoprotein (Wu et al., 2003).  The SARS-
CoV E protein appears to have a unique structural feature in that it forms a highly 
unusually short, palindromic transmembrane helical hairpin around a previously 
unidentified pseudo-center of symmetry (Arbely et al., 2004).  It is through the action of 
this hairpin, by way of deforming the lipid bilayer and increasing membrane curvature, 
that there finally may be a molecular explanation of the E proteins pivotal role in virus 
budding (Arbely et al., 2004).    
Hemagglutinin-Esterase Glycoprotein 
 Although not found in the SARS-CoV, another protein found on some 
coronaviruses is the hemagglutinin-esterase (HE) glycoprotein (Rota et al., 2003).  The 
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protein exists as a homodimer of  65 to 70 kDa proteins that form short spikes on the 
surface of some group II coronavirus virions as well as turkey coronavirus virions 
(Hogue, Kienzle, and Brian, 1989; Kienzle et al., 1990; Kunkel and Herrler, 1993; 
Schultze et al., 1991).  Cotranslational N-linked glycosylation occurs in the rough 
endoplasmic reticulum after which the dimerization of proteins occurs by disulfide 
interactions to form a 165 to 170 kDa protein complex (Hogue, Kienzle, and Brian, 1989; 
Kienzle et al., 1990; Yokomori et al., 1989).  This protein complex is then incorporated 
into the envelope of budding virus particles after being transported to the Golgi where the 
N-linked glycans are converted to the complex form (Yokomori et al., 1989).  HE that 
does not incorporate into the virion envelope is expressed on cellular surfaces (Kienzle et 
al., 1990).  Some studies have hypothesized that the HE protein is dispensable for viral 
replication since the presence or absence is highly inconsistent even among the group II 
coronaviruses.  In addition, the HE gene is frequently mutated or completely deleted 
during serial virus passaging in cell culture (Yokomori, Banner, and Lai, 1991).  The HE 
protein of various coronaviruses binds 9-O-acetylated neuraminic acid residues which is 
comparable to the binding activity of S in BCoV and HCoV-OC43 (Schultze and Herrler, 
1992; Schultze et al., 1991; Vlasak et al., 1988).  This activity is expected to contribute to 
the hemagglutination and hemadsorption activities of coronaviruses.  The HE protein also 
has an acetylesterase activity that cleaves acetyl groups from 9-O-acetylated neuraminic 
acid (Vlasak et al., 1988; Yokomori et al., 1989) which reverses or prevents the 
hemagglutination and hemadsorption activity induced by S and HE.  This acetylesterase 
activity, along with the inhibition of BCoV infectivity through neutralization of HE with 
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monoclonal antibodies (Deregt et al., 1989), points to a role for HE in virus entry or virus 
release from infected cells. 
Spike Glycoprotein 
The SARS spike glycoprotein, a 1,255-amino-acid type I membrane glycoprotein 
(Rota et al., 2003), is the major protein present in the viral membrane forming the typical 
spike structure found on all coronavirions.  Mature proteins form oligomers in the form 
of homotrimers (Delmas and Laude, 1990; Xiao et al., 2004) and are known to be 
glycosylated.  Posttranslational glycosylation occurs on at least four different sites of the 
spike protein (Krokhin et al., 2003; Ying et al., 2004).  Once fully processed the protein 
exists as a 180 kDa single protein species with the homotrimer species of approximately 
500 kDa.  Although some S oligomers can be found on the infected cell surface where it 
may mediate cell-cell fusion, most newly synthesized S accumulates in the Golgi of 
infected cells where it participates in virus particle assembly (Griffiths and Rottier, 1992; 
Vennema et al., 1990).  The S glycoprotein of mouse hepatitis virus (MHV) is cleaved 
into (Cavanagh, 1995) S1 and S2 subunits, although cleavage is not necessarily required 
for virus-cell fusion (Bos, Luytjes, and Spaan, 1997; Gombold, Hingley, and Weiss, 
1993; Stauber, Pfleiderera, and Siddell, 1993). Similarly, the SARS-CoV S glycoprotein 
seems to be cleaved into S1 and S2 subunits in Vero-E6 infected cells (Wu et al., 2004), 
but it is not known whether this cleavage affects S-mediated cell fusion.  This cleavage of 
the SARS-CoV S protein, however, may be attributed to overexpression of the protein 
and may not occur in the context of the virus (personal communication). The S protein in 
group I coronaviruses appears not to be cleaved although some of the viruses can induce 
cell-cell fusion (De Groot et al., 1989).  The S1 subunit contains the receptor binding 
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domain which causes it to be the main determinate of viral tropism (Hingley et al., 1994; 
Sanchez et al., 1999; Suzuki and Taguchi, 1996).  Angiotensin converting enzyme 2 
(ACE2) (Li et al., 2003) and CD209L (L-SIGN) (Jeffers et al., 2004) have been identified 
to be two receptors for the SARS-CoV.  The S2 subunit contains internal hydrophobic 
sequences which are thought to be responsible for the membrane fusion activity of the 
protein (Luo and Weiss, 1998).  It is worth noting, however, that sequences in multiple 
sites of S2 as well as in S1 can affect fusion activity (Gallagher, Escarmis, and 
Buchmeier, 1991; Routledge et al., 1991).  Expression of the S protein alone has been 
shown to induce membrane fusion on cells that are susceptible to coronavirus infection 
(De Groot et al., 1989; Taguchi, 1993; Yoo, Parker, and Babiuk, 1991). 
The internal hydrophobic sequences that are found in the S2 portion of the SARS 
S glycoprotein are known as heptad repeats (HR). These regions contain a sequence motif 
characteristic of coiled-coils which appear to be a common motif in many viral and 
cellular fusion proteins (Skehel and Wiley, 1998). These coiled-coil regions allow the 
protein to fold back upon itself as a prerequisite step to initiating the membrane fusion 
event. There are usually two HR regions: an N terminal HR region adjacent to the fusion 
peptide and a C-terminal HR region close to the transmembrane region of the protein. 
Within the HR segments, the first amino acid (a) and fourth amino acid (d) are typically 
hydrophobic amino acids that play a vital role in maintaining coiled-coil interactions. 
Based on structural similarities, two classes of viral fusion proteins have been 
established. Class I viral fusion proteins contain two heptad repeat regions and an N-
terminal or N-proximal fusion peptide. Class II viral fusion proteins lack heptad repeat 
regions and contain an internal fusion peptide (Lescar et al., 2001).  The MHV S 
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glycoprotein, which is similar to other coronavirus S glycoproteins, is a class I membrane 
protein that is transported to the plasma membrane after being synthesized in the 
endoplasmic reticulum (Bosch et al., 2003). Typically, the ectodomains of the S2 
subunits of coronaviruses contain two regions with a 4, 3 hydrophobic (heptad) repeat the 
first being adjacent to the fusion peptide and the other being in close proximity to the 
transmembrane region (de Groot et al., 1987). 
The S glycoprotein is primarily responsible for entry of all coronaviruses into 
susceptible cells through binding to specific receptors on cells and mediating subsequent 
virus-cell fusion (Cavanagh, 1995). Although the exact mechanism by which the SARS-
CoV enters the host cell has not been elucidated, it is most likely similar to other 
coronaviruses. Upon receptor binding at the cell membrane, the S glycoprotein is thought 
to undergo a dramatic conformational change causing exposure of a hydrophobic fusion 
peptide, which is subsequently inserted into cellular membranes. This conformational 
change of the S glycoprotein causes close apposition followed by fusion of the viral and 
cellular membranes resulting in entry of the virion nucleocapsids into cells (Eckert and 
Kim, 2001; Tsai et al., 2003; Zelus et al., 2003). This series of S-mediated virus entry 
events is similar to other class I virus fusion proteins (Baker et al., 1999; Melikyan et al., 
2000; Russell, Jardetzky, and Lamb, 2001). 
Nonstructural Proteins  
The Replicase Protein 
 Two replicase polyproteins, termed pp1a and pp1ab,  are produced from two open 
reading frames (ORF1a and ORF1b) contained within the first 21 kb of the 
approximately 29.7 kb SARS-CoV genome (Marra et al., 2003; Rota et al., 2003; Thiel et 
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al., 2003).  Pp1a is an approximately 486 kDa polyprotein that has been predicted to 
include a papain-like protease (PLpro), two putative membrane proteins, MP1 (nsp4) and 
MP2 (nsp6), a picornavirus 3C-like protease (3CLpro), and several other products of 
unknown function.  Pp1ab is approximately 790 kDa.  It is generated by ribosomal 
frameshifting so that both ORF1a and ORF1b are included in the translation.  It is 
predicted that ORF1b contains a helicase domain (nsp13) (Ivanov et al., 2004) as well as 
the predicted core RNA polymerase (nsp12), exonuclease (nsp14), endoribonuclease 
(nsp15), and methyltransferase (nsp16) activities (Schmidt-Mende et al., 2001; Snijder et 
al., 2003).  A total of 16 protein products (nonstructural proteins nsp1 to nsp16), 
produced from the processed pp1a and pp1ab polyproteins, are predicted to assemble into 
a membrane-associated viral replication complex (Snijder et al., 2003; Stadler et al., 
2003; Thiel et al., 2003).  This processing of the polyproteins has been hypothesized to be 
coordinated by two virus-encoded proteinases, the picornavirus 3C-like proteinase 
(3CLpro) and a papain-like proteinase (PLP) (Denison et al., 1992; Snijder et al., 2003; 
Thiel et al., 2003).  The precursor proteins and mature processed replicase proteins likely 
mediate the progression from replication complex formation, followed by subgenomic 
mRNA transcription, and finally genome replication.  Essential functions carried out by 
the replication complex are as follows: 1) transcription of genome-length negative and 
positive stranded RNAs, 2) transcription of a 3´-coterminal nested set of subgenomic 
mRNAs that have a common 5´ “leader” sequence derived from the 5´ end of the 
genome, and 3) transcription of the subgenomic derived negative-stranded RNAs with 
common 5´ ends and complementary leader sequences at their 3´ ends (Lai and Holmes, 
2001; Thiel et al., 2003).  Replicase complex activity has been shown to take place at 
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double-membrane vesicles in the host cell cytoplasm (Gosert et al., 2002; Pedersen et al., 
1999; Prentice et al., 2004).   
Novel SARS-CoV Specific Proteins 
 In addition to the four main structural proteins (S, E, M, and N) and the viral 
encoded RNA dependent RNA polymerase, there are nine other potential ORFs found in 
the SARS-CoV genome that vary from 39 to 274 amino acids in length (Marra et al., 
2003; Rota et al., 2003; Thiel et al., 2003).  The functions of these additional ORFs are 
largely unknown and further characterization of these proteins is necessary to be able to 
assess any impact on the virus life cycle.   
U274 
The largest of the additional ORFs (ORF 3a) and the second largest subgenomic 
mRNA encode a protein that has been termed U274 because of its length of 274 amino 
acids (Tan et al., 2004c).  The subgenomic mRNA encoding U274 has been found in high 
quantities in infected cells and also has a strong match to the transcription regulating 
consensus sequence close to and upstream of its first ORF (Marra et al., 2003; Rota et al., 
2003; Thiel et al., 2003).  The exact function of the protein is unknown but a region in its 
carboxyl terminus is similar to calcium-transporting adenosine triphosphatases (Marra et 
al., 2003; Rota et al., 2003; Snijder et al., 2003; Thiel et al., 2003).  Analysis of sera taken 
from patients infected with the SARS-CoV has shown that the sera contains antibodies 
against the U274 protein, which indicates that the protein may play a role in the 
biogenesis of SARS-CoV (Tan et al., 2004b).  In cells infected with SARS-CoV and cells 
transiently transfected with U274, the protein localized to the plasma membrane as well 
as to the perinuclear region (Tan et al., 2004c).  This surface expression may explain the 
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presence of U274 antibodies found in sera taken from infected patients mentioned above 
(Tan et al., 2004b).  Surfaced expressed U274 is able to undergo endocytosis and its 
cytoplasmic domains contain sorting signals that allow proper transport of the protein 
(Tan et al., 2004c).  Interactions were observed between the U274 protein and other 
structural proteins (M, E, and S) as well as the uncharacterized SARS-CoV protein U122.  
This suggests that the U274 protein may play a role in virus assembly (Tan et al., 2004c).    
U122 
 Another group specific gene product encoded by ORF7a (also known as ORFX4 
or ORF8) (Marra et al., 2003; Rota et al., 2003; Snijder et al., 2003) has been partially 
characterized (Fielding et al., 2004).  Like the U274 protein, U122 derives its name from 
its amino acid length.  The U122 appears to localize to the perinuclear region and is 
associated with the endoplasmic reticulum in both cells infected with the SARS-CoV and 
in cells transiently transfected with the U122 protein (Fielding et al., 2004).  From 
sequence analysis, it appears that the protein is a type I membrane protein because of its 
probable cleaved signal peptide located on its amino terminal and a carboxyl terminal 
transmembrane helix (Fielding et al., 2004).  Another study has indicated that over-
expression of U122 is able to induce apoptosis via a caspase-dependent pathway (Tan et 
al., 2004a). 
Protein Antigenicity 
 The induction of the host immunological response against coronavirus infection is 
largely due to the spike glycoprotein (Collins et al., 1982; Koolen et al., 1990; Spaan, 
Cavanagh, and Horzinek, 1988).  Analysis of its antigenic structure has been useful 
particularly in vaccine design (Posthumus et al., 1990).  Particular emphasis has been 
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placed on locating potential neutralization epitopes on the spike glycoprotein which 
include linear and conformational epitopes (Daniel et al., 1993; Kubo, Yamada, and 
Taguchi, 1994; Moore, Jackwood, and Hilt, 1997; Takase-Yoden et al., 1991; Talbot and 
Buchmeier, 1985; Vautherot, Laporte, and Boireau, 1992; Vautherot et al., 1992).  
Induction of a protective immune response was able to be accomplished through 
immunization of animals with a synthetic peptide from a particular immunodominant 
region of the MHV spike protein (Daniel, Lacroix, and Talbot, 1994; Koo et al., 1999; 
Koolen et al., 1990; Yu et al., 2000).  This immunodominant region of the MHV spike 
was also shown to be recognized by viral neutralizing antibodies (Daniel et al., 1993; 
Luytjes et al., 1989; Talbot and Buchmeier, 1985; Talbot et al., 1984).  As with other 
coronaviruses, there have been regions of the SARS-CoV spike that have been found that 
are able to elicit a neutralizing antibody response from animals injected with the synthetic 
peptides from these regions (Zhang et al., 2004).  Expression of the other structural 
proteins (M, E, or N), in the absence of SARS-CoV spike expression, is unable to provide 
protective immunity to SARS-CoV infection (Buchholz et al., 2004).   
Organization of the Viral Genome 
The genomes of several coronaviruses are compared and shown in Figure 1.2.  
Coronaviral genomes are capped, polyadenylated, positive stranded RNAs of 27 to 32 kb 
in length.  Since they are positive strand genomes, they are able to serve as mRNAs and it 
has been shown that the purified genomic RNA is infectious (Lomniczi, 1977; 
Schochetman, Stevens, and Simpson, 1977).  The leader RNA is a sequence of 65 to 98 
nucleotides that is present at the 5' end of the genome as well as at the 5' ends of all 
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Figure 1.2.  Genomic Organization of several serotypes of coronavirus.  The genome 
structure for five previously sequenced coronavirus RNAs are shown.  All genes, except 
for gene 1 (pp1ab) are drawn approximately to scale.  The severe acute respiratory 
syndrome (SARS-CoV), mouse hepatitis virus (MHV), avian infectious bronchitis virus 
(IBV), porcine transmissible gastroenteritis virus (TGEV), and human respiratory 
coronavirus (HCoV-229E) are composed of positive stranded RNA genomes of 
approximately 29.7, 31.2, 27.6, 28.5, and 27.2 kb respectively.  The 5' end of RNA 
genome is capped and contains a 65- to 98-base long leader sequence (L).  Structural 
proteins represented by shaded boxes while nonstructural proteins are shown as unshaded 
boxes.  Vertical lines shown between open reading frames (ORFs) represent intergenic 
sequences.  The area found bracketed by two intergenic sequences represents a single 
gene.  Each separate ORF within that single gene is translated from a single mRNA 
species.  Several variations exist between the serotypes of coronaviruses in the number, 
location, and sequence of ORFs encoding nonstructural proteins.  The positive stranded 
RNAs encoding the coronavirus genomes are polyadenylated at their 3' end. 
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subgenomic mRNAs (Lai et al., 1983; Shieh et al., 1987; Spaan et al., 1983).  This leader 
sequence is followed by an untranslated region of approximately 200 to 400 nucleotides.  
There is another untranslated region of approximately 200 to 500 nucleotides at the 3' end 
of the genome which is followed by a poly(A) tail that varies in length.  The sequences 
that make up both the 5' and 3' untranslated region are essential for RNA transcription 
and replication.  The remaining genome is made up of 7 to 10 open reading frames that 
encode the genes necessary for virus replication.  Specifically for SARS, the genome 
contains 10 open reading frames encoding the replicase gene, 4 structural proteins, and 5 
potential nonstructural genes that are more than 50 amino acids in length (Rota et al., 
2003).  The first open reading frame makes up two thirds of the viral genome 
(approximately 20 to 22 kb in length) and encodes a polyprotein that is the precursor of 
the viral polymerase.  This gene actually consists of two over lapping open reading 
frames that is effectively combined into a single open reading frame through ribosomal 
frame shifting.  The order in which the polymerase polyprotein and the four structural 
proteins found in all coronaviruses is 5'-Pol-S-E-M-N-3'.  Several other open reading 
frames that encode a variety of nonstructural proteins can be found interspersed between 
the known structural proteins. Some coronaviruses also contain a gene that encodes for a 
hemagglutinin-esterase protein.  The number of nonstructural genes present as well as 
their order in the viral genome, sequence, and method of expression vary widely among 
coronaviruses (Lai and Cavanagh, 1997).  The functions of most of these nonstructural 
proteins are widely unknown; some are even absent in genomes of some coronaviruses 
(Schwarz, Routledge, and Siddell, 1990; Yokomori and Lai, 1991). 
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The Coronavirus Lifecycle 
 A general schematic of the major occurrences in the coronavirus lifecycle are 
depicted in Figure 1.3.  
Viral Attachment and Entry 
 The initial step in any virus life cycle is the binding of virions to the plasma 
membrane of the host cell.  The viral protein that is primarily responsible for the binding 
of the virion to the plasma membrane of the host cell is the spike glycoprotein.  It is the 
spike glycoprotein that drives infection of the host cell by facilitating viral attachment to 
the target cell and promoting fusion between the host cell plasma membrane and the viral 
membrane.  This fusion of the two membranes allows the insertion of the viral genome 
into the cellular cytoplasm.  Viral attachment is accomplished through the interaction of 
the spike protein and specific-receptor glycoproteins on the cell surface.  Given its role in 
viral attachment, the spike protein is the main determinant of viral tropism.   
 After binding to the specific cellular receptor, the virus enters the cell through the 
fusion event between the viral envelope and the plasma membrane or the endosomal 
membrane of the host cell.  The pH of the environment has been shown to affect the 
efficiency of membrane fusion for some coronaviruses such as BCoV, MHV, and IBV 
whose optimum pH for cell-cell fusion is either neutral or slightly alkaline (Li and 
Cavanagh, 1992; Payne and Storz, 1988; Sturman, Ricard, and Holmes, 1990; Weismiller 
et al., 1990).   Given that these viruses may cause fusion of the viral envelop with the 
plasma membrane at the typical physiological pH of the extracellular environment, it is 
likely that they probably enter cells by virus-cell fusion at the plasma membrane.  For 
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Fig. 1.3.  Schematic diagram of a typical coronavirus replication cycle.  Interactions 
between the spike protein on the virion particle and specific receptor glycoproteins or 
glycans found on the surface of the target host cell facilitate virion binding to the plasma 
membrane of the host cell.  Spike protein mediated fusion between plasma membrane or 
endosomal membrane with the viral envelop allows penetration of the cell by the virus.  
Once inside the cell, gene one encoded by the positive sensed RNA genome is translated 
into a large polyprotein.  Cotranslational or posttranslational processing of this large 
polyprotein produces an RNA-dependent RNA polymerase as well as several other 
proteins that are involved in viral RNA synthesis.  The genomic RNA is then used as a 
template by the RNA-dependent RNA polymerase and the other polyprotein products to 
synthesize negative stranded RNAs.  These negative stranded RNAs are subsequently 
used to produce genomic and subgenomic mRNAs.  These mRNAs have an overlapping 
nested set of 3' coterminal RNAs that possess a common leader sequence at the 5' end.  
Each of the subgenomic mRNAs, with few exceptions, only have their 5' most ORF 
translated into viral proteins effectively making them monocistronic.  Proteins produced 
include the S, spike glycoprotein; M, membrane glycoprotein; E, small envelope protein; 
and N nucleocapsid phosphoprotein as well as several nonstructural proteins.  Also the 
HE (hemagglutinin-esterase glycoprotein) is produced in a small subset of coronaviruses.  
Once translated, the N protein interacts in the cytoplasm with newly synthesized genomic 
RNA in order to form helical nucleocapsids.  The M and E proteins are inserted in the 
endoplasmic reticulum and anchored in the Golgi apparatus.  The helical nucleocapsid, 
produced through N protein and RNA interactions, most likely first joins with M at the 
budding compartment which is located between the rough endoplasmic reticulum and the 
Golgi apparatus.  Interactions between the M and E proteins elicit the budding of virions 
which encloses the helical nucleocapsid. Also associated in the Golgi, the S and HE 
structural proteins are translated on membrane-bound polysomes, inserted into the rough 
endoplasmic reticulum and then transported to the Golgi complex.  During protein 
transport, some of the S and HE proteins interact with the M protein and are incorporated 
into maturing virion particles.  S and HE proteins not incorporated into virions are 
transported to the cellular surface where they may play a role in mediating cell-cell fusion 
or hemaadsorption, respectively.  Virions seem to be released by exocytosis-like fusion of 
smooth-walled vesicles that contain the virion particles with the plasma membrane.  
Virions also may remain attached to the plasma membranes of infected cells.  The entire 
coronavirus replication cycle takes place solely in the cytoplasm of the host cell.   
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MHV, however, the efficiency of virus infectivity has been shown to be reduced through 
the use of lysosomotropic drugs which suggests that the virus utilizes the endosomal 
pathway for entry (Gallagher, Escarmis, and Buchmeier, 1991; Krzystyniak and Dupuy, 
1984; Mizzen et al., 1985).  Further experimental evidence indicates that different 
coronaviruses can enter cells either by the acidic pH-dependent endocytosis or by pH 
independent fusion at the plasma membrane (Kooi, Cervin, and Anderson, 1991).   Once 
the virus has entered the host cell, the next step in life cycle is the uncoating of the virus 
and the release of the genomic RNA into the cytoplasm.  The mechanism for this 
uncoating and release is not currently clear and may require specific cellular proteins in 
addition to the incorporated viral elements.  Some murine cells, despite having the 
presence of a functional MHV receptor, are known to block MHV infections at 
penetration, uncoating, or other steps in entry (Asanaka and Lai, 1993; Flintoff, 1984; 
Yokomori et al., 1993).  These cell types can by grouped into three complementation 
groups which suggests that at least three cellular genes are involved in the entry process 
(Asanaka and Lai, 1993)   
Viral Receptors 
Receptors have been elucidated for several coronaviruses.  For mouse hepatitis 
virus, the receptor is a murine biliary glycoprotein which belongs to the 
carcinoembryonic antigen (CEA) family in the Ig superfamily (Dveksler et al., 1991; 
Williams, Jiang, and Holmes, 1991).  The spike glycoprotein binds to the N-terminal Ig-
like domain of the mouse hepatitis virus receptor in order to facilitate the fusion of the 
two membranes (Dveksler et al., 1993b).  MHV attachment to host cells can be blocked 
by monoclonal antibodies to the viral receptor (Parker, Gallagher, and Buchmeier, 1989; 
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Shieh et al., 1987).  Further studies have shown that the MHV is able to use other 
members of the CEA family and several human CEA-related glycoproteins as receptors 
for viral entry (Chen et al., 1997; Chen et al., 1995; Dveksler et al., 1993a; Nedellec et 
al., 1994; Yokomori and Lai, 1992a; Yokomori and Lai, 1992b).   Other coronaviruses 
such as HCoV-229E, TGEV, FIPV, and most likely canine coronavirus, use the cell 
membrane-bound metalloprotease, aminopeptidase N (APN) that is specific for their host 
species (Benbacer et al., 1997; Delmas et al., 1992; Yeager et al., 1992) as their entry 
receptor.  Unlike the CEA molecules which are normally expressed in cells of the liver, 
gastrointestinal tract, macrophages, and B cells, but not thymic T cells (Coutelier et al., 
1994; Godfraind et al., 1995), APN is widely dispersed on many cell types which include 
respiratory and enteric epithelial cells as well as neuronal and glial cells (Kusters et al., 
1989).  Some monoclonals against APN have been shown to block binding of TGEV or 
HCoV-229E virions to the host cell receptor (Delmas et al., 1992; Yeager et al., 1992); 
however APN protease activity is not a requirement for viral infection (Delmas et al., 
1992; Williams, Jiang, and Holmes, 1991).  The cellular receptor for SARS-CoV was 
originally found to be the metallopeptidase angiotensin-converting enzyme 2 (ACE2) (Li 
et al., 2003; Wang et al., 2004).  Recently, however, an additional receptor, CD209L (L-
SIGN), has been shown to function as a receptor for the SARS-CoV (Jeffers et al., 2004). 
Angiotensin Converting Enzyme 2 
Angiotensin-converting enzyme 2 is a type I transmembrane protein that is made 
up of 805 amino acids.  It contains a single metalloprotease active site with an HEXXH 
zinc binding domain (Kuhn et al., 2004).  The ACE2 protein is synthesized in the human 
heart muscle, kidneys, testis (Donoghue et al., 2000), gastrointestinal tract, and the lungs 
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(Hamming et al., 2004).  In particular, high levels of ACE2 expression have been found 
by immunohistochemical examinations in the endothelium of intramyocardial and 
intrarenal vessels and in the renal tubular epithelium (Donoghue et al., 2000).  The 
enzyme appears be the physiological counterweight of the related angiotensin-converting 
enzyme (ACE) which is known to cleave the inactive peptide angiotensin I in order to 
produce the highly potent vasoconstrictor angiotensin II (Kuhn et al., 2004).  Specifically, 
ACE2 has been shown to cleave angiotensin I to the metabolite angiotensin (1-9), which 
in turn is cleaved to angiotensin (1-7) (Donoghue et al., 2000; Harmer et al., 2002).   It 
also cleaves des-arg-bradykinin, neurotensin, and kinetensin (Donoghue et al., 2000).  
There is significant overlap between the tissues that express the ACE2 protein and those 
tissues that are most correlated with SARS-CoV replication and symptomatic 
manifestation (Hamming et al., 2004).  An obvious example of this overlap would be the 
lungs.  The lungs are the primary site of SARS-CoV infection (Kuiken et al., 2003) ,and 
the lungs express the ACE2 protein (Donoghue et al., 2000; Hamming et al., 2004; 
Harmer et al., 2002; Li et al., 2003).  A less obvious example is the gastrointestinal tract 
and kidneys.  These areas have high levels of ACE2 expression and have also been 
shown to be an active site of SARS-CoV infection (Donoghue et al., 2000; Hamming et 
al., 2004; Harmer et al., 2002).  SARS-CoV has not, however, been found to replicate in 
the human heart which is a site a high expression of ACE2 (Donoghue et al., 2000).   
CD209L (L-SIGN) 
 CD209L, a homologue of CD209, is a type II transmembrane glycoprotein in the 
C-type lectin family that serve as adhesion receptors for ICAM-2 and ICAM-3 
(Bashirova et al., 2001; Geijtenbeek et al., 2000; Mummidi et al., 2001).  The isoform 
 31
that has been identified as the receptor for the SARS-CoV is composed of 376 amino 
acids.  Structurally, the protein has a short cytoplasmic tail, a transmembrane domain, an 
extracellular stalk that contains seven repeats of a 23 amino acid sequence 
(KAAVGELXEKSKXQEIYQELTXL), and a large carboxyl terminal carbohydrate 
recognition domain (Jeffers et al., 2004).  This carbohydrate recognition domain has been 
shown to bind specifically to high mannose glycans on glycoproteins (Geijtenbeek, 
Engering, and Van Kooyk, 2002).  It has not yet been determined if it is this carbohydrate 
recognition domain that participates in viral interactions with the SARS-CoV spike 
glycoprotein, or if the SARS-CoV spike glycoprotein recognizes the protein’s specific 
amino acid sequence.   
Genome Expression 
 Once released into the cytoplasm, the viral RNA serves as a template for the 
synthesis of the viral RNA dependent RNA polymerase.  This RNA dependent RNA 
polymerase first synthesizes negative stranded RNAs which are used as templates for the 
synthesis of multiple subgenomic RNAs as well as full length copies of the genome.  It 
has been shown that there are comparable levels of negative polarity genomic and 
subgenomic RNA to levels of corresponding positive sense genomic and subgenomic 
mRNA in infected cells (Sawicki and Sawicki, 1990; Sethna, Hofmann, and Brian, 1991; 
Sethna, Hung, and Brian, 1989).  Although levels were comparable, there was no single-
stranded negative sense RNA found in the infected cell, only double-stranded (Perlman et 
al., 1986; Sawicki and Sawicki, 1986; Sawicki and Sawicki, 1990).  These subgenomic 
RNAs account for all of the viral proteins except for the ORF 1ab polyprotein.  
Depending on the strain of the virus, coronaviruses produce five to seven subgenomic 
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mRNAs.  All of the mRNAs form a nested set that have common 3′ ends followed by a 
poly(A) tail.  Each of these mRNAs, except for the smallest, contain two or more ORFs 
in which only the 5′ most ORF, with few exceptions, is translated. This effectively makes 
each subgenomic mRNA functionally monocistronic.  The coronavirus subgenomic 
RNAs and the genomic RNA share an identical 5′ end leader sequence that is 65 to 98 
bases long (Lai et al., 1983; Shieh et al., 1987; Spaan et al., 1983).  The leader sequence 
is a unique part of the viral genome and only shares partial homology with sequences 
found between each gene that have been termed both the transcription-associated 
sequence (Hiscox et al., 1995) and the intergenic sequence (Baric et al., 1987).  The latter 
term will be used for the purposes of this literature review.  The core intergenic sequence 
shares a common homology with the seven to eighteen nucleotides found at the 3′ end of 
the leader (Shieh et al., 1987).  Depending on which cell type is used, coronavirus RNA 
synthesis occurs at membranous structures associated with the endoplasmic reticulum, 
late endosomes, or Golgi complex (Denison et al., 1999; Shi et al., 1999; van der Meer et 
al., 1999).  Studies have shown that in addition to the RNA dependent RNA polymerase, 
the N protein as well as other host components may be involved in viral RNA synthesis 
(Compton et al., 1987; Li et al., 1999; Li et al., 1997).     
Several models have been proposed to clarify how the subgenomic mRNAs are 
synthesized so that the leader sequence RNA is fused to the subgenomic mRNAs are 
produced (Figure 1.4).  Proposed models of transcription include a discontinuous 
transcription process by which the leader and mRNA sequences come from two different 
RNA molecules (Jeong and Makino, 1994; Zhang, Liao, and Lai, 1994).   
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Figure 1.4  Schematic diagram of the three proposed models of coronavirus mRNA 
transcription.  Positive stranded RNA is represented by solid black lines while negative 
stranded RNA is represented by dashed grey lines.  Leader RNA and antileader RNA is 
represented by black and grey boxes respectively.  Arrows are used to indicate direction 
of transcription.   
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One model uses a leader-primed transcription (Figure 1.4A) in which a discontinous 
transcription occurs throughout positive-stranded RNA synthesis (Lai, 1986).  The first 
step in this model is the genomic RNA being transcribed into a full-length negative-
stranded copy of the RNA genome.  This is followed by the transcription of the leader 
RNA beginning at the 3’ end of the negative-stranded RNA.  Termination of transcription 
occurs at the end of the leader sequence which allows the leader to dissociate from the 
template.  The dissociated leader, possibly with the polymerase still bound to it, then 
reanneals to any of the intergenic sequences on the negative-stranded RNA allowing the 
priming of mRNA transcription.  In this model, the intergenic sequences function as 
promoters for mRNA transcription.  These intergenic sequences, at least in the case of 
MHV, have a minimal core promoter sequence of seven nucleotides (UCUAAAC) (Joo 
and Makino, 1992; Makino and Joo, 1993).  A novel subgenomic RNA is produced from 
this seven nucleotide sequence when it is incorporated into a defective interfering (DI) 
RNA which is allowed to be expressed in MHV-infected cells (Makino, Joo, and Makino, 
1991).  This shows that the seven nucleotide sequence is capable of priming the synthesis 
of a subgenomic RNA that is normally not synthesized.  The mRNAs produced in this 
model include a leader sequence from the 5’ end of the same RNA molecule or a 
different RNA molecule (Zhang, Liao, and Lai, 1994).  Fusion of the leader RNA occurs 
within the core promoter sequence (UCUAAAC), although adjacent sequences may 
possibly contribute to the joining of the leader RNA and the subsequent subgenomic 
RNA (van der Most, de Groot, and Spaan, 1994).  Mutagenesis or deletion of the leader 
RNA eradicates or severely compromises mRNA transcription (Liao and Lai, 1994; 
Zhang, Liao, and Lai, 1994).  Several studies have been concluded whose data support 
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this model of transcription.  Cells infected with MHV contain dissociated free leader 
RNA ranging in size from 50 to 90 nucleotides (Baric et al., 1987).  Although in the case 
of bovine coronavirus, such free leader RNAs were not found in infected cells (Chang, 
Krishnan, and Brian, 1996).  Another experiment in which two distinct strains of MHV 
are used to infect the same cell shows that leader RNAs transcribed can be 
indiscriminately joined to the subgenomic RNAs from either strain (Makino, Stohlman, 
and Lai, 1986).  Leader RNAs can also be incorporated into subgenomic mRNAs when 
exogenously added to an in vitro transcription system using lysates obtained from MHV-
infected cells (Baker and Lai, 1990).     
 A second model is based on discontinous transcription during the negative-
stranded RNA synthesis (Figure 1.4B) from the full-length genomic RNA template 
(Sawicki and Sawicki, 1990).  In this model, the polymerase pauses transcription at one 
of the intergenic sequences and then “jumps” to the 3’ end of the leader sequence in the 
genomic RNA template.  This jumping mechanism generates a negative-stranded 
subgenomic RNA with an antisensed leader sequence at its 3’ end which serves as a 
template for the synthesis of mRNAs.  Intergenic sequences on the positive-stranded 
strand may serve as transcriptional termination sites. It is also possible that these 
sequences interact with the leader RNA to promote polymerase jumping during negative-
strand RNA synthesis.  It is during this phase of negative-strand synthesis in which the 
intergenic sequences facilitate leader-mRNA fusion. As with the first model proposed, 
there have been several studies that support this model of transcription.  One such study 
shows that there are equal amounts of subgenomic RNAs and their negative-stranded 
counterparts found in infected cells (Sethna, Hung, and Brian, 1989).  It has also been 
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shown that the negative-stranded RNAs are exact complementary copies of the viral 
subgenomic RNAs complete with 5’ poly(U) sequence and an antisensed leader sequence 
at the 3’ end (Hofmann and Brain, 1991; Sethna, Hofmann, and Brian, 1991).  Also, it 
appears that each subgenomic mRNA is possibly transcribed from a corresponding 
subgenomic-sized, negative-stranded template (Sawicki and Sawicki, 1990).  These 
negative-stranded RNAs have also been found in membrane associated replication 
complexes (Sethna and Brian, 1997).          
 The third and final model proposed for the synthesis of subgenomic mRNAs are 
based on the findings of incorporated subgenomic mRNAs (Figure 1.4C), along with the 
full length viral genome, within the virions of some coronaviruses such as BCoV, TGEV, 
and IBV (Hofmann, Sethna, and Brian, 1990; Sethna, Hung, and Brian, 1989; Zhao, 
Shaw, and Cavanagh, 1993).  It is postulated by this model that subgenomic RNAs 
brought in with the infecting virion are used directly as templates for the synthesis of 
negative-sensed subgenomic RNAs.  These negative-sensed RNAs then serve as 
templates for additional copies of subgenomic mRNAs (Schwarz, Routledge, and Siddell, 
1990; Senanayake et al., 1992).  This model does not correspond with the discontinous 
nature of coronaviral RNA synthesis.  Also, not all coronaviruses have been shown to 
have subgenomic mRNAs incorporated in the virion.  Studies have also tried to promote 
mRNA amplification by transfecting subgenomic RNAs into infected cells but were 
unsuccessful (Chang et al., 1994; Liao and Lai, 1994).  Currently, it cannot be 
unequivocally said which of these proposed models is the correct explanation for 
coronavirus mRNA synthesis.  It is very possible that various aspects of these proposed 
models are active at different points in the virus lifecycle.        
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 The leader RNA and the intergenic sequences are not the only regulators of 
coronavirus mRNA transcription.  Several other facets of the RNA have been found to 
play a role in transcriptional regulation.  One such regulator is the 3’ end of the viral 
genome (Lin, Liao, and Lai, 1994; Lin et al., 1996).  A significant portion of the 3’ end, 
approximately 55 nucleotides at the 3’ end of the genomic RNA as well as the poly(A) 
sequence, is required for the initiation of negative-stranded RNA synthesis (Lin, Liao, 
and Lai, 1994).  Another example of regulation is the need for the complete 3’-UTR to be 
present in order for the transcription of the subgenomic mRNAs to occur (Lin et al., 
1996).  These two findings seem to indicate that the 3’ end (or the 5’ end in the case of 
the negative-stranded RNA) cis-acting sequence is involved in the synthesis of positive-
stranded RNA which in turn indicates that it probably interacts with the leader or 
intergenic sequences of the genome to regulate mRNA transcription. 
Replication of Genomic RNA 
 
 The majority (95%) of the genome sized RNA in the infected cell is packaged into 
nucleocapsids and virions while the other 5% is used to synthesize mRNA encoding the 
polymerase polyprotein (Perlman et al., 1986; Spaan et al., 1981).  The replication of the 
full length RNA would seemingly require a different mechanism than transcription of the 
subgenomic mRNAs since replication of the full length RNA relies on continuous 
transcription rather than the discontinuous transcription of subgenomic mRNA synthesis.  
This presumption, however, may not be the case.  Some studies suggest that some 
genome length replication may actually be performed by discontinuous transcription.  It 
has been shown that some genome sized MHV genomic RNA is in fact a fusion of the 
leader sequence to an intergenic sequence that immediately follows the leader RNA 
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which creates a genome sized RNA with a small deletion (Zhang and Lai, 1996).  It has 
also been found that the leader sequence of MHV DI RNA can be replaced with that of 
the helper virus leader sequence (Makino and Lai, 1989b).  This substitution of the leader 
sequence by the helper virus implies that the transcription of the full length genome 
utilizes a step in which the leader sequence dissociates from the template and then 
rebinds are some point downstream to begin transcription.  This mechanism is also 
utilized in subgenomic mRNA synthesis.  The quantity of UCUAA repeats at the 3’ end 
of the leader have been shown to undergo rapid evolution (Makino and Lai, 1989a) and it 
is at these regions that high levels of RNA recombination occur (Keck et al., 1987).  
These studies suggest that genomic RNA replication uses the leader dissociation 
discontinous synthesis involved in mRNA transcription.   
 Defective Interfering (DI) RNAs have been used to delineate which cis-acting 
sequences are required for the replication of the genomic RNA (Brian and Spaan, 1997; 
Makino, Fujioka, and Fujiwara, 1985; Makino et al., 1988a; Makino et al., 1988b; van 
der Most, Bredenbeek, and Spaan, 1991).  For MHV, replication of the viral genome 
requires a 135 nucleotide internal replication sequence along with approximately 400 to 
800 nucleotides at both the 3’ and 5’ ends of the viral genome (Kim, Lai, and Makino, 
1993; Lin and Lai, 1993).  A 57 nucleotide portion of the replication sequence in the 
MHV DI RNAs, which is required for DI replication, has been found to form a secondary 
structure in the positive strand  (Kim and Makino, 1995; Lin and Lai, 1993).  Both the 
higher order structure and the sequence itself have been shown to be vital for the function 
of the replication signal (Repass and Makino, 1998).  The length of required cis-acting 
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regions for viral genome replication and subgenomic mRNA synthesis differ slightly 
from one another (Liao and Lai, 1994; Lin and Lai, 1993; Lin et al., 1996).    
Translation of Viral Proteins 
 
 As previously noted, transcription of the viral genome results in multiple 
subgenomic mRNAs which, with the exception of the smallest mRNA, contain two or 
more ORFs in which only the 5’ most ORF, with few exceptions, is translated.  Structural 
proteins are translated by a cap-dependent ribosomal scanning mechanism from separate 
mRNAs.  Translation in virus infected lysates is enhanced by a 5’ leader sequence found 
in all of the subgenomic mRNAs (Tahara et al., 1994).  This enhancement of translation 
may give viral mRNAs an advantage as host cell translation is being shut off by the viral 
infection.  Besides the structural proteins, the virus encoded polymerase is encoded 
within two large overlapping ORFs (ORF1AB) that utilize a ribosomal frameshifting 
mechanism in order to synthesize the entire polyprotein (Boursnell et al., 1987; Brierley, 
Jenner, and Inglis, 1992; Eleouet et al., 1995; Herold et al., 1993; Lee et al., 1991).  This 
translation is initiated by the conventional cap-dependent translation mechanism.  For 
several coronaviruses, the second or third ORF has the highest efficiency of translation.  
This is due to the presence of an internal ribosomal entry site just before the ORF that 
allows the ribosome to bypass the preceding ORFs.  This allows the translation of the 
targeted ORF through a cap-independent translation mechanism (Liu and Inglis, 1992b; 
Thiel and Siddell, 1994).  Other than the virus encoded polymerase, there are other 
proteins in the genome that contain more than one ORF.  These proteins are translated by 
unknown mechanisms.  Examples of this include an internal ORF within the N genes of 
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MHV and BCoV (Fischer et al., 1997; Senanayake et al., 1992) and the two ORFs found 
on the fifth subgenomic mRNA of IBV (Liu and Inglis, 1992a). 
Assembly and Release of Virions 
 The initial step in virion assembly is the formation of helical nucleocapsids by the 
nucleocapsid proteins binding to the viral RNA.  This binding of viral RNA to 
nucleocapsid protein is facilitated by a sequence of nucleotides found in ORF 1B which 
is only present in the genomic-length RNA.  This sequence has been shown to bind the 
nucleocapsid protein (Masters et al., 1994), and is thought to facilitate packaging of viral 
genomes into virions.  Small DI RNAs composed only of terminal sequences are able to 
be packaged into virions, which indicate that there is some form of packaging signal 
contained within these terminal sequences.  This packaging has been observed in several 
coronaviruses such as TGEV, BCoV, and IBV (Hofmann, Sethna, and Brian, 1990; 
Sethna, Hung, and Brian, 1989; Zhao, Shaw, and Cavanagh, 1993).  Although the 
terminal signals allow packaging of the DI particle, it may not be responsible for 
packaging the viral genome.  A 69 nucleotide packaging signal has been identified 
through the creation of artificial chimeric DI RNAs of MHV (Fosmire, Hwang, and 
Makino, 1992; Makino, Yokomori, and Lai, 1990; van der Most, Bredenbeek, and Spaan, 
1991).  This putative packaging signal maps to a region within ORF 1b and has been 
shown to function by maintaining secondary structure (Fosmire, Hwang, and Makino, 
1992), which allows interaction between the packaging signal and the RNA being 
packaged (Bos et al., 1997; Woo et al., 1997).  Packaging of reporter RNAs has also been 
accomplished by fusing a homologous region of the bovine coronavirus genome to the 
nonviral RNAs (Cologna and Hogue, 2000).  Packaging efficiency for large TGEV DI 
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RNAs is affected by the presence of other portions of the ORF 1B suggesting that the 
packaging of viral RNA may use additional packaging signals found in this region (Izeta 
et al., 1999).   
 Once the nucleocapsid forms, it interacts with the matrix protein at cellular 
membranes (Sturman, Holmes, and Behnke, 1980) of the ER or the Golgi complex.  The 
nucleocapsid protein can only be incorporated into virions when complexed with the viral 
RNA; no unbound protein is able to be packaged into virions (Bos et al., 1996; Vennema 
et al., 1996).  This suggests that the M protein must interact with the viral genome 
directly.  Alternatively, a conformational change may occur when the N protein interacts 
with the viral genome promoting the interaction between the N and M proteins.  This 
interaction may enable the nucleocapsid to be packaged into budding virus particles 
formed on the membranes of the ER and the Golgi while simultaneously allowing the 
formation of the spherical internal core shell surrounding the nucleocapsid (Risco et al., 
1996).     
Virus like particles are able to be formed by the expression of the M and E 
proteins without the presence of any other additional viral proteins (Bos et al., 1996; 
Vennema et al., 1996).  This suggests, for most coronaviruses, that the interactions 
between the M and E proteins facilitate the formation of virion particles.  Mutations 
introduced into the E and M proteins have shown altered virus morphology (Fischer et 
al., 1998) and abrogated virus like particle formation (de Haan et al., 1998), respectively.  
Unlike other coronaviruses, the SARS coronavirus can produce virus like particles 
through expression of the M and N proteins alone but particles are not formed with 
expression of the M and E proteins (Huang et al., 2004).  Regardless of the coronavirus 
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type, these experiments show that the spike protein is dispensable in virus particle 
formation.  This conclusion is also supported by the fact that tunicamycin-treated cells 
infected with MHV produce noninfectious particles that do not contain the spike protein 
(Holmes, Doller, and Sturman, 1981).  It should be noted, however, that when the spike 
protein is expressed along with M and E (M and N for the SARS-CoV), virus like 
particles are produced with the spike protein incorporated in them (Bos et al., 1996; 
Huang et al., 2004; Vennema et al., 1996).     
 The budding compartment, located between the ER and Golgi, is the site at which 
virus budding is first detected (Dubois-Dalcq et al., 1982; Klumperman et al., 1994; 
Tooze, Tooze, and Warren, 1984; Tooze and Tooze, 1985).  Interaction between the M 
protein, which accumulates at the budding compartment (Klumperman et al., 1994) and 
the E protein is thought to trigger virus budding.  Because virus budding has only been 
shown to occur at the budding compartment and the E protein has been detected at sites 
other than that of virus budding (Godet et al., 1994; Yokomori and Lai, 1992a), it is 
thought that the M protein dictates the location of virus budding.  Although the E protein 
is required for particle formation, it may only serve as a scaffolding protein which is not 
essential part of virus maturation.  This is because the E protein is present in such low 
quantities compared to that of the M protein (Vennema et al., 1996).  It may function in 
the pinching off of the budding virions at the budding compartment because it has been 
shown to induce curvature of intracellular membranes containing M (Vennema et al., 
1996).   
 Incorporation of the spike protein and the HE protein into virions is directed by 
interactions with the M protein which occurs in the pre-Golgi complex (Nguyen and 
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Hogue, 1997; Opstelten et al., 1995).  The glycoproteins S and HE are processed as the 
virions pass through the Golgi where they may undergo additional morphological 
changes resulting in the compact, electron dense internal core typical of the mature virus 
particle (Risco et al., 1998; Salanueva, Carrascosa, and Risco, 1999).  After the Golgi, 
mature virions accrue in large, smooth-walled vesicles that fuse with plasma membrane  
in order to release the virions into the extracellular space (Griffiths and Rottier, 1992).  
Although virus release is restricted to certain areas of the cell, the exact mechanism 
dictating this site restriction is poorly understood.   
Cellular Proteins Involved in Coronavirus Replication  
 
 Coronaviruses require cellular proteins in addition to its viral proteins in order to 
replicate.  These cellular proteins are hijacked from their normal functions in the cell to 
assist the virus in its replication.  Crosslinking experiments failed to show any 
interactions, with the exception of the N protein, between the viral RNA and any of the 
coronavirus proteins which suggest that viral proteins interact with the viral RNA 
indirectly through cellular proteins.  Several cellular proteins have been shown to bind to 
MHV viral RNA.  These portions of viral RNA are known to play regulatory functions in 
other aspects of the virus lifecycle.  Such regulatory elements include the 5’ and 3’ ends 
of the genomic RNA, intergenic regions of the RNA genome, and the 3’ end of the 
negative-strand RNA.    
HNRNP A1 
 Several different cellular proteins have been identified that bind to the intergenic 
regions of the template coronavirus RNA (Zhang and Lai, 1995a).  Deletion analysis and 
mutagenesis of the intergenic sites have correlated transcription efficiency with RNA 
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protein binding.  This suggests that these cellular RNA binding proteins play an 
important role in the regulation of coronavirus mRNA transcription.  One of the proteins 
was identified by partial peptide mapping to be hnRNP A1 (Li et al., 1997).  This cellular 
protein is known to be an RNA-binding protein that contains two RNA-binding domains 
along with a glycine-rich domain responsible for protein-protein interactions.  hnRNP A1 
primarily exists as a nuclear protein, but it also has a shuttling function that cycles it 
between the nucleus and the cytoplasm (Pinol-Roma and Dreyfuss, 1992).  Its primary 
function depends on its location.  When in the cytoplasm, hnRNP A1 modulates mRNA 
turnover and translation by binding to AU-rich elements on cytoplasmic mRNA 
(Hamilton et al., 1997; Hamilton et al., 1993; Henics et al., 1994).  While in the nucleus, 
it is involved in pre-mRNA splicing and transport of cellular RNAs (Dreyfuss et al., 
1993).  Specifically for MHV, hnRNP A1 binds the negative-strand leader along with 
intergenic sequences (Furuya and Lai, 1993; Li et al., 1997).  These sequences are known 
to be critical elements for discontinuous viral RNA transcription.  Mutagenesis of the 
intergenic sequences disrupts hnRNP A1 binding which hinders efficiency of 
transcription from the altered intergenic site (Furuya and Lai, 1993; Li et al., 1997; Zhang 
and Lai, 1995b).  Another function of hnRNP A1 may be in its interaction with the 
nucleocapsid protein (Wang and Zhang, 1999) which is known to bind to the viral RNA 
directly (Baric et al., 1988; Stohlman et al., 1988).   
PTB 
 PTB, also known as hnRNP I, is another cellular protein found to be involved in 
coronavirus replication.  It is known to bind to the UC-rich RNA sequences found near 
the 3’ end of introns, to play a role in the regulation of translation of viral and cellular 
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RNAs, as well as alternative splicing of pre-mRNAs, and is similar in function to hnRNP 
A1 in that it also shuttles between the nucleus and the cytoplasm (Kaminski et al., 1995; 
Svitkin et al., 1996; Valcarcel and Gebauer, 1997).  Immunoprecipitation and 
crosslinking studies have established PTB binds to the MHV positive-strand leader RNA 
(Li et al., 1999).  This region of the MHV RNA has been shown previously to be needed 
for MHV RNA synthesis and to regulate transcription (Kim, Jeong, and Makino, 1993; 
Liao and Lai, 1994; Tahara et al., 1994).  Deletion of the mentioned binding sites causes 
significant inhibition of RNA transcription (Li et al., 1999).   This suggests that PTB may 
play a role in coronavirus mRNA translation although it does not have a direct effect on 
the cap-dependent MHV RNA translation (Choi and Lai, unpublished data). 
PABP 
 Poly(A)-binding protein (PABP) binds to the 3’ UTR region of coronaviral RNA 
which is necessary for the synthesis of negative-stranded viral RNA and both genomic 
and subgenomic positive-strand RNA synthesis (Kim, Jeong, and Makino, 1993; Lin and 
Lai, 1993; Lin, Liao, and Lai, 1994; Lin et al., 1996).  These 3’ UTR regions contain 
structures that are conserved among several different strains of coronaviruses (Hsue, 
Hartshorne, and Masters, 2000; Hsue and Masters, 1997; Liu, Johnson, and Leibowitz, 
2001).  It is known that PABP is a highly abundant cytoplasmic protein that binds to the 
3’ poly(A) tail on eukaryotic mRNAs (Gorlach, Burd, and Dreyfuss, 1994).  Binding of 
PABP to the 3’ UTR of DI RNA replicons correlates with the ability of the RNA to 
replicate which suggests that the PABP interaction with the poly(A) tail may have an 
effect on coronavirus RNA replication (Huang and Lai, 2001; Liu, Yu, and Leibowitz, 
1997; Spagnolo and Hogue, 2000; Yu and Leibowitz, 1995a; Yu and Leibowitz, 1995b).   
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Mitochondrial Aconitase 
 Despite the absence of a consensus RNA-binding domain, crosslinking 
experiments have indicated that mitochondrial aconitase binds to the MHV 3’ protein-
binding element (Burd and Dreyfuss, 1994).  This binding increases the stability on the 
viral mRNA enhancing the translation of viral proteins.  In addition to binding to the 
MHV genome, mitochondrial aconitase also colocalizes with the MHV nucleocapsid 
protein suggesting a potential interaction with the MHV replication complex (Nanda and 
Leibowitz, 2001).      
Pathology and Disease 
 Coronaviruses are known to cause a wide array of pathologies including acute 
respiratory disease, hepatitis, chronic demyelination in the central nervous system (CNS), 
encephalitis, and enteritis (Holmes, 1996).  Generally the virus infects the respiratory and 
enteric mucosal surfaces (Navas-Martin and Weiss, 2003) and is able to cause both self-
limiting acute and chronic persistent infections.  Some coronaviruses, such as MHV, 
target other cells such as hepatocytes, endothelial cells, neurons, macrophages, 
astrocytes, and oligodendrocytes (Haring and Perlman, 2001).   
 Before the discovery of the SARS-CoV only two coronaviruses were known to 
infect humans, HCoV-229E and HCoV-OC43.  The infections caused by theses viruses 
were self-limiting upper respiratory tract infections (Myint, 1994) that account for 
approximately 30% of all common colds.  These viruses, however, have never been 
reported to cause severe illness.  Other coronaviruses such as TGEV (porcine), BCoV 
(bovine), and IBV (avian), cause respiratory and enteric diseases that can result in severe 
economic loss in the farming industry.  The SARS-CoV originated in Guangdong 
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Province, China in late 2002 (Parry, 2003).  From there it spread throughout Asia and by 
the end of the epidemic caused more than 8000 cases of infection worldwide, according 
to the Centers for Disease Control (CDC) and the World Health Organization (WHO) 
(Navas-Martin and Weiss, 2003).  Out of the more than 8000 cases reported, more than 
800 of these resulted in death with mortality rates, depending on the age of the victim, as 
high as 15% (Anand et al., 2003). 
 The SARS-CoV infection exhibits a wide clinical course characterized by fever, 
dyspnea, lymphopenia and lower tract respiratory infection (Nie et al., 2003; Tsui et al., 
2003) along with gastrointestinal symptoms and diarrhea (Booth et al., 2003; Lee et al., 
2003; Leung et al., 2003; Peiris et al., 2003).  A three stage disease model that has been 
proposed consists of viral replication, immune hyperactivity, and pulmonary destruction 
(Tsui et al., 2003).  SARS pathology of the lung has been correlated with diffuse alveolar 
damage, epithelial cell proliferation, and an increase of macrophages (Navas-Martin and 
Weiss, 2004).  Similar to many coronavirus infections, multinucleate giant-cell infiltrates 
of macrophage and epithelial origin have been associated with putative syncytium-like 
formation (Nicholls et al., 2003).  As found in the fatal influenza subtype H5N1 disease 
in 1997, lymphopenia, hemophagocytosis in the lung and white-pulp atrophy of the 
spleen are also observed during the SARS-CoV infection (To et al., 2001).  This 
hemophagocytosis found in the lung supports a cytokine dysregulation (Fisman, 2000) 
which may have a role in the pathogenesis of SARS due to the proinflammatory 
cytokines being released by stimulatory macrophages in the alveoli.   
 Based on the known pathology of the SARS-CoV, several treatments have been 
tried including the administration of steroids to try to control the exacerbated cytokine 
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response (Lai et al., 2003).  However, treatments of the infection have been largely 
ineffective (Koren et al., 2003; Lee et al., 2003; Tsui et al., 2003).  SARS-CoV infection 
is also resistant to ribavirin, a nucleoside analog that normally has a broad antiviral 
activity and is presently being used for the treatment of respiratory syncytial virus (RSV) 
(Everard et al., 2001) and hepatitis C (Lipman and Cotler, 2003; Martin et al., 1998).  
Interferons α, β, and γ have also been tested for their antiviral properties against the 
SARS-CoV in vitro with interferon β showing the most promise (Cinatl et al., 2003).   
 The exact mechanism that allowed the emergence of the SARS-CoV possible is 
unknown.  Although the coronavirus biological vector is not known, it is speculated that 
the virus jumped from an animal species to humans (Holmes, 2003).  Several domestic 
and wild animals from the Guangdong Province have been examined in order to 
determine if any of them were carrying the SARS-CoV.  Viruses similar to SARS have 
been isolated from Himalayan palm civets, raccoon dogs, and Chinese ferret badgers 
found in a retail market in China (Guan et al., 2003).  It is speculated that the SARS-CoV 
does indeed have an animal reservoir (Holmes, 2003).   
In addition to the recent impact that the SARS-CoV has had on public health, 
other coronaviruses have an economic impact in the cattle industry.  Primarily, bovine 
coronaviruses were known to be enteropathogenic viruses that caused severe diarrhea in 
neonatal calves.  Coronavirus virions were able to be isolated from diarrhea fluid and 
intestinal samples from animals infected with the disease (Doughri et al., 1976; Mebus et 
al., 1973).  Theses enteric viruses were also able to be isolated from the feces of adult 
cattle with winter dysentery (Saif et al., 1988).  It was not until recently that 
coronaviruses were able to be isolated from the nasal secretions and lung tissues of cattle 
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infected with fatal cases of shipping fever pneumonia.  These isolated viruses were 
termed respiratory coronaviruses (Storz et al., 2000a; Storz et al., 2000b) in order to 
differentiate them from the commonly found enteric strains known as enteropathogenic 
bovine coronaviruses.  There two related viruses are separated by phenotypic variation, 
antigenic differences, and genetic divergence (Chouljenko et al., 1998; Chouljenko et al., 
2001; Lin et al., 2000; Storz et al., 2000a).  A comparison study between respiratory and 
enteropathogenic coronavirus isolated from the same animal with fatal shipping 
pneumonia suggests that the difference in viral tropism is due to slight variations in the 
S1 subunit of the Spike glycoprotein (Chouljenko et al., 1998; Gelinas et al., 2001; 
Hasoksuz et al., 2002; Rekik and Dea, 1994). 
It is the continuing research on all coronaviruses as well as the SARS-CoV 
specifically that will allow a better understanding of the SARS virus and its implications 
on public health.   
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CHAPTER II 
GENETIC ANALYSIS OF THE SARS-CORONAVIRUS SPIKE 
GLYCOPROTEIN FUNCTIONAL DOMAINS INVOLVED IN CELL-SURFACE 
EXPRESSION AND CELL-TO-CELL FUSION* 
 
INTRODUCTION  
 An outbreak of atypical pneumonia, termed severe acute respiratory syndrome 
(SARS), appeared in the Guangdong Province of southern China in November, 2002. The 
mortality rates of the disease reached as high as 15% in some age groups (Anand et al., 
2003). The etiological agent of the disease was found to be a novel coronavirus (SARS-
CoV), which was first isolated from infected individuals by propagation of the virus on 
Vero E6 cells (Drosten et al., 2003; Ksiazek et al., 2003; Peiris et al., 2003). Analysis of 
the viral genome has demonstrated that the SARS-CoV is phylogenetically divergent 
from the three known antigenic groups of coronaviruses (Drosten et al., 2003; Ksiazek et 
al., 2003). Analysis of the polymerase gene alone, however, has indicated that the SARS-
CoV may be an early off-shoot from the group 2 coronaviruses (Snijder et al., 2003).  
The coronaviruses are the largest of the enveloped RNA viruses with a positive-
stranded RNA genome of 28 to 32 kb (Holmes, 2003). Coronaviruses possess a wide host 
range, capable of infecting mammalian and avian species.  All identified coronaviruses 
have a common group of indispensable genes that encode nonstructural proteins 
including the RNA replicase gene open reading frame (ORF) 1ab and the structural 
proteins nucleocapsid (N), membrane protein (M), envelope protein (E), and spike 
glycoprotein (S), which are assembled into virus particles. A hemagglutinin-esterase 
                                                 
* Reprinted from Virology , Vol 341 (2), C. M. Petit, J. M. Melancon, V. N. Chouljenko, R. Colgrove, M. 
Farzan, D. M. Knipe, and K. G. Kousoulas, Genetic Analysis of the SARS-Coronavirus Spike Glycoprotein 
Functional Domains Involved in Cell-surface Expression and Cell-to-Cell Fusion, Pages 215-308, 
Copyright 2005, with permission from the Elsevier. 
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(HE) protein is also encoded by some coronaviruses. Distributed among the major viral 
genes are a series of ORFs that are specific to the different coronavirus groups. Functions 
of the majority these ORFs have not been determined.   
 The SARS spike glycoprotein, a 1,255-amino-acid type I membrane glycoprotein 
(Rota et al., 2003), is the major protein present in the viral membrane forming the typical 
spike structure found on all coronavirions.  The S glycoprotein is primarily responsible 
for entry of all coronaviruses into susceptible cells through binding to specific receptors 
on cells and mediating subsequent virus-cell fusion (Cavanagh, 1995). The S 
glycoprotein specified by mouse hepatitis virus (MHV), is cleaved into S1 and S2 
subunits, although cleavage is not necessarily required for virus-cell fusion (Bos, Luytjes, 
and Spaan, 1997; Gombold, Hingley, and Weiss, 1993; Stauber, Pfleiderera, and Siddell, 
1993).  Similarly, the SARS-CoV S glycoprotein seems to be cleaved into S1 and S2 
subunits in Vero-E6 infected cells (Wu et al., 2004), while it is not known whether this 
cleavage affects S-mediated cell fusion. The SARS-CoV receptor has been recently 
identified as the angiotensin converting enzyme 2 (ACE2) (Li et al., 2003). Although the 
exact mechanism by which the SARS-CoV enters the host cell has not been elucidated, it 
is most likely similar to other coronaviruses.  Upon receptor binding at the cell 
membrane, the S glycoprotein is thought to undergo a dramatic conformational change 
causing exposure of a hydrophobic fusion peptide, which is subsequently inserted into 
cellular membranes. This conformational change of the S glycoprotein causes close 
apposition followed by fusion of the viral and cellular membranes resulting in entry of 
the virion nucleocapsids into cells (Eckert and Kim, 2001; Tsai et al., 2003; Zelus et al., 
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2003).  This series of S-mediated virus entry events is similar to other class I virus fusion 
proteins (Baker et al., 1999; Melikyan et al., 2000; Russell, Jardetzky, and Lamb, 2001). 
Heptad repeat (HR) regions, a sequence motif characteristic of coiled-coils, 
appear to be a common motif in many viral and cellular fusion proteins (Skehel and 
Wiley, 1998). These coiled-coil regions allow the protein to fold back upon itself as a 
prerequisite step to initiating the membrane fusion event. There are usually two HR 
regions: an N terminal HR region adjacent to the fusion peptide and a C-terminal HR 
region close to the transmembrane region of the protein.  Within the HR segments, the 
first amino acid (a) and fourth amino acid (d) are typically hydrophobic amino acids that 
play a vital role in maintaining coiled-coil interactions.  Based on structural similarities, 
two classes of viral fusion proteins have been established. Class I viral fusion proteins 
contain two heptad repeat regions and an N-terminal or N-proximal fusion peptide.  Class 
II viral fusion proteins lack heptad repeat regions and contain an internal fusion peptide 
(Lescar et al., 2001).  The MHV S glycoprotein, which is similar to other coronavirus S 
glycoproteins, is a class I membrane protein that is transported to the plasma membrane 
after being synthesized in the endoplasmic reticulum (Bosch et al., 2003). Typically, the 
ectodomains of the S2 subunits of coronaviruses contain two regions with a 4, 3 
hydrophobic (heptad) repeat the first being adjacent to the fusion peptide and the other 
being in close proximity to the transmembrane region (de Groot et al., 1987).  
In the present study, we investigated the role of several predicted structural and 
functional domains of the SARS spike glycoprotein by introducing specific alterations 
within selected S glycoprotein regions. The results show that the SARS-CoV S 
glycoprotein conforms to the general structure and function relationships that have been 
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elucidated for other coronaviruses, most notably the MHV (Chang, Sheng, and Gombold, 
2000; Ye, Montalto-Morrison, and Masters, 2004) . However, in contrast to the MHV 
endodomain, the carboxyl terminus of the SARS-CoV S glycoprotein contains multiple 
non-overlapping domains that function in intracellular transport, cell-surface expression, 
and endocytosis as well as in S glycoprotein-mediated cell-to-cell fusion.   
RESULTS 
Genetic Analysis of S Glycoprotein Functional Domains   
 To delineate domains of the S glycoprotein that function in membrane fusion, 
intracellular transport, and cell-surface expression, two types of mutations were 
introduced within the S gene: a) mutations were introduced within and adjacent to the 
predicted amino terminal heptad repeat (HR1) core and the predicted fusion peptide, 
which are known to play important roles in membrane fusion (Bosch et al., 2004; Bosch 
et al., 2003; Ingallinella et al., 2004; Tripet et al., 2004); b) mutations and carboxyl 
terminal truncations of the S glycoprotein were engineered to delineate S cytoplasmic 
domains that function in glycoprotein synthesis, intracellular transport, and membrane 
fusion (Fig. 2.1). Specifically, to investigate the amino acid requirements of the HR1 of 
the SARS-CoV S glycoprotein, the a and d amino acid positions L(898) and N(901) were 
both replaced by lysine residues in the cluster mutation CL2, effectively collapsing the 
predicted α-helical structure at the amino terminal terminus of the HR. This amino acid 
sequence is thought to align with the L(1184) of HR2 in the formation of the HR1/HR2 
core complex (Xu et al., 2004).  In addition, cluster-to-lysine mutations CL3 and CL4 
replaced the a and d positions within the HR1 region (Fig. 2.1B).  The CL5 cluster 
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Figure 2.1.  Schematic diagram of the SARS-CoV S glycoprotein.  (A) Graphical 
representation of the S glycoprotein showing the approximate location of the cluster to 
lysine mutations CL1-CL5 relative to known and indicated functional domains.  (B) 
Shown on the top of the diagram is a graphical representation of the SARS-CoV S 
glycoprotein.  The predicted fusion peptide and the HR1 region are enlarged below to 
show the sets of amino acids replaced by lysines in the cluster mutations. The heptad 
repeat a and d positions are labeled above the corresponding amino acid. Amino acids 
changed to lysine are demarcated by arrows with the name of that particular mutation 
shown in brackets.  (C) Amino acid sequences of the carboxyl termini of the truncation 
and acidic cluster associated mutations.  Cysteine clusters (CRM1 and CRM2) are 
denoted by underlined italicized text as well as a bracket encompassing their respective 
regions.  The charged cluster is bracketed over the region.  Amino acids mutated to 
alanines for the CL6 and CL7 cluster mutations are in bold.
 84
 85
mutation was placed adjacent to the HR1 region to investigate whether regions proximal 
to HR1 had any effect on S mediated cell fusion. Similarly, the role of the a and d 
positions within the predicted fusion peptide, located immediately proximal to the N 
terminus of HR1, was investigated by constructing the CL1 cluster mutation (Fig. 2.1B). 
 It has been shown for other viral class I fusion proteins that the carboxyl terminus 
plays a regulatory role in membrane fusion (Bagai and Lamb, 1996; Sergel and Morrison, 
1995; Seth, Vincent, and Compans, 2003; Tong et al., 2002; Yao and Compans, 1995). 
Specifically for coronaviruses, the MHV S  glycoprotein endodomain has been shown to 
contain charged-rich and cysteine-rich regions, which are critical for fusion of infected 
cells (Bos et al., 1995; Chang, Sheng, and Gombold, 2000; Ye, Montalto-Morrison, and 
Masters, 2004). The carboxyl terminal portion of the S glycoprotein contains a consensus 
acidic amino acid cluster containing a motif, which is predicted by the NetPhos 2.0 
software to be phosphorylated (Blom, Gammeltoft, and Brunak, 1999). To investigate the 
potential role of the acidic amino acid cluster in synthesis, transport and cell fusion, serial 
truncations of S were constructed. The acidic cluster was specifically targeted by 
mutagenizing the predicted phosphorylation site embedded within the acidic cluster as 
well as by replacing acidic residues of the acidic cluster with alanine residues. In 
addition, carboxyl-terminal truncations of 8, 17, 26, and 41 amino acids were engineered 
by insertion of stop codons within the S glycoprotein gene. The 8 aa truncation (T1247) 
was designed to bring the predicted charged cluster DEDDSE proximal to the carboxyl 
terminus of the mutated S glycoprotein (Fig. 2.1C). Similarly, the 17 aa truncation 
(T1238) was designed to delete the DEDDSE acidic cluster. The SARS-CoV S 
glycoprotein endodomain contains two cysteine residue clusters, a CCMTSCCSC 
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(CRM1) cluster immediately adjacent to the membrane and a CSCGSCC (CRM2) 
downstream of the first cluster. To address the role of these domains in S glycoprotein-
mediated cell-to-cell fusion, the 26 aa truncation (T1229) was designed to delete the 
CRM2 domain (T1229), while the 41 aa truncation (T1214) deleted both the CRM1 and 
CRM2 domains (Fig. 2.1C).    
Effect of Mutations on S Synthesis   
 To investigate the effect of the different mutations on S synthesis, western 
immunoblot analysis was used to detect and visualize all of the constructed mutant 
glycoproteins as well as the wild type S (Fig. 2.2).   Cellular lysates prepared from 
transfected cells at 48 hours post transfection were electrophoretically separated by SDS-
PAGE and the S glycoproteins were detected via chemiluminescence using a monoclonal 
antibody specific for the SARS-CoV S glycoprotein. Carbohydrate addition was shown to 
occur in at least four different locations of the SARS-CoV S glycoprotein (Krokhin et al., 
2003; Ying et al., 2004). Furthermore, transiently expressed S glycoprotein in Vero E6 
cells was proteolytically cleaved into S1 and S2 components (Wu et al., 2004). The anti-S 
monoclonal antibody SW-111 detected a protein species in cellular extracts from 
transfected cells, which migrated with an apparent molecular mass of approximately 180 
kDa, as reported previously (Song et al., 2004).  All mutated S glycoproteins produced 
similar S-related protein species to that of the wild-type S indicating that none of the 
engineered mutations adversely affect S synthesis and intracellular processing (Fig. 
2.2A).  The SARS S glycoprotein  is known to form homotrimers in its native state (Song 
et al., 2004).  To investigate the effect of the mutations on S oligomerization, cellular 
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Figure 2.2.  Western blot analysis of the expressed mutant SARS-CoV S mutant 
glycoproteins.  (A,B) Immunoblots of wild-type (3xFLAG So (WT)), cluster to lysine, 
cluster to alanine, and carboxyl truncation mutant S glycoproteins probed with 
monoclonal anti-SARS S antiserum.  "Cells only" represents a negative control in which 
Vero cells with no protein transfected into them were probed with the monoclonal 
antibody to SARS S glycoprotein.  (B) In order to detect trimer formation more 
efficiently, the protein extracts of the mutants were neither boiled nor subject to treatment 
with beta mercaptoethanol. 
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lysates from transfected cells were electrophoretically separated without prior boiling of 
the samples and in the absence of reducing agents (Song et al., 2004).  The different S 
species were detected via chemiluminescence using the monoclonal SW-111 to the SARS 
S glycoprotein.  A S protein species was detected that had an approximate apparent 
molecular mass of 500 kDa, which was consistent with previously published data (Song 
et al., 2004) (Fig 2.2B).  Although levels of oligomer expression seemed to vary slightly 
between mutant forms, all mutated S glycoproteins produced similar species to the wild 
type, indicating that none of the mutations blocked oligomerization from occurring.    
Ability of Mutant S Glycoproteins to be Expressed on the Cell Surface   
 To determine if the mutant S glycoproteins were expressed on the surface of cells, 
immunohistochemical analysis was used to label cell-surface expressed S under live cell 
conditions that restrict antibody binding to cell surfaces. In addition, 
immunohistochemistry was used to detect the total amount of S expressed in cells by 
fixing and permeabilizing the cells prior to reaction with the antibody. A recombinant S 
protein having the 3xFLAG added in-frame to the carboxyl terminus of S was used as a 
negative control; since it would not be stained by the live cell reaction conditions (see 
Materials and Methods). Both wild-type versions of S having the 3xFLAG, either at the 
amino or carboxyl terminus of S, caused similar amounts of fusion (Fig. 2.3), which also 
was similar to that obtained with the untagged wild-type S (not shown). The relative 
amounts of cell-surface versus total cellular expression of S were obtained through the 
use of an ELISA. A ratio between the cell-surface localized S and total cellular S 
expression was then calculated and normalized to the corresponding ratio obtained with 
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Figure 2.3. Immunohistochemical detection of cell-surface and total expression of 
the SARS-CoV S wild-type and mutant proteins.  Vero cells were transfected with the 
wild-type SARS-CoV optimized S (3xFLAG So (WT)) (F1, F2), CL1 (A1, A2), CL2 
(B1, B2), CL3 (C1, C2), CL4 (D1, D2), CL5 (E1, E2), CL6 (L1, L2), CL7 (M1, M2), 
T1214 (K1, K2), T1229 (J1, J2), T1238 (I1, I2), T1247(H1, H2) and a wild-type SARS-
CoV optimized S labeled with a 3xFLAG carboxyl tag (G1, G2), which served as a 
negative control.  At 48 hours post-transfection, cells were immunhistochemically 
processed either under live conditions to show surface expression. (A2, B2, C2, D2, E2, 
F2, G2, H2, I2, J2, K2, L2, and M2) or fixed and permeabilized conditions to show total 
expression(A1, B1, C1, D1, E1, F1, G1, H1, I1, J1, K1, L1, and M1) with anti-FLAG 
antibody.  
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the wild-type S glycoprotein (see Materials and Methods) (Fig. 2.4).  The CL1 (95%), 
CL2 (78%), CL3 (86%), CL4 (80%), CL5 (92%), CL6 (86%) mutants as well as the 
T1229 (91%), T1238 (94%), and T1247 (79%) truncations were expressed on the cellular 
surface by the percentages indicated when compared to the cell surface expression of the 
wild type protein.  In contrast, the 1214T mutant expressed 77% less S on cell surfaces in 
comparison to the wild-type S (Fig. 2.4). 
Effect of Mutations on S-mediated Cell-to-Cell Fusion   
 Transiently expressed wild type S causes extensive cell-to-cell fusion (syncytial 
formation), especially in the presence of the SARS-CoV ACE2 receptor (Li et al., 2003).  
To determine the ability of each mutant S glycoprotein to cause cell-to-cell fusion and the 
formation of syncytia, fused cells were labeled by immunohistochemistry using the anti-
FLAG antibody (Fig. 2.5), and the extent of cell-to-cell fusion caused by each mutant 
glycoprotein was calculated by obtaining the average size of approximately 300 syncytia. 
The average syncytium size for each mutant was then normalized to that found in wild 
type S transfected cells (see Materials and Methods). The CL1 (73%), CL2 (75%), CL3 
(68%), CL4 (71%), CL5 (76%), CL6 (51%) as well as the T1214 (86%) and T1247 
(66%) mutants inhibited the formation of syncytia by the percentages indicated. The 
T1229 truncation and the cluster mutant CL7 produced syncytia, which were on the 
average 22% and 15% smaller, respectively, than that of the wild-type S.  In contrast, the 
T1238 mutant produced on the average 43% larger syncytia than that of the wild-type S 
(Fig. 2.5).  
 Comparison of the membrane fusion and cell-surface expression results allowed the 
grouping of the different mutant S phenotypes into four distinct groups (Table 2.1): 1) S 
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Figure 2.4.  Ratios of cell-surface to total cellular expression of mutant SARS-CoV S 
glycoproteins.  Detection of cell surface and total glycoprotein distribution was 
determined by immunohistochemistry and ELISA (see Materials and Methods).  Cell-
surface expression of the S glycoprotein was measured by incubating the transfected cell 
monolayers with anti-FLAG antibody at room temperature before permeabilization.  For 
total S glycoprotein detection, cells were fixed and permeabilized prior to incubation with 
the anti-FLAG antibody. A ratio between the surface localization and the total expression 
was calculated and normalized to the wild type protein, then set to a percentage of the 
wild-type.  The error bars represent the maximum and minimum surface to total ratios 
obtained from three independent experiments, and the bar height represents the average 
surface to total ratio. 
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Figure 2.5. Quantitation of the extent of S-mediated cell fusion.  The average size of 
syncytia for each mutant was determined by digitally analyzing the area of approximately 
300 syncytia stained by immunohistochemistry for S glycoprotein expression using the 
Image Pro Plus 5.0 software package (see Materials and Methods). Error bars shown 
represent the standard deviations calculated through comparison of the data from each of 
three experiments.
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mutant forms in group I (CL1-CL6 and T1247) resulted in high levels of cell-surface 
expression (78-95% of the wild-type S);  however, the average size of syncytial formed 
by these mutated S glycoproteins was reduced substantially in comparison to the wild-
type S (23-48% of the wild-type). CL1 affects the predicted fusion peptide, CL2-CL4 
affect the HR1 domain, and CL5 affects a region downstream of the HR1 domain. The 
CL6 mutation is located within the S carboxyl terminal acidic cluster. The T1247 
mutation truncates the S carboxyl terminus by 8 amino acids; 2) S mutant forms in group 
II produced high levels of S cell-surface expression and an average size of syncytia 
slightly smaller than that of the wild-type S. These mutations included CL7, which 
modified the acidic cluster and the T1229 truncations that deleted the cysteine-rich motif 
CRM2; 3) The single S mutant in group III, T1214, produced significantly less cell-
surface expression and concomitantly the average size of syncytia was substantially 
reduced in comparison to the wild type S; 4) The T1238 truncation in group IV produced 
high levels of cell surface expression equivalent to that of the wild-type (94% of the wild-
type S), while the average syncytium size was 43% larger than that the syncytial 
produced by the wild-type S (Table 2.1).  
Detection of the Intracellular Distribution of S Mutant Glycoproteins Via Confocal 
Microscopy 
 
 To visualize the intracellular distribution of S mutant glycoproteins, cells were 
transfected with plasmids encoding the wild type or S mutants and examined by confocal 
microscopy at 48 h post transfection (Fig. 2.6). The wild type and all the S mutants were 
detected throughout the cytoplasm of transfected cells and exhibited similar intracellular 
distribution patterns (Fig. 2.6, panels B, D, F, H, J, L). To determine and compare the 
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Figure 2.6.  Confocal microscopic visualization of endocytosed and intracellular 
distribution of SARS-CoV S glycoprotein mutants.  Vero cells expressing wild-type 
SARS-CoV S glycoprotein (3xFLAG So (WT)) (A and B), CL6 (C and D), CL7 (E and 
F), T1229 (G and H), T1238 (I and J) and T1247 (K and L) were processed for confocal 
microscopy using two different methods in order to assess different properties of the 
mutants.  Endocytosis patterns (A,C,E,G,I, and K) were visualized by adding anti-FLAG 
(green) antibody into the media 12 h prior to processing, enabling detection of the mutant 
protein after endocytosis from cellular surfaces. Early endosomes were also detected for 
these panels using a polyclonal anti-early endosomal antigen I antibody (red).  For total 
glycoprotein detection (B, D, F, H, J, and L), cells were fixed and permeabilized prior to 
labeling with anti-FLAG (green).  
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endocytotic profiles of wild-type and S mutant forms, transfected cells were reacted with 
the anti-FLAG antibody under live conditions for 12 hours at 37ºC and visualized by 
confocal microscopy.  The majority of the wild-type S detected by the anti- FLAG 
antibody appeared to remain on cell surfaces (Fig. 2.6, panel A). In contrast, a significant 
fraction of cell-surface expressed CL6 and CL7 as well as the T1229, T1238 and T1247 S 
mutants appeared to partially endocytose to cytoplasmic compartments (Fig. 2.6, panels 
C, E, G, I, K). The CL7 mutant, but not the other S mutants, appeared to colocalize with 
the early endosomal marker EEA-1 (Fig. 2.6, panel E). The S mutants CL1, CL2, CL3, 
CL4, and CL5 remained in plasma membranes exhibiting profiles similar to that of the S 
wild-type glycoprotein (data not shown).   
Time-dependent Endocytotic Profiles of Wild-type and Mutant S Proteins   
 A time-dependent endocytosis assay was utilized to better visualize the endocytotic 
patterns of the wild-type and mutant S glycoproteins as well as to exclude the possibility 
that the observed plasma membrane accumulation of the wild-type S and some of the S 
mutants was due to recirculation of endocytosed S to cell-surfaces. In this assay, cell-
surface expressed S was reacted with anti-FLAG antibody at 4°C and subsequently, cells 
were incubated at 37°C for different time periods before processing for confocal 
microscopy (see Materials and Methods). Generally, these time-dependent endocytosis 
studies were in agreement with the results shown in Figure 2.6.  Specifically, in cells that 
were not shifted to 37ºC, referred to as time zero cells, wild type and mutant spike were 
detected exclusively at the surface of the cells (Fig. 2.7, panels A1, B1, C1, D1, E1, F1).  
At five and fifteen minutes after the shift to 37ºC, the wild-type S remained exclusively at 
the surface while the other S mutants were detected in numerous intracellular vesicles 
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Figure 2.7.  Analysis of the endocytotic kinetic profile of the truncation mutants and 
the acidic cluster mutants using confocal microscopy.  After transfection, SARS-CoV 
S glycoprotein wild-type (3xFLAG So (WT)) (A1-A4), T1229 (B1-B4), T1238 (C1-C4), 
T1247 (D1-D4), CL6 (E1-E4), and CL7 (F1-F4) expressing cells were incubated with an 
anti-FLAG monoclonal antibody (green) for 1 hr and then returned to 37ºC for different 
times. Cell nuclei were labeled with To-Pro-3 Iodide (blue).  Panels A1-A4, B1-B4, C1-
C4, D1-D4, E1-E4, and F1-F4 correspond to 0-, 5-, 15-, and 60-min incubation times at 
37ºC, respectively.   
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dispersed inside the cell (Fig. 2.7, panels A2 and A3 compared to panels B2 and B3, C2 
and C3, D2 and D3, E2 and E3, F2 and F3).  By sixty minutes after the shift to 37ºC, the 
wild type S was still localized exclusively to the surface of the cell (Fig. 2.7, panel A4), 
while the T1229, T1238, CL6 and CL7 S mutants appeared to be present throughout the 
cytoplasm of the cell (Fig. 2.7, panels B4, C4, E4, F4). The T1247 S mutant seemed to 
undergo rapid and complete endocytosis during the 60 min observation and appeared to 
localize into punctuate structures in the cytoplasm of cells unlike the fairly even cellular 
distribution of all other S mutants (Fig. 2.7, panels D1-D4 compared A4, B4, C4, D4, E4, 
F4).   
DISCUSSION 
 The mechanism by which class I fusion proteins such as the coronavirus S 
glycoprotein, the hemagglutinin protein (HA) of influenza virus, the gp41 of human 
immunodeficiency virus (HIV), the Ebola virus surface glycoprotein (GP), and the fusion 
protein (F) of paramyxovirus facilitate membrane fusion during viral entry into cells has 
been extensively investigated (Eckert and Kim, 2001; Hernandez et al., 1996; Tsai et al., 
2003; White, 1992; Zelus et al., 2003). Currently, specific membrane fusion models have 
been proposed all of which include the following general steps: a) binding of a receptor 
through a receptor specific domain located within the ectodomain of the viral 
glycoprotein; b) induction of a conformational change via low pH or binding to the 
receptor that exposes a fusion peptide, typically a hydrophobic region in the membrane 
anchored subunit, which inserts into the cellular lipid membrane; c) formation of a 
trimer-of-hairpins like structure by α-helical peptides, termed heptad repeat segments, via 
a transient pre-hairpin intermediate that facilitates the juxtaposition of the viral and 
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cellular membranes which then leads to fusion of the viral envelope with cellular 
membranes (reviewed in (Eckert and Kim, 2001; Hernandez et al., 1996)). Although the 
most important domains of the class I fusion proteins are naturally located in their 
ectodomains, it has been reported that intracytoplasmic endodomains play an important 
role in intracellular transport and virus-induced cell fusion  (Bagai and Lamb, 1996; Bos 
et al., 1995; Chang, Sheng, and Gombold, 2000; Lontok, Corse, and Machamer, 2004; 
Schwegmann-Wessels et al., 2004; Sergel and Morrison, 1995; Seth, Vincent, and 
Compans, 2003; Tong et al., 2002; Waning et al., 2004; Yao and Compans, 1995).  
 In this paper, we show that mutations that alter the HR1 and predicted fusion 
peptide domains of the SARS-CoV S glycoprotein as well as mutations located within α-
helical regions well separated from the HR1, HR2 and predicted fusion peptide domains 
drastically affected S-mediated cell fusion. Importantly, mutagenesis of the S cytoplasmic 
domains suggests that the carboxyl terminus of the S glycoprotein contains multiple but 
distinct regulatory domains that may function in virus-induced cell fusion through 
different mechanisms.  
Functional Domains of the S Ectodomain  
 The CL1 cluster mutation is located within the predicted fusion peptide. The 
constructed cluster mutations replaced the amino terminal a and d positions of the 
predicted fusion peptide resulting in shortening the predicted α-helical portion of the 
fusion peptide. The S mutant glycoprotein carrying the CL1 mutation was apparently 
synthesized in comparable levels to the wild type S glycoprotein. As expected, although 
this mutant S form was able to be expressed on cell surfaces (95% of wild-type S levels), 
its ability to cause cell fusion was inhibited by more than 70% (Table 1; Group I 
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mutants). This result confirms that the predicted fusion peptide it absolutely essential for 
S mediated cell fusion, although the engineered collapse of the predicted region does not 
significantly effect glycoprotein synthesis, processing, and cell-surface expression. 
 Recent studies have shown that interactions between HR1 and HR2 of SARS-CoV 
are critical in producing the necessary conformation changes that result in exposure of the 
fusion peptide and its insertion into apposed membranes (Ingallinella et al., 2004; Tripet 
et al., 2004; Xu et al., 2004). Biochemical and x-ray crystallography studies have shown 
that the HR1 and HR2 form a stable six-helix bundle, in which the HR1 helices form a 
central coiled-coil surrounded by three HR2 helices in an oblique, antiparallel manner 
termed the fusion core (Ingallinella et al., 2004; Tripet et al., 2004; Xu et al., 2004), 
which is consistent with other class I fusion proteins (Baker et al., 1999; Bullough et al., 
1994; Caffrey et al., 1998; Chan et al., 1997; Lu, Blacklow, and Kim, 1995; Tan et al., 
1997; Weissenhorn et al., 1998a; Weissenhorn et al., 1998b; Weissenhorn et al., 1997).  
Amino acid residues 902-947 in the SARS-CoV S HR1 domain fold into a predicted 12-
turn α-helix (entire length of the fusion core) with hydrophobic amino acids 
predominantly occupying the a and d positions. The CL3 and CL4 mutations were 
designed to change the a and d hydrophobic residues to hydrophilic (lysine) residues. 
Both mutant glycoproteins were expressed on cell surfaces at reduced levels in 
comparison to the wild-type S glycoprotein (14% and 20% reduction, respectively). 
However, these mutations inhibited S-mediated fusion by 68% and 71%, respectively 
(Table 1; Group I mutants). Therefore, the inability of the CL3 and CL4 mutants to cause 
fusion is most likely due to ectodomain structural changes involving the HR1 domain. 
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Inhibition of proper HR1 interaction with HR2 may be the primary cause of the observed 
inhibition of S-mediated cell fusion. 
 The CL2 and CL5 cluster mutations are located upstream and downstream of HR1 
within a predicted α-helical portion of the S ectodomain extending from residues 875 to 
1014. Both CL2 and CL5 S mutant forms exhibited reduced S-mediated cell fusion (75% 
and 76% reduction in comparison to the S wild-type, respectively), while they were 
synthesized and expressed on cell-surfaces at levels similar to the S wild-type (Table 1; 
Group I mutants). These data suggest that the inability of these S mutants to cause 
extensive cell fusion was mostly due to structural alterations of the extracellular portion 
of the S glycoprotein. Furthermore, these results suggest that α-helical portions of the S 
ectodomain that are well-separated from HR1 and HR2 or the predicted fusion peptide 
are important for S-mediated cell fusion. It is possible that these mutations affect HR1 
interactions with HR2 by inhibiting ectodomain conformational changes required for 
their optimal interactions. Specifically, the CL2 mutation is only 16 amino acids 
downstream of the predicted fusion peptide. Therefore, this mutation may interfere with 
fusion peptide-associated functions  
Functional Domains of the Endodomain of S  
 The T1247 S mutation deletes 8 amino acids from the carboxyl terminus of S.  This 
S mutant exhibited a 65% reduction in cell fusion in comparison to the wild-type S, while 
cell-surface expression was reduced by 20% in comparison to the wild type S (Table 1; 
Group I mutants).  Kinetic endocytosis experiments revealed that the T1247 S mutant 
also endocytosed much faster than the wild-type S glycoprotein. Acidic cluster motifs are 
known to serve as endocytotic signals (Brideau et al., 1999; Zhu et al., 1996). The rapid 
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endocytosis of the T1247 S mutant form may be due to the relocation of the acidic cluster 
KFDEDDSE proximal to the carboxyl terminus of the S glycoprotein after removal of the 
terminal 8 amino acids resulting in more efficient endocytosis. Therefore, the inability of 
the S mutant form to cause extensive cell fusion may be due primarily  to its rapid 
endocytosis from cell surfaces. It is worth noting that a similar deletion of 8 amino acids 
from the carboxyl terminus of the MHV S glycoprotein resulted in enhanced S-mediated 
cell fusion (Chang, Sheng, and Gombold, 2000).  A comparison of the carboxyl terminal 
amino acid sequences of these two glycoproteins reveals that the MHV S does not have a 
well-defined acidic cluster in the SARS-COV S homologous location; however, the last 
three amino acids of the MHV S are charged residues (HED). Therefore, the ability of the 
truncated MHV S to cause more cell fusion may be due to increased surface retention 
resulting from a reduction in endocytosis mediated by these charged residues. 
Alternatively, the MHV deletion may cause structural changes that enhance the MHV S 
fusogenicity by destabilizing the overall structure of the glycoprotein. Stabilization of the 
carboxyl terminus has been shown to decrease the fusion activity of the vesicular 
stomatitis virus G glycoprotein (Waning et al., 2004), therefore, conversely, it is possible 
that destabilization of the carboxyl terminus may cause an increase in fusion.    
 Of particular interest is the T1238 truncation which removed the S carboxyl 
terminal acidic domain. This S mutant glycoprotein exhibited a more than 40% increase 
in cell fusion relative to the S wild type, while there was only a slight decrease in cell-
surface expression (Table 1; Group IV mutants). The fact that the overall levels of S 
glycoprotein detected on cell surfaces as well as the endocytosis profile were not altered 
suggests that this deletion may enhance fusion via a structural destabilization of the 
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glycoprotein. In contrast, changing acidic amino acids of the acidic motif to alanine 
residues inhibited cell fusion indicating that the acidic motif was important for S-
mediated cell fusion. Specifically, the CL6 cluster mutation changed the acidic residues 
(DEDDSE) to alanine residues (AAAASA).  This mutant protein, while being efficiently 
expressed at cellular surfaces (87% of the wild type protein), exhibited a 51% reduction 
in fusion activity in comparison to the wild type (Table 1; group I mutant).  The observed 
reduction in S-mediated cell fusion suggests that the acidic cluster plays an important 
regulatory role in S-mediated cell fusion without appreciably affecting intracellular 
transport and cell-surface expression.  This result is in sharp contrast to the T1238 
truncation that deleted the acidic cluster and caused enhanced S-mediated cell fusion. A 
possible explanation for these seemingly disparate results is that modifications of the 
carboxyl terminus produce differential effects on the structure and function of the protein 
by rendering the S glycoprotein more or less prone to S-mediated fusion. Alternatively, it 
is possible that the acidic cluster plays important roles only in the context of the entire S 
glycoprotein by regulating binding to other viral or cellular proteins that may modify the 
S fusogenic properties.  
  The acidic cluster located in the cytoplasmic portion of the SARS CoV S contains a 
predicted phosphorylation site (DEDDSE). To address the role of this predicted 
phosphorylation site within the acidic cluster, the CL7 cluster mutation was constructed. 
The CL7 replaces the serine residue with an alanine residue within the acidic cluster.  
This mutant S protein fused cells extensively (85% of the wild type) and was expressed 
on cell-surfaces at levels similar to that of the wild type S (88% of the wild type) (Table 
1; Group II mutants), suggesting that the potential phosphorylation site does not play an 
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important role in S-mediated cell fusion and cell-surface expression. However, the CL7 
mutant appeared to recycle to early endosomes in contrast to the wild type S, which 
remained mostly on cell surfaces. Therefore, it is possible that the altered putative 
phosphorylation site within the acidic cluster may play a yet unknown role in S retention 
at cell surfaces. Conversely, lack of this signal may cause aberrant endocytosis to early 
endosomes. The overall charge of the carboxyl terminus may also play some role in the 
structure and function of S. In this regard, there are additional charged amino acids 
dispersed upstream and downstream of the mutated charged cluster that may play some 
role in S transport and S-mediated fusion through electrostatic interactions with other 
viral and cellular proteins. Additional alanine scanning mutations would be needed to 
resolve their potential contribution to S functions. 
 In contrast to the MHV S glycoprotein, in which the domains overlap, the charged 
region of the SARS-CoV S glycoprotein and the two cysteine-rich motifs CRM1 and 
CRM2 are separate distinct regions (Fig 2.8). The T1229 mutation deleted the CRM2 
domain, while the T1214 truncation deleted both CRM1 and CRM2. Deletion of the 
CRM2 slightly inhibited surface expression (91% of the wild type) while reducing fusion 
activity by 22% (Table 1; Group II mutants). A similar truncation of the MHV S 
glycoprotein produced a comparable effect on cell fusion (Chang, Sheng, and Gombold, 
2000). The 1214 truncation severely inhibited cell surface expression by 77%, when 
compared to the wild type, while cell-to-cell fusion activity was reduced by 84% (Table 
1; Group III mutant).  These results differ from previously published data on similar 
truncations of the MHV S glycoprotein.  Specifically, it was found that the replacement 
of the entire cysteine rich domain with amino acid sequences derived from the 
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Figure 2.8.  Cluster alignment of the carboxyl terminus of the SARS-CoV S and the 
MHV S glycoproteins. The shaded residues indicate the position of the cysteine rich 
motif in their respective protein.  The cysteine residues are bolded. The charged clusters 
are indicated by a bracket over the corresponding regions.
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cytoplasmic terminus of the herpes simplex virus 1 (HSV-1) glycoprotein D (gD) 
severely inhibited MHV S glycoprotein function without necessarily affecting cell-
surface expression (Chang, Sheng, and Gombold, 2000; Ye, Montalto-Morrison, and 
Masters, 2004). In contrast, the SARS-CoV S T1214 mutant glycoprotein failed to be 
expressed on cell surfaces explaining the inability of this glycoprotein to cause cell 
fusion. These results suggest that the proximal cysteine residues of the SARS CoV S play 
crucial roles in intracellular transport and cell-surface expression. The discrepancy with 
the MHV S carboxyl terminal replacements may be due to additional gD sequences that 
facilitated intracellular transport and cell-surface expression. It is worth noting that 
depending on the algorithm used to predict the membrane spanning domain of S, a few of 
the cysteine residues may be included in the membrane spanning region (Chang, Sheng, 
and Gombold, 2000; Ye, Montalto-Morrison, and Masters, 2004).  Therefore, it is 
possible that deletion of these cysteine residues may lead to S misincorporation into 
membranes, resulting in the apparent transport defects.   
 Overall, these results suggest that the S-mediated cell fusion is regulated by both 
the ecto- and endodomains, which play important roles in cell-surface expression. 
Furthermore, the data suggest that the 17 carboxyl terminal amino acid residues of S 
exert a negative regulatory (repressor) effect on S-mediated cell fusion, while both the 
carboxyl terminal acidic cluster and CRM2 domains exert secondary regulatory roles in 
S-mediated cell fusion. Additional studies are required to elucidate the specific amino 
acid requirements of the S endodomain that can affect S-mediated cell fusion potentially 
via a transmembrane signal transduction process that leads to destabilization of the S 
ectodomain.  
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MATERIALS AND METHODS 
Cells   
 African green monkey kidney (Vero) cells were obtained from the American Type 
Culture Collection (Rockville, Md.). Cells were propagated and maintained in Dulbecco 
modified Eagle medium (Sigma Chemical Co., St. Louis, Mo.) containing sodium 
bicarbonate and 15 mM HEPES supplemented with 10% heat-inactivated fetal bovine 
serum. 
Plasmids  
 The parental plasmid used in the present study, SARS-S-Optimized, has been 
previously described (Li et al., 2003).  The Spike-3XFLAG-N gene construct was 
generated by cloning the codon-optimized S gene, without the DNA sequence coding for 
the signal peptide, into the p3XFLAG-CMV-9 plasmid vector (Sigma). PCR overlap 
extension (Aiyar, Xiang, and Leis, 1996) was used to construct the alanine mutants, 
cluster mutants, and the single point mutants.  In order to construct the truncation 
mutants, primers were designed that incorporated a stop codon and a BamHI restriction 
site at the appropriate gene site.  Restriction endonuclease sites HindIII and BamHI were 
then used to clone the gene construct into the Spike-3XFLAG-N plasmid.   
 The constructed cluster mutants targeting the S ectodomain changed the following 
sets of amino acids to lysine residues: CL:1 Y(855), L(859), G(862); CL2: L(898), N 
(901); CL3: L(927), L(930), V(934); CL4: L(941), L(944); CL5: L(983), L(986).  The 
cluster mutants targeting the S endodomain changed the following amino acids to alanine 
residues: CL6: D(1239), E(1240), D(1241), D(1242), E(1244);  CL7: S(1243) (Figs. 2.1B 
and 2.1C).    
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Production of SARS-CoV S Monoclonal Antibodies   
The monoclonal antibodies SW-111 was raised against the Spike envelope 
glycoprotein of the SARS virus. A synthetic, codon-optimized gene corresponding to 
SAR-CoV S glycoprotein coding sequences (Li et al., 2003) was engineered to produce 
truncated, secreted proteins containing C-terminal His-tags which encode either the entire 
ectodomain or just the receptor binding domain of S1.  These genes were cloned into 
baculoviral vectors, and the resulting virus was used to infect insect cell lines (High Five) 
(Invitrogen, Carlsbad, CA).  The supernatants were then tested by western blotting using 
anti-6-His antibodies. Protein was partially purified from supernatants by passage 
through a nickel column and then concentrated by ultrafiltration.  Additional protein 
derived in an analogous fashion was provided by the laboratory of Stephen Harrison. 
Standard protocols for mouse immunization were used. The animals were maintained in 
the animal facility of Dana-Farber Cancer Institute, and hybridomas and monoclonal 
antibodies were produced in the Dana Farber/Harvard Cancer Center Monoclonal 
Antibody Core. Spleenocytes from immunogenized mice were fused with NS-1 myeloma 
cells (ATCC) using standard protocols.  Antibody-producing clones were identified by 
Western blot analysis, using purified SARS-CoV S.  The positive cells were then sub-
cloned and re-tested against the purified SARS-CoV S glycoprotein.  Isotype analysis 
revealed that the antibody belonged to the IgG-1 class.     
Western Blot and S Oligomerization Analysis   
 Vero cell monolayers in six-well plates were transfected with the indicated plasmids 
utilizing the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s 
directions.  At 48 hours (h) post transfection, cells were collected by low-speed 
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centrifugation, washed with Tris-buffered saline (TBS), and lysed at on ice for 15 min in 
mammalian protein extraction reagent supplemented with a cocktail of protease inhibitors 
(Invitrogen/Life Technologies). Insoluble cell debris was pelleted, samples were 
electrophoretically separated by SDS-PAGE, transferred to nitrocellulose membranes, 
and probed with anti-SARS CoV monoclonal antibody at a 1:10 dilution.  Samples being 
analyzed for transport and processing were boiled for 5 min and treated with beta 
mercaptoethanol, while samples being analyzed for trimer formation were not.  
Subsequently, blots were incubated for 1 h with a peroxidase-conjugated secondary 
antibody at a 1:50,000 dilution and then visualized on X-ray film by chemiluminescence 
(Pierce Chemicals, Rockford, Ill.). All antibody dilutions and buffer washes were 
performed in TBS supplemented with 0.135 M CaCl2 and 0.11 M MgCl2 (TBS-Ca/Mg). 
Cell Surface Immunohistochemistry  
 Vero cell monolayers in six-well plates were transfected with the indicated plasmids 
utilizing the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s 
directions. At 48 h post transfection, the cells were washed with TBS-Ca/Mg and either 
fixed with iced cold methanol or left unfixed (live). Immunohistochemistry was 
performed by utilizing the Vector Laboratories Vectastain Elite ABC kit (Vector 
Laboratories, Burlingame, CA) essentially as described in the manufacturer’s directions. 
Briefly, cells were washed with TBS-Ca/Mg and incubated in TBS supplemented with 
5% normal horse serum and 5% bovine serum albumin at room temperature for 1 h. After 
blocking, cells were reacted with anti-FLAG antibody (1:500) in TBS blocking buffer for 
3 h, washed four times with TBS-Ca/Mg, and incubated with biotinylated horse anti-
mouse antibody. Excess antibody was removed by four washes with TBS-Ca/Mg and 
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subsequently incubated with Vectastain Elite ABC reagent for 30 min. Finally, cells were 
washed three times with TBS-Ca/Mg, and reactions were developed with NovaRed 
substrate (Vector Laboratories) according to the manufacturer’s directions. 
Determination of Cell-surface to Total Cell S Glycoprotein Expression   
 Vero cell monolayers in six-well plates were transfected with the indicated plasmids 
and processed for immunohistochemistry as described above with the exception that the 
ABTS Substrate Kit , 2, 2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (Vector 
Laboratories) was used instead of the NovaRed substrate. After the substrate was allowed 
to develop for 30 min, 100 μl of the developed substrate was transferred, in triplicate, to a 
96 well plate. The samples were then analyzed for color change at a wavelength of 405 
nm. The absorbance reading from cell-surface labeling experiments obtained from live 
cells were divided by the total labeled absorbance readings obtained from fixed cells 
which was then normalized to the wild type protein values.  The measurements were then 
converted to percentages reflecting the ratio of S present on cell-surfaces versus the total 
S expressed in the transfected cells.   
Confocal Microscopy  
 Vero cell monolayers grown on coverslips in six-well plates were transfected with 
the indicated plasmids utilizing the Lipofectamine 2000 reagent (Invitrogen) according to 
the manufacturer’s directions.  For the endocytosis analysis of the mutants, anti-FLAG 
diluted 1:500 in TBS supplemented with 5% normal goat serum and 5% bovine serum 
albumin (TBS blocking buffer) was added to the cell culture media for 12 hours before 
processing. At 48 h post transfection, cells were washed with TBS and fixed with 
electron microscopy-grade 3% paraformaldehyde (Electron Microscopy Sciences, Fort 
 118
Washington, Pa.) for 15 min, washed twice with TBS-Ca/Mg, and permeabilized with 
0.1% Triton X-100. Monolayers were blocked for 1 hour with TBS blocking buffer 
before incubation for 3 h with anti-FLAG antibody (sigma) diluted 1:500 in TBS 
blocking buffer. Cells were then washed extensively and subsequently incubated for 1 h 
with Alexafluor 488-conjugated anti-immunoglobulin G (IgG) (Molecular Probes) 
diluted 1:750 in TBS blocking buffer.  To visualize the early endosomes, cells were 
stained with a 1:500 dilution of anti-early endosomal antigen I antibody (Affinity 
Bioreagents Inc). Cells were examined by using a Leica TCS SP2 laser-scanning 
microscope (Leica Microsystems, Exton, Pa.) fitted with a 63x Leica objective lens 
(Planachromatic; 1.4 numerical aperture). Individual optical sections in the z axis, 
averaged eight times, were collected simultaneously in the different channels at a 512 x 
512 pixel resolution as described previously (Foster et al., 2004; Lee et al., 2000). Images 
were compiled and rendered in Adobe Photoshop. 
S Glycoprotein Endocytosis Assay   
 Vero cell monolayers grown on coverslips in six-well plates were transfected with 
the indicated plasmids utilizing the Lipofectamine 2000 reagent (Invitrogen) according to 
the manufacturer’s directions.  At 48 hours posttransfection, the cells were washed once 
with room temperature TBS-Ca/Mg.  The plates were then moved to a 4ºC cold room and 
washed with 4ºC TBS-Ca/Mg.  The cells were labeled for 1 hour at 4°C with anti-FLAG 
antibody diluted 1:500 in TBS blocking buffer. The cells were washed with 4ºC  TBS 
three times and then brought back to 37°C and allowed to incubate for their respective 
time points.  Then, the cells were immediately fixed and permeabilized with ice cold 
methanol.  Monolayers were blocked for 2 hrs in TBS blocking buffer before incubation 
 119
for 1 h with Alexafluor 488-conjugated anti-immunoglobulin G (IgG) (Molecular Probes) 
diluted 1:750 in TBS-Ca/Mg blocking buffer.  After incubation, excess antibody was 
removed by washing five times with TBS-Ca/Mg. The nuclei was counterstained for 15 
min with TO-PRO-3 iodide (1:5,000 dilution) and visualized at 647 nm. Cells were 
examined by using a Leica TCS SP2 laser-scanning microscope (Leica Microsystems, 
Exton, Pa.) fitted with a 63x Leica objective lens (Planachromatic; 1.4 numerical 
aperature). Individual optical sections in the z axis, averaged eight times, were collected 
simultaneously in the different channels at 512 x 512 pixel resolution as described 
previously (Foster et al., 2004; Lee et al., 2000). Images were compiled and rendered in 
Adobe Photoshop. 
Quantitation of the Extent of S-mediated Cell Fusion   
Vero cell monolayers in six-well plates were transfected in triplicate with the indicated 
plasmids utilizing the Lipofectamine 2000 reagent (Invitrogen) according to the 
manufacturer’s directions. Concurrently, Vero cell monolayers in six-well plates were 
transfected with the plasmid encoding the ACE2 receptor protein utilizing the 
Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s directions.  At 
24 h post transfection, cells containing the mutant plasmids, the ACE2 receptor, and 
normal untransfected cells were washed with TBS-Ca/Mg, trypsinized, and overlayed in 
a single well of a six-well plate at a ratio of 2 ml (cells transfected with the ACE2 
receptor) : 0.5 ml (cells transfected with the mutant) : 1.5 ml (untransfected cells). All of 
the cells transfected with ACE2 were pooled to ensure that every well had an equal 
amount of cells with receptor expressed on their surface.  After incubation for 24 h, the 
cells were washed with TBS-Ca/Mg and fixed with ice cold methanol. 
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Immunohistochemistry was performed by utilizing the Vector Laboratories Vectastain 
Elite ABC kit essentially as described in the manufacturer’s directions. Briefly, cells were 
washed with TBS-Ca/Mg and incubated in TBS blocking buffer supplemented with 
normal horse serum at room temperature for 1 h. After blocking, cells were reacted with 
anti-FLAG antibody (1:500) in TBS blocking buffer for 3 h, washed four times with 
TBS-Ca/Mg, and incubated with biotinylated horse anti-mouse antibody. Excess antibody 
was removed by four washes with TBS-Ca/Mg and subsequently incubated with 
Vectastain Elite ABC reagent for 30 min. Finally, cells were washed three times with 
TBS-Ca/Mg, and reactions were developed with NovaRed substrate (Vector 
Laboratories) according to the manufacturer’s directions. The average size of syncytia for 
each mutant was determined by analyzing the area of approximately 300 syncytia, from 
digital images, using the Image Pro Plus 5.0 software package.  The averages were then 
converted to percentages of the average syncytia size of the wild type SARS-CoV S.  
Error bars shown represent the standard deviations calculated through comparison of the 
data from each of three experiments. 
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CHAPTER III 
GENETIC ANALYSIS OF THE CYSTEINE RICH DOMAINS IN THE 
CARBOXYL TERMINUS OF THE SARS-COV SPIKE GLYCOPROTEIN 
 
INTRODUCTION 
An outbreak of atypical pneumonia, termed severe acute respiratory syndrome 
(SARS), appeared in the Guangdong Province of southern China in November, 2002. The 
mortality rates of the disease reached as high as 15% in some age groups (Anand et al., 
2003). The etiological agent of the disease was found to be a novel coronavirus (SARS-
CoV), which was first isolated from infected individuals by propagation of the virus on 
Vero E6 cells (Drosten et al., 2003; Ksiazek et al., 2003; Peiris et al., 2003). Analysis of 
the viral genome has demonstrated that the SARS-CoV is phylogenetically divergent 
from the three known antigenic groups of coronaviruses (Drosten et al., 2003; Ksiazek et 
al., 2003). Analysis of the polymerase gene alone, however, has indicated that the SARS-
CoV may be an early off-shoot from the group 2 coronaviruses (Snijder et al., 2003). 
The coronaviruses are the largest of the enveloped RNA viruses with a positive-
stranded RNA genome of 28 to 32 kb (Holmes, 2003). Coronaviruses possess a wide host 
range, capable of infecting mammalian and avian species. All identified coronaviruses 
have a common group of indispensable genes that encode nonstructural proteins 
including the RNA replicase gene open reading frame (ORF) 1ab and the structural 
proteins nucleocapsid (N), membrane protein (M), envelope protein (E), and spike 
glycoprotein (S), which are assembled into virus particles. A hemagglutinin-esterase 
(HE) protein is also encoded by some coronaviruses. Distributed among the major viral 
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genes are a series of ORFs that are specific to the different coronavirus groups. Functions 
of the majority of these ORFs have not been determined. 
The SARS spike glycoprotein, a 1255-amino-acid type I membrane glycoprotein 
(Rota et al., 2003), is the major protein present in the viral membrane forming the typical 
spike structure found on all coronavirions. The S glycoprotein facilitates virion entry of 
all coronaviruses into susceptible cells by binding to specific receptors on cells and 
mediating  virus-cell fusion (Cavanagh, 1995). The S glycoprotein specified by mouse 
hepatitis virus (MHV) is cleaved into S1 and S2 subunits, although cleavage is not 
necessary for virus-cell fusion (Bos, Luytjes, and Spaan, 1997; Gombold, Hingley, and 
Weiss, 1993; Stauber, Pfleiderera, and Siddell, 1993). Similarly, the SARS-CoV S 
glycoprotein seems to be cleaved into S1 and S2 subunits in VeroE6-infected cells (Wu et 
al., 2004), while it is not known whether this cleavage affects S-mediated cell fusion. The 
SARS-CoV receptor has been recently identified as the angiotensin-converting enzyme 2 
(ACE2) (Li et al., 2003). Although the exact mechanism by which the SARS-CoV enters 
the host cell has not been elucidated, it is most likely similar to other coronaviruses.  
Upon receptor binding at the cell membrane, the S glycoprotein is thought to undergo a 
dramatic conformational change causing exposure of a hydrophobic fusion peptide, 
which is subsequently inserted into cellular membranes. This conformational change of 
the S glycoprotein causes close apposition followed by fusion of the viral and cellular 
membranes resulting in entry of the virion nucleocapsids into cells (Eckert and Kim, 
2001; Tsai et al., 2003; Zelus et al., 2003). This series of S-mediated virus entry events is 
similar to other class I virus fusion proteins (Baker et al., 1999; Melikyan et al., 2000; 
Russell, Jardetzky, and Lamb, 2001). 
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Heptad repeat (HR) regions, a sequence motif characteristic of coiled-coils, 
appear to be a common motif in many viral and cellular fusion proteins (Skehel and 
Wiley, 1998). These coiled-coil regions allow the protein to fold back upon itself as a 
prerequisite step to initiating the membrane fusion event. There are usually two HR 
regions: an N terminal HR region adjacent to the fusion peptide and a C-terminal HR 
region close to the transmembrane region of the protein. Within the HR segments, the 
first amino acid (a) and fourth amino acid (d) are typically hydrophobic amino acids that 
play a vital role in maintaining coiled-coil interactions. Based on structural similarities, 
two classes of viral fusion proteins have been established. Class I viral fusion proteins 
contain two heptad repeat regions and an N- terminal or N-proximal fusion peptide. Class 
II viral fusion proteins lack heptad repeat regions and contain an internal fusion peptide 
(Lescar et al., 2001). The MHV S glycoprotein, which is similar to other coronavirus S 
glycoproteins, is a class I membrane protein that is transported to the plasma membrane 
after being synthesized in the endoplasmic reticulum (Bosch et al., 2003). Typically, the 
ectodomains of the S2 subunits of coronaviruses contain two regions with a 4, 3 
hydrophobic (heptad) repeat the first being adjacent to the fusion peptide and the other 
being in close proximity to the transmembrane region (de Groot et al., 1987).  
 In addition, the SARS-CoV S glycoprotein has a high (3%) cysteine content (39 
residues.  Nine of the cysteine resides are concentrated in a domain that spans the 
transmembrane region and the cytoplasmic domain, with six of these residues extremely 
well conserved throughout all coronaviruses (Fig 3.1).  This unusual concentration of 
cysteine residues along with the conservation of the residues among all coronaviruses  
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Figure 3.1. Alignment of the membrane spanning domain and endodomain of the 
spike glycoprotein from ten different coronaviruses (Abraham et al., 1990; Binns et 
al., 1985; Delmas et al., 1992; Kunkel and Herrler, 1993; Luytjes et al., 1987; Marra et 
al., 2003; Mounir and Talbot, 1993; Parker, Gallagher, and Buchmeier, 1989; Raabe, 
Schelle-Prinz, and Siddell, 1990; Rasschaert and Laude, 1987).  A schematic diagram of 
the SARS-CoV S protein is shown on top from amino acid 1 to amino acid 1255.  A 
vertical line demarcates the approximate location of the division between the S1 and S2 
subunits of the protein.  The carboxyl terminus (amino acids 1193 to 1255) of the SARS-
CoV S glycoprotein is shown enlarged below and is aligned with the same region of the S 
glycoprotein from nine other coronaviruses.  Viruses from antigenic group I (feline 
infectious peritonitis virus [FIPV], transmissible gastroenteritis virus [TGEV], human 
coronavirus 229E [HCoV-229E]), antigenic group II (three different mouse hepatitis 
virus strains [A59, JHM, and MHV2], bovine coronavirus [BCoV], and human 
coronavirus OC43 [HCoV-OC43]), and antigenic group III (infectious bronchitis virus 
[IBV]) are represented in the alignment.  The membrane spanning domain and the 
cytoplasmic tail are denoted with arrows above the alignment.  Residues conserved in at 
least eight of the ten coronaviruses represented are indicated by the shaded residues.  
Cysteines that are highly conserved throughout all of the S proteins are noted by 
asterisks. 
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suggest that these residues play an important role in S glycoprotein function although this 
exact role is largely unknown.  For MHV, studies have shown that the cysteine rich 
domain is required for coronavirus-induced membrane fusion.  Substituting the 
cytoplasmic portion of this cysteine rich region and the cytoplasmic tail with the 
cytoplasmic tail of the VSV-G protein abolished MHV S glycoprotein mediated cell-cell 
fusion (Bos et al., 1995).  Also,  it was shown that while not being the sole functional 
domain of the transmembrane anchor required for fusion activity, it was necessary for 
fusion activity (Chang, Sheng, and Gombold, 2000). 
 In this study, cluster to alanine mutagenesis was used to elucidate which cysteine 
clusters were dispensable for protein transport and SARS-CoV S mediated cell-cell 
fusion.  The results indicate that the SARS-CoV S glycoprotein conforms to the general 
structure and function relationships that have been elucidated for the cysteine rich 
domains of other coronaviruses, most notably the MHV (Bos et al., 1995; Chang, Sheng, 
and Gombold, 2000).  Specifically, the results show that the cysteine residues proximal to 
the membrane are required for S-mediated fusion. 
RESULTS 
Genetic Analysis of S Glycoprotein Cysteine Rich Domain 
 It has been shown for other viral class I fusion proteins that the carboxyl terminus 
plays a regulatory role in membrane fusion (Bagai and Lamb, 1996; Sergel and Morrison, 
1995; Seth, Vincent, and Compans, 2003; Tong et al., 2002; Yao and Compans, 1995).  
Specifically for coronaviruses, the MHV S glycoprotein endodomain has been shown to 
contain cysteine rich regions, which are critical for fusion of infected cells (Bos et al., 
1995; Chang, Sheng, and Gombold, 2000; Ye, Montalto-Morrison, and Masters, 2004).  
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To elucidate the role of the cytoplasmic cysteine rich domain in membrane fusion, 
intracellular transport, and cell surface expression, cysteine cluster to alanine mutations 
were made in the four cysteine clusters in the cytoplasmic domain of the S glycoprotein 
(Fig. 3.2) (as described in materials and methods).   
Effects of Mutations on S Synthesis 
 In order to investigate the effect of the different cluster to alanine mutations, 
western immunoblot analysis was used to detect and visualize all of the mutant 
glycoproteins as well as the wild type glycoprotein (Fig. 3.3).  Cellular lysates prepared 
from transfected cells at 48 hours post transfection were electrophoretically separated by 
SDS-PAGE and the S glycoproteins were detected via chemiluminescence using a 
monoclonal antibody specific for the SARS-CoV S glycoprotein.  Carbohydrate addition 
was shown to occur in at least four different locations of the SARS-CoV S glycoprotein 
(Krokhin et al., 2003; Ying et al., 2004).  Furthermore, transiently expressed S 
glycoprotein in Vero E6 cells was proteolytically cleaved into S1 and S2 components 
(Wu et al., 2004).  The anti-S monoclonal antibody SW-111 detected a protein species in 
cellular extracts from transfected cells, which migrated with an apparent molecular mass 
of approximately 180 kDa, as reported previously (Song et al., 2004).  All mutated S 
glycoproteins produced similar S-related protein species to that of wild-type S indicating 
that none of the engineered mutations adversely affected S synthesis and intracellular 
processing (Fig. 3.3).   
Ability of Mutant S Glycoproteins to Be Expressed on the Cell Surface 
 To determine if the mutant S glycoproteins were expressed on the surface of cells 
efficiently, immunohistochemical analysis was used to label cell-surface expressed S 
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Figure 3.2.  Schematic diagram of the SARS-CoV S glycoprotein endodomain and 
the cysteine cluster to alanine mutations.  Amino acid sequences of the carboxyl 
termini and the cysteine cluster to alanine mutations are shown for the wild-type as well 
as the mutant proteins.  The cysteine cluster and the charged rich regions of the S proteins 
are encompassed in brackets and appropriately labeled.  The transmembrane portion of 
the endodomain is italicized and underlined.  Amino acids mutated to alanines for the 
C1217A, C1223A, C1230A, and C1235A cluster mutations are in bold.  
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Figure 3.3 Western blot analysis of the expressed mutant SARS-CoV mutant 
glycoproteins.  Immunoblots of wild-type [So-3xF(WT)] and cysteine to alanine mutant 
S glycoproteins probed with monoclonal anti-SARS S antiserum.  “Cells only” represents 
a negative control for which Vero were mock transfected and probed with the 
monoclonal antibody to the SARS-CoV S glycoprotein.
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under live cell conditions that restrict antibody binding to cell surfaces.  In addition, 
immunohistochemistry was used to detect the total amount of S expressed in cells by 
fixing and permeabilizing the cells prior to reaction with the antibody (see Materials and 
Methods) (Fig 3.4).  An ELISA was used to quantitatively determine the relative amounts 
of cell-surface and total cellular expressed S glycoprotein.  A ratio between the cell-
surface localized S and total cellular S expressed was then calculated and normalized to 
the corresponding ratio obtained with the wild-type S glycoprotein (see Materials and 
Methods) (Fig 3.5).  All cysteine cluster to alanine mutants were expressed on the cell 
surface at levels comparable to that of the wild-type.  Specifically, the CL2-C1217A 
(91%), CL3-C1223A (87%), CL2-C1230A (101%), and CL2-C1235A (110%) were 
expressed on the cellular surface by the percentages indicated when compared to the cell 
surface expression of the wild-type protein. 
Effect of Mutations of S-mediated Cell-to-Cell Fusion 
Transiently expressed wild-type S causes extensive cell-to-cell fusion (syncytial 
formation), especially in the presence of the SARS-CoV ACE2 receptor (Li et al., 2003).  
To determine the ability of each cysteine cluster to alanine mutant S glycoprotein to 
cause cell-to-cell fusion and the formation of syncytia, fused cells were labeled by 
immunohistochemistry using the anti-FLAG antibody, and the extent of cell-to-cell 
fusion caused by each mutant glycoprotein was calculated by obtaining the average size 
of approximately 300 syncytia (Fig 3.6).  The average syncytium size for each mutant 
was then normalized to that found in wild type S transfected cells (see Materials and 
Methods).  The C1217A (54%), C1223A (62%), C1230A (15%), and C1235A (14%) 
mutants inhibited the formation of syncytia by the percentages indicated.  
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Figure 3.4 Immunohistochemical detection of cell-surface and total expression of the 
SARS-CoV S wild-type and mutant proteins.  Vero cells were transfected with the 
wild-type SARS-CoV optimized S (SARS So 3xF) (E1, E2), C1217A (A1, A2), C1223A 
(B1,B2), C1230A (C1,C2), C1235A (D1,D2), and a wild-type SARS-CoV optimized S 
labeled with a 3xFLAG carboxyl tag (F1, F2), which served as a negative control.  At 48 
hours post-transfection, cells were immunohistochemically processed wither under live 
conditions to show surface expression (A1, B1, C1, D1, E1, and F1) and permeablilized 
conditions to show total expression (A2, B2, C2, D2, E2, and F2) with anti-FLAG 
antibody. 
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Figure 3.5.  Ratios of cell-surface to total cellular expression of mutant SARS-CoV S 
glycoproteins.  Detection of cell surface and total glycoprotein distribution was 
determined by immunohistochemistry and ELISA (see materials and methods).  Cell-
surface expression of the S glycoprotein was measured by incubating the transfected cell 
monolayers with anti-FLAG antibody at room temperature before permeabilization.  For 
total S glycoprotein detection, cells were fixed and permeabilized prior to incubation with 
the anti-FLAG antibody.  A ratio between the surface localization and the total 
expression was calculated and normalized to the wild-type protein, then set to a 
percentage of the wild-type.  The error bars represent the maximum and minimum 
surface to total ratios obtained from three independent experiments, and the bar height 
represents the average surface to total ratio as a percentage of the wild-type. 
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Figure 3.6  Quantitation of the extent of S-mediated cell fusion.  The average size of 
syncytia for each mutant was determined by digitally analyzing the area of approximately 
300 syncytia stained by immunohistochemistry for S glycoprotein expression using the 
Image Pro Plus 5.0 software package (see Materials and Methods).  Error bars shown 
represent the standard deviation calculated through comparison of the data from each of 
three experiments.
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DISCUSSION 
 Although the most important domains of the class I fusion are naturally located in 
their ectodomains, it has been reported that intracytoplasmic endodomains play an 
important role in intracellular transport and virus-induced cell-to-cell fusion (Bagai and 
Lamb, 1996; Bos et al., 1995; Chang, Sheng, and Gombold, 2000; Lontok, Corse, and 
Machamer, 2004; Petit et al., 2005; Schwegmann-Wessels et al., 2004; Sergel and 
Morrison, 1995; Tong et al., 2002; Waning et al., 2004; Yao and Compans, 1995). This 
study shows that the two cysteine clusters closest to the transmembrane regions were 
vital for the protein to be able to induce cell-to-cell fusion while the two cysteine clusters 
closest to the carboxyl end of the protein did not drastically affect cell-to-cell fusion. Two 
similar studies performed on the MHV S glycoprotein produced similar results found for 
the SARS-CoV S glycoprotein.   
The C1217A and C1223A are cysteine to alanine cluster mutations that target the 
two cysteine rich clusters most proximal to the transmembrane region of the S 
glycoprotein.  Both of these proteins were expressed on cell surfaces at levels comparable 
to that of the wild-type (91% and 87% of the of the wild-type protein, respectively).  
However, these mutant forms had a significant impact on S glycoprotein induced cell-to-
cell fusion.  Similar mutations of the cysteine clusters in the MHV S glycoprotein 
produced a comparable effect on cell fusion (Chang, Sheng, and Gombold, 2000).  The 
C1217A cluster mutant reduced fusion activity by 55 % while the equivalent cysteine to 
serine mutation in MHV reduced fusion by 56% (Chang, Sheng, and Gombold, 2000).  In 
addition, the C1223A cluster to alanine mutation had a substantial effect on fusion (60% 
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reduction) in a similar manner to the corresponding MHV S mutant which caused a 94% 
inhibition of S-mediated cell fusion. (Chang, Sheng, and Gombold, 2000).   
The S2 fragment of the S glycoprotein is palmitylated on its carboxyl-terminal 
region (Niemann and Klenk, 1981; Sturman, Holmes, and Behnke, 1980; van Berlo et al., 
1987).  In general, cysteines proximal to the inner leaflet of the plasma membrane in viral 
proteins often undergo palmitate attachment through a thioester bond (Ponimaskin and 
Schmidt, 1995; Rose, Adams, and Gallione, 1984; Schlesinger, Veit, and Schmidt, 1993; 
Schmidt, 1989; Sefton and Buss, 1987). Both MHV mutants corresponding to the SARS-
CoV C1217A and C1223 mutants have been shown to be acylation sites for the MHV S 
glycoprotein (Bos et al., 1995).  Covalent palmitic acid attachment to these cysteines may 
have an impact on the conformation of the transmembrane and subsequently fusion.    
Since palmytilation is able to affect an assortment of processes either mediated by or 
involving fusion proteins including membrane fusion, infection of cells, and virus 
assembly (Glick and Rothman, 1987; Jin et al., 1996; Melikyan et al., 2000; Naim et al., 
1992; Schroth-Diez et al., 1998; Zurcher, Luo, and Palese, 1994), it is plausible that 
mutation of these cysteine clusters prevented palmytilation which in turn adversely 
affected S-mediated fusion. 
The C1230A and C1235A cluster mutations are the two cysteine clusters that are 
closest to the carboxyl end of the S glycoprotein.  Both C1230A and C1235A mutant 
forms exhibited levels of S-mediated cell fusion that were similar to that of the wild-type 
(85% and 88% of the wild-type protein, respectively, while they were synthesized and 
expressed on cell-surfaces at levels similar to that of the wild-type S.  These data suggests 
that the two cysteine clusters are not vital for the proper synthesis, transport, or function 
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of the S glycoprotein.  Instead of participating in protein function and trafficking, these 
two cysteine clusters may play a role in virion assembly or virus-protein interactions. 
MATERIALS AND METHODS 
Cells 
 African green monkey kidney (Vero) cells were obtained from the American Type 
Culture Collection (Rockville, Md.). Cells were propagated and maintained in Dulbecco 
modified Eagle medium (Sigma Chemical Co., St. Louis, Mo.) containing sodium 
bicarbonate and 15 mM HEPES supplemented with 10% heat-inactivated fetal bovine 
serum. 
Plasmids  
 The parental plasmid used in the present study, SARS-S-Optimized, has been 
previously described (Li et al., 2003).  The Spike-3XFLAG-N gene construct was 
generated by cloning the codon-optimized S gene, without the DNA sequence coding for 
the signal peptide, into the p3XFLAG-CMV-9 plasmid vector (Sigma). PCR overlap 
extension (Aiyar, Xiang, and Leis, 1996) was used to construct the cluster to alanine 
mutants.  To construct the truncation mutants, primers were designed that incorporated a 
stop codon and a BamHI restriction site at the appropriate gene site.  Restriction 
endonuclease sites BamHI and Pml-I were then used to clone the gene construct into the 
Spike-3XFLAG-N plasmid.   
 The constructed cluster mutants targeting the S cysteine rich region changed the 
following sets of amino acids to alanine residues: C1217A: C(1217), C(1218); C1223A: 
C(1223), C (1224), C(1226); C1230A: C(1230), C(1232); C1235A: C(1235), C(1236). 
(Fig 3.2) 
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Production of SARS-CoV S Monoclonal Antibodies 
The monoclonal antibodies SW-111 was raised against the Spike envelope 
glycoprotein of the SARS virus. A synthetic, codon-optimized gene corresponding to 
SAR-CoV S glycoprotein coding sequences (Li et al., 2003) was engineered to produce 
truncated, secreted proteins containing C-terminal His-tags which encode either the entire 
ectodomain or just the receptor binding domain of S1.  These genes were cloned into 
baculoviral vectors, and the resulting virus was used to infect insect cell lines (High Five) 
(Invitrogen, Carlsbad, CA).  The supernatants were then tested by western blotting using 
anti-6-His antibodies. Protein was partially purified from supernatants by passage 
through a nickel column and then concentrated by ultrafiltration.  Additional protein 
derived in an analogous fashion was provided by the laboratory of Stephen Harrison. 
Standard protocols for mouse immunization were used. The animals were maintained in 
the animal facility of Dana-Farber Cancer Institute, and hybridomas and monoclonal 
antibodies were produced in the Dana Farber/Harvard Cancer Center Monoclonal 
Antibody Core. Spleenocytes from immunogenized mice were fused with NS-1 myeloma 
cells (ATCC) using standard protocols.  Antibody-producing clones were identified by 
Western blot analysis, using purified SARS-CoV S.  The positive cells were then sub-
cloned and re-tested against the purified SARS-CoV S glycoprotein.  Isotype analysis 
revealed that the antibody belonged to the IgG-1 class.     
Western Blot Analysis   
 Vero cell monolayers in six-well plates were transfected with the indicated plasmids 
utilizing the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s 
directions.  At 48 hours (h) post transfection, cells were collected by low-speed 
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centrifugation, washed with Tris-buffered saline (TBS), and lysed at on ice for 15 min in 
mammalian protein extraction reagent supplemented with a cocktail of protease inhibitors 
(Invitrogen/Life Technologies). Insoluble cell debris was pelleted, samples were 
electrophoretically separated by SDS-PAGE, transferred to nitrocellulose membranes, 
and probed with anti-SARS CoV monoclonal antibody at a 1:10 dilution.  Samples were 
boiled for 5 min and treated with beta mercaptoethanol.  Subsequently, blots were 
incubated for 1 h with a peroxidase-conjugated secondary antibody at a 1:50,000 dilution 
and then visualized on X-ray film by chemiluminescence (Pierce Chemicals, Rockford, 
Ill.). All antibody dilutions and buffer washes were performed in TBS supplemented with 
0.135 M CaCl2 and 0.11 M MgCl2 (TBS-Ca/Mg). 
Cell Surface Immunohistochemistry  
 Vero cell monolayers in six-well plates were transfected with the indicated plasmids 
utilizing the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s 
directions. At 48 h post transfection, the cells were washed with TBS-Ca/Mg and either 
fixed with iced cold methanol or left unfixed (live). Immunohistochemistry was 
performed by utilizing the Vector Laboratories Vectastain Elite ABC kit (Vector 
Laboratories, Burlingame, CA) essentially as described in the manufacturer’s directions. 
Briefly, cells were washed with TBS-Ca/Mg and incubated in TBS supplemented with 
5% normal horse serum and 5% bovine serum albumin at room temperature for 1 h. After 
blocking, cells were reacted with anti-FLAG antibody (1:500) in TBS blocking buffer for 
3 h, washed four times with TBS-Ca/Mg, and incubated with biotinylated horse anti-
mouse antibody. Excess antibody was removed by four washes with TBS-Ca/Mg and 
subsequently incubated with Vectastain Elite ABC reagent for 30 min. Finally, cells were 
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washed three times with TBS-Ca/Mg, and reactions were developed with NovaRed 
substrate (Vector Laboratories) according to the manufacturer’s directions. 
Determination of Cell-surface to Total Cell S Glycoprotein Expression   
 Vero cell monolayers in six-well plates were transfected with the indicated plasmids 
and processed for immunohistochemistry as described above with the exception that the 
ABTS Substrate Kit , 2, 2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (Vector 
Laboratories) was used instead of the NovaRed substrate. After the substrate was allowed 
to develop for 30 min, 100 μl of the developed substrate was transferred, in triplicate, to a 
96 well plate. The samples were then analyzed for color change at a wavelength of 405 
nm. The absorbance reading from cell-surface labeling experiments obtained from live 
cells were divided by the total labeled absorbance readings obtained from fixed cells 
which was then normalized to the wild type protein values.  The measurements were then 
converted to percentages reflecting the ratio of S present on cell-surfaces versus the total 
S expressed in the transfected cells.   
Quantitation of the Extent of S-mediated Cell Fusion   
 Vero cell monolayers in six-well plates were transfected in triplicate with the 
indicated plasmids utilizing the Lipofectamine 2000 reagent (Invitrogen) according to the 
manufacturer’s directions. Concurrently, Vero cell monolayers in six-well plates were 
transfected with the plasmid encoding the ACE2 receptor protein utilizing the 
Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s directions.  At 
24 h post transfection, cells containing the mutant plasmids, the ACE2 receptor, and 
normal untransfected cells were washed with TBS-Ca/Mg, trypsinized, and overlayed in 
a single well of a six-well plate at a ratio of 2 ml (cells transfected with the ACE2 
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receptor) : 0.5 ml (cells transfected with the mutant) : 1.5 ml (untransfected cells). All of 
the cells transfected with ACE2 were pooled to ensure that every well had an equal 
amount of cells with receptor expressed on their surface.  After incubation for 24 h, the 
cells were washed with TBS-Ca/Mg and fixed with ice cold methanol. 
Immunohistochemistry was performed by utilizing the Vector Laboratories Vectastain 
Elite ABC kit essentially as described in the manufacturer’s directions. Briefly, cells were 
washed with TBS-Ca/Mg and incubated in TBS blocking buffer supplemented with 
normal horse serum at room temperature for 1 h. After blocking, cells were reacted with 
anti-FLAG antibody (1:500) in TBS blocking buffer for 3 h, washed four times with 
TBS-Ca/Mg, and incubated with biotinylated horse anti-mouse antibody. Excess antibody 
was removed by four washes with TBS-Ca/Mg and subsequently incubated with 
Vectastain Elite ABC reagent for 30 min. Finally, cells were washed three times with 
TBS-Ca/Mg, and reactions were developed with NovaRed substrate (Vector 
Laboratories) according to the manufacturer’s directions. The average size of syncytia for 
each mutant was determined by analyzing the area of approximately 300 syncytia, from 
digital images, using the Image Pro Plus 5.0 software package.  The averages were then 
converted to percentages of the average syncytia size of the wild type SARS-CoV S.  
Error bars shown represent the standard deviations calculated through comparison of the 
data from each of three experiments. 
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CHAPTER IV 
GENETIC COMPARISON OF THE SARS-COV AND BCOV S 
GLYCOPROTEINS 
 
INTRODUCTION 
 In November 2002, an outbreak of atypical pneumonia, termed severe acute 
respiratory syndrome (SARS), appeared in the Guangdong Province of southern China. 
The etiological agent of the disease was found to be a novel coronavirus (SARS-CoV), 
which was first isolated from infected individuals by propagation of the virus on Vero E6 
cells (Drosten et al., 2003; Ksiazek et al., 2003; Peiris et al., 2003). For some age groups 
the mortality rates of the disease reached as high as 15% (Anand et al., 2003). 
In addition to the recent impact that coronaviruses, in the form of the SARS-CoV, 
have had on public health, other coronaviruses produce significant diseases and economic 
impact in various animal species.  These viral infections include transmissible 
gastroenteritis virus (TGEV), infectious bronchitis virus (IBV) ,and murine hepatitis virus 
(MHV). Of particular interest are bovine coronaviruses since their disease spectrum seem 
to be similar to that of the SARS-CoV.  Primarily, bovine coronaviruses were known to 
be enteropathogenic viruses that caused severe diarrhea in neonatal calves.  The enteric 
strains of the virus were known as enteric bovine coronavirus (EBCoV).  Recently, 
however, respiratory bovine coronaviruses were identified as the primary cause of acute 
respiratory disease “shipping fever” as well as deep lung pneumonia in two Texas-based 
epizootics (Storz et al., 2000a; Storz et al., 2000b). These isolated viruses were termed 
respiratory coronaviruses (RBCoV). In a similar scenario to SARS-CoV, bovine 
coronavirus virions were isolated from both diarrhea fluid and intestinal samples as well 
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as from nasal secretions and lung tissues of animals experiencing both respiratory and 
enteric disease (Doughri et al., 1976; Mebus et al., 1973; Storz et al., 2000a; Storz et al., 
2000b).  These RBCoV and EBCoV strains can be differentiated on the basis of 
phenotypic variation, antigenic differences, and genetic divergence (Chouljenko et al., 
1998; Chouljenko et al., 2001; Lin et al., 2000; Storz et al., 2000a).  It is not known 
however, whether respiratory and enteric disease are caused by different viruses or 
alternatively, whether viruses are selected from a parental strain for their ability to 
replicate in specific tissues. A comparison study between respiratory and 
enteropathogenic coronavirus spikes isolated from the same animal with fatal shipping 
pneumonia indicated at least 7 amino acid differences including amino acid changes 
within the S1 portion that may account for a potential alteration in tissue specificity 
(Chouljenko et al., 1998; Gelinas et al., 2001; Hasoksuz et al., 2002; Rekik and Dea, 
1994).  A comparison of the RBCoV and EBCoV S glycoproteins is shown in Figure 4.1.   
The coronaviruses are the largest of the enveloped RNA viruses with a positive-
stranded RNA genome of 28 to 32 kb (Holmes, 2003). Coronaviruses possess a wide host 
range, capable of infecting mammalian and avian species. All identified coronaviruses 
have a common group of indispensable genes that encode nonstructural proteins 
including the RNA replicase gene open reading frame (ORF 1ab) and the structural 
proteins: nucleocapsid (N), membrane protein (M), envelope protein (E), and spike 
glycoprotein (S), which are assembled into virus particles. A hemagglutinin-esterase 
(HE) protein is also encoded by some coronaviruses. The SARS-CoV does not contain  
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Figure 4.1. Schematic diagram of the BCoV S glycoprotein denoting the 
differences between RBCoV and EBCoV (Chouljenko et al., 2001). A schematic 
diagram of the BCoV S protein is shown on top from amino acid 1 to amino acid 1363.  
The transmembrane region of the protein is noted with a grey box labeled “Tm”.  The 
two heptad repeat regions are indicated with grey boxes labeled HR1 and HR2, 
respectively.  A vertical line demarcates the location of the division between the S1 and 
S2 subunits of the protein with the amino acid number between S1 and S2 shown.  
Amino acid differences are denoted with the amino acid number shown and the 
corresponding residues listed below.
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the HE protein while it is found in the BCoV (Lai and Cavanagh, 1997; Rota et al., 
2003). 
The SARS S glycoprotein is composed of 1255-amino-acid with an estimated 
post-translational mass of approximately 180 kDa.  S is a type I membrane glycoprotein 
(Rota et al., 2003) that is the major protein present in the viral membrane forming the 
typical spike structure found on all coronavirions. After posttranslational modifications 
are completed, the SARS-CoV S glycoprotein may be cleaved into S1 and S2 subunits in 
VeroE6-infected cells (Wu et al., 2004). The receptor for SARS-CoV S has been  
recently identified as the angiotensin-converting enzyme 2 (ACE2) (Li et al., 2003) and 
CD209L (L-SIGN) (Jeffers et al., 2004). 
 The bovine coronavirus spike glycoprotein is made up of 1363 amino acids with 
an estimated preglycosylated mass of 151 kDa (Abraham et al., 1990; Boireau, Cruciere, 
and Laporte, 1990; Jeffers et al., 2004; Parker et al., 1990; Zhang, Kousoulas, and Storz, 
1991).  Once fully glycosylated, the BCoV S glycoprotein has an estimated mass of 190 
kDa with 19 potential sites of glycosylation (Abraham et al., 1990; Cavanagh, 1995).  
After posttranslational modification, the S glycoprotein is cleaved into two subunits, the 
N-terminal S1 (110 kDa) and the C-terminal S2 (100 kDa) (Cyr-Coats and Storz, 1988).  
This cleavage into the two subunits occurs between amino acid 768 and 769 of the spike 
glycoprotein and is thought to be mediated by cellular trypsin-like proteases (Storz, Rott, 
and Kaluza, 1981).   
 The S glycoprotein is primarily responsible for entry of all coronaviruses into 
susceptible cells through binding to specific receptors on cells and mediating subsequent 
virus-cell fusion (Cavanagh, 1995). Although the exact mechanism by which the SARS-
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CoV enters the host cell has not been elucidated, it is most likely similar to other 
coronaviruses.  Upon receptor binding at the cell membrane, the S glycoprotein is 
thought to undergo a dramatic conformational change causing exposure of a hydrophobic 
fusion peptide, which is subsequently inserted into cellular membranes. This 
conformational change of the S glycoprotein causes close apposition followed by fusion 
of the viral and cellular membranes resulting in entry of the virion nucleocapsids into 
cells (Eckert and Kim, 2001; Tsai et al., 2003; Zelus et al., 2003). This series of S-
mediated virus entry events is similar to other class I virus fusion proteins (Baker et al., 
1999; Melikyan et al., 2000; Russell, Jardetzky, and Lamb, 2001). 
Although the most important domains of the class I fusion proteins are naturally 
located in their ectodomains, it has been reported that their cytoplasmic endodomains 
play an important role in intracellular transport and virus-induced cell fusion (Bagai and 
Lamb, 1996; Bos et al., 1995; Chang, Sheng, and Gombold, 2000; Lontok, Corse, and 
Machamer, 2004; Schwegmann-Wessels et al., 2004; Sergel and Morrison, 1995; Seth, 
Vincent, and Compans, 2003; Tong et al., 2002; Waning et al., 2004; Yao and Compans, 
1995).  Both the BCoV and SARS-CoV S glycoprotein have similar motifs in their 
intracytoplasmic tails that could possibly play a role in the proper functioning of the 
protein (Fig 4.2).  In this study BCoV and SARS Spikes were compared with regard to 
their ability to cause S-mediated cell fusion paying particular attention to comparing and 
contrasting the functional domains contained within their carboxyl termini.  The salient 
features of this study are: 1) Transient expression of the RBCoV in Vero cells produced 
significantly less cell fusion than the SARS-CoV; 2) Surprisingly, both RBCoV and 
EBCoV spike proteins induced similar amounts of cell fusion; 3) The carboxyl 
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Figure 4.2.  Schematic diagram of the SARS-CoV and BCoV S glycoprotein 
endodomains.  Amino acid sequences of the carboxyl termini are shown for the wild-
type S glycoproteins.  The cysteine cluster and the charged rich regions of the S proteins 
are encompassed in brackets and appropriately labeled.  The shaded residues represent 
the transmembrane portion of the endodomain.  Amino acids that serve as predicted 
phosphorylation sites are denoted by asterisks.
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terminal domains of RBCoV S function substantially differently than their homologous 
domains of the SARS-CoV. 
RESULTS 
Comparison of the Ectodomain of the SARS-CoV and BCoV Spike Glycoproteins 
Analysis of the viral genome has demonstrated that the SARS-CoV is 
phylogenetically divergent from the three known antigenic groups of coronaviruses 
(Drosten et al., 2003; Ksiazek et al., 2003). Analysis of the polymerase gene alone, 
however, has indicated that the SARS-CoV may be an early off-shoot from the group 2 
coronaviruses (Snijder et al., 2003).  Both the BCoV and the SARS-CoV S glycoprotein 
contain multiple analogous motifs as well as unique motifs to their corresponding 
antigenic group.  Comparison of the S1 portions reveals no apparent homologies with 
respect to potential domains that function in receptor binding indicating that there is 
substantial divergence with respect to this function. However, a comparison between the 
amino acid sequences between the SARS-CoV and BCoV S proteins reveal a variety of 
regions that are conserved throughout the majority of the coronavirus families whose 
exact functions have yet to be determined.  One such highly conserved amino acid 
sequence (KWPWYVWL) can be found proximal to the transmembrane region (Fig 4.3).  
The exact function of this eight-residue sequence has yet to be elucidated, but it may play 
a structural role in the stabilization of the protein in the membrane. The S2 ectodomain 
portion of the coronavirus S glycoprotein was found to have a higher degree of homology 
(38% homology) when compared to that of the S1 subunit (16% homology), the 
transmembrane region (22% homology), or the endodomain of the S2 subunit (16% 
homology).  Heptad repeats (HR), a sequence motif characteristic of coiled-coils, are 
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Figure 4.3. Alignment of the membrane spanning domain and endodomain of the 
spike glycoprotein from ten different coronaviruses (Abraham et al., 1990; Binns et 
al., 1985; Delmas et al., 1992; Kunkel and Herrler, 1993; Luytjes et al., 1987; Marra et 
al., 2003; Mounir and Talbot, 1993; Parker, Gallagher, and Buchmeier, 1989; Raabe, 
Schelle-Prinz, and Siddell, 1990; Rasschaert and Laude, 1987).  A schematic diagram of 
the SARS-CoV S protein is shown on top from amino acid 1 to amino acid 1255.  A 
vertical line demarcates the approximate location of the division between the S1 and S2 
subunits of the protein.  The carboxyl terminus (amino acids 1193 to 1255) of the SARS-
CoV S glycoprotein is shown enlarged below and is aligned with the same region of the S 
glycoprotein from nine other coronaviruses.  Viruses from antigenic group I (feline 
infectious peritonitis virus [FIPV], transmissible gastroenteritis virus [TGEV’, human 
coronavirus 229E [HCoV-229E]), antigenic group II (three different mouse hepatitis 
virus strains [A59, JHM, and MHV2], bovine coronavirus [BCoV], and human 
coronavirus OC43 [HCoV-OC43]), and antigenic group III (infectious bronchitis virus 
[IBV]) are represented in the alignment.  The membrane spanning domain and the 
cytoplasmic tail are denoted with arrows above the alignment.  Residues conserved in at 
least eight of the ten coronaviruses represented are indicated by the shaded residues.  
Cysteines that are highly conserved throughout all of the S proteins are noted by 
asterisks.
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found in the S2 portion of the S molecule and are common motifs in many viral and 
cellular fusion proteins (Skehel and Wiley, 1998) (Fig 4.4).These repeat regions allow the 
protein to fold back upon itself.  This event is critical to the function of the protein in that 
it is the first step in initiating the membrane fusion event.  The BCoV and SARS-CoV 
HR regions are highly homologous to one another with the amino most HR region (HR1) 
having 56% homology and the HR region proximal to the transmembrane sequence 
(HR2) having 39% homology between the two viruses.   
Comparison of the Endodomain of the SARS-CoV and BCoV Spike Glycoproteins 
A common motif that is found in the coronavirus spike protein is the presence of a 
charge-rich region in the endodomain.  Analysis of the endodomains indicate that both 
the BCoV and SARS-CoV S glycoprotein contain a homologous charged region (Fig 
4.2).  The charged rich region of the SARS-CoV S protein contains six out of seven 
charged residues and has been shown to be a potent endocytosis signal that may be 
stabilized by the rest of the endodomain (Petit et al., 2005).  The charged rich region of 
the BCoV S protein contains ten out of twenty-four charged residues and is located on the 
carboxyl terminus of the protein’s endodomain.  Although the entire amino acid sequence 
of S contains little homology between different strains of coronaviruses, all S 
glycoproteins contain a cysteine-rich region in their endodomain. Contained within the 
BCoV and SARS-CoV S glycoprotein endodomains are regions of eight out of eighteen 
and nine out of twenty amino acids that are cysteine residues, respectively.  Many of 
these cysteine residues located in the S protein are conserved throughout all of the 
coronavirus families (Fig 4.3).   
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Figure 4.4. Alignment heptad repeat regions of the S1 subunit of the  spike 
glycoprotein from SARS-CoV and BCoV (Abraham et al., 1990; Marra et al., 2003).  A 
schematic diagram of the SARS-CoV S protein is shown on top from amino acid 1 to 
amino acid 1255.  The transmembrane region of the protein is noted with a black box 
labeled “Tm”.  The two heptad repeat regions are indicated with striped boxes and labels 
HR1 and HR2 respectively.  A vertical line demarcates the approximate location of the 
division between the S1 and S2 subunits of the protein.  The two regions containing the 
heptad repeats (amino acids 879 to 980) of the SARS-CoV S glycoprotein is shown 
enlarged below and is aligned with the same region of the S glycoprotein from BCoV.  
Residues conserved between the two viruses represented are overlayed by shaded boxes.
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It has been shown for other viral class I fusion proteins that the carboxyl terminus 
plays a regulatory role in membrane fusion (Bagai and Lamb, 1996; Sergel and Morrison, 
1995; Seth, Vincent, and Compans, 2003; Tong et al., 2002; Yao and Compans, 1995).  
Specifically for coronaviruses, the MHV S glycoprotein endodomain contains charged-
rich and cysteine-rich regions, which are critical for fusion of infected cells (Bos et al., 
1995; Chang, Sheng, and Gombold, 2000; Ye, Montalto-Morrison, and Masters, 2004).  
To elucidate the role of the specific motifs found in both the BCoV and the SARS-CoV 
spike proteins, a series of truncations targeting specific motifs in both proteins were made 
and tested for their cell-to-cell fusion activity (Fig 4.5). 
Effect of Mutations of S-mediated Cell-to-Cell Fusion 
Wild-type SARS-CoV S is able to cause extensive cell-to-cell fusion (syncytial 
formation) in a transient system especially when overlayed with cells expressing the 
SARS-CoV ACE2 receptor (Li et al., 2003).  To determine the ability of each truncation 
mutant to cause cell-to-cell fusion, fused cells were first labeled by 
immunohistochemistry using the anti-FLAG antibody (Fig 4.6).  This 
immunohistochemical analysis serves to visualize both protein expression as well as 
approximate cell-cell fusion activity.  The extent of cell-to-cell fusion caused by each 
mutant glycoprotein was quantified by calculating the average size of approximately 300 
syncytia using digital analysis software.  The average syncytium size for each mutant was 
then normalized to that found in wild type S transfected cells (see Materials and 
Methods) (Fig 4.7).  For the truncations made in the SARS-CoV S glycoprotein, a range 
of different phenotypes were observed (see Chapter 2). For the T1214 (86%) and T1247 
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Figure 4.5.  Schematic diagram of the SARS-CoV and BCoV S glycoprotein 
endodomains.  Amino acid sequences of the carboxyl termini are shown for the wild-
type S glycoproteins as well as truncated proteins.  Each SARS-CoV S truncation is 
coupled with its corresponding BCoV S truncation.  The cysteine cluster and the charged 
rich regions of the S wild-type proteins are encompassed in brackets and appropriately 
labeled.  The shaded residues represent the transmembrane portion of the endodomain.  
Amino acids that serve as predicted phosphorylation sites are denoted by asterisks.
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Figure 4.6. Immunohistochemical detection of total expression of the BCoV S 
wild-type and truncated proteins.  Vero cells were transfected with T1359 (Panel A), 
T1355 (Panel B), T1346 (Panel C), and T1333 (Panel D), and wild-type respiratory 
(BCoV-Lun So 3xF) (Panel E) and enteric (BCoV-End So 3xF) (Panel F) strains of the 
BCoV optimized S) labeled with an amino terminus 3xFLAG tag.  At 48 hours post-
transfection, cells were immunohistochemically processed wither under permeabilized 
conditions to show total expression with anti-FLAG antibody.
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Figure 4.7.  Quantitation of the extent of S-mediated cell fusion.  The average 
size of syncytia for each mutant was determined by digitally analyzing the area of 
approximately 300 syncytia stained by immunohistochemistry for S glycoprotein 
expression using the Image Pro Plus 5.0 software package (see Materials and Methods).  
The fusion levels quantitated for the VERO-E6 cell line are represented by black bars 
while the levels for VERO cells are represented by grey bars.  Error bars shown represent 
the standard deviation calculated through comparison of the data from each of three 
experiments.
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(66%) mutants, the formation of syncytia was inhibited by the percentages indicated. The 
T1229 truncation had less impact on cell-to-cell fusion reducing the average size of 
syncytia by 22%.  In contrast, the T1238 mutant produced on the average 43% larger 
syncytia than that of the wild-type SARS-CoV S. 
For the BCoV Spike, transiently expression of codon optimized S is only able to 
produce moderate amounts of fusion.  Unlike the SARS-CoV, the receptor for BCoV has 
yet to be elucidated.  There is no significant difference in cell-to-cell fusion between S 
proteins of the respiratory and enteric strains of the virus (Fig 4.7).  Two different cell 
lines, VERO and VERO-E6 were used since the BCoV receptor is not available to 
augment fusion in order to gain a consensus of fusion activity.  Levels of fusion were 
reduced greater for VERO-E6 cells when compared to VERO cells.  The T1359 
truncation, which is closest to the carboxyl end of the protein and had the smallest impact 
on cell-to-cell fusion, reduced the size of the syncytium by 10% and 3% for VERO-E6 
and VERO cells respectively.  The T1346 and T1333 truncations had similar effects on 
the level fusion observed with reductions in fusion by 15% and 13% for VERO-E6 cells 
and 9% and 9% for VERO cells respectively.  The truncation that had the most impact on 
cell-cell fusion was that T1355, which reduced syncytium formation by 17% and 9% for 
VERO-E6 and VERO cells respectively.   
DISCUSSION 
Comparison Between the SARS-CoV and BCoV Spike Proteins 
As stated above, there is significantly less homology in the S1 portion between 
different strains of coronaviruses when compared to that of the S2 proteins.  A possible 
explanation for this lack of similarity between the two viruses in this region is that the S1 
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subunit of the S protein contains a domain which is the determinant of viral tropism.  The 
SARS-CoV S protein that ACE2 is able to bind to a 193 amino acid fragment (amino 
acids 318-510 of the SARS-CoV protein) in the S1 portion of the S protein which 
indicates that this region is potentially the receptor binding domain primarily responsible 
for virus binding to the target cell (Babcock et al., 2004; Chakraborti et al., 2005; Wong 
et al., 2004; Xiao et al., 2003).  The receptor binding domain for BCoV is currently 
unknown.  However for the MHV S protein, a protein highly homologous to the BCoV S,  
the receptor binding domain has been localized to the amino terminal 330 amino acids of 
S1  (Kubo, Yamada, and Taguchi, 1994; Suzuki and Taguchi, 1996; Taguchi et al., 
1995).  It is probably because of virus receptor specificity that these regions are not very 
well conserved. 
The SARS-CoV S2 ectodomain was found to have a high degree of homology 
(38% homologous) when compared that of the BCoV S2 ectodomain.  This region is 
probably more highly conserved because of the HR domains found in this portion of the 
S glycoprotein.  Virus infectivity depends on the folding back mechanism, which is 
dependent on the two HR regions, in order to facilitate virus entry.  Also, this portion of 
the protein maybe limited structurally in how many amino acid changes, additions, and 
deletions it can accommodate and still function efficiently to initiate the virus-to-cell 
fusion event.  The differences seen in the amount of fusion generated by these viruses 
may be linked to structural differences found between the two proteins.  Activation 
leading to membrane fusion may occur more efficiently with the SARS-CoV as 
compared with BCoV.  Conversely, the fusion caused by the BCoV S may in fact be 
 181
more regulated and controlled as opposed to the fusion event involving the SARS-CoV S 
protein which may be somewhat deregulated.   
For the endodomains of the two S proteins, there were two important domains that 
were found in both proteins.  These two domains were the charged rich region and the 
cysteine rich domain.  For the charged rich region, there was not a high degree of 
homology in that same specific amino acids were present but rather the homology was 
achieved through the presence of charged residues found in high concentrations in the 
same areas.  The charged-rich region of the murine hepatitis virus (MHV) S endodomain, 
which has high sequence homology to the BCoV S glycoprotein, has been found to play a 
major role in determining the ability of the protein to be assembled into virions (Ye, 
Montalto-Morrison, and Masters, 2004).  There are high concentrations of cysteine 
residues found in both proteins’ endodomains.  These cysteine residues are often 
conserved throughout a majority of the coronavirus S glycoproteins.  For MHV and the 
SARS-CoV, studies have shown the cysteine rich domain if required for coronavirus-
induced membrane fusion (Bos et al., 1995; Chang, Sheng, and Gombold, 2000; Godeke 
et al., 2000; Petit et al., 2005; Ye, Montalto-Morrison, and Masters, 2004) (Fig 4.4).  
Furthermore, substituting the wild-type cytoplasmic portion of the cysteine rich region 
and cytoplasmic tail with the cytoplasmic tail of the VSV-G abolished MHV S 
glycoprotein mediated cell-cell fusion (Bos et al., 1995). 
S-mediated Cell-to-Cell Fusion 
Several studies have shown that the intracytoplasmic endodomain of the class I 
fusion proteins may play an more important role in intracellular transport as well as virus-
induced cell-to-cell fusion (Bagai and Lamb, 1996; Bos et al., 1995; Chang, Sheng, and 
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Gombold, 2000; Lontok, Corse, and Machamer, 2004; Petit et al., 2005; Schwegmann-
Wessels et al., 2004; Sergel and Morrison, 1995; Tong et al., 2002; Waning et al., 2004; 
Yao and Compans, 1995).  To compare predicted functional domains in the BCoV and 
SARS-CoV S glycoproteins, serial truncations were made at sites that were predicted to 
contain domains that may contribute to the function and transport of the entire protein.  
The ability of the BCoV truncated proteins to produce S-mediated cell-to-cell fusion was 
then quantitated and compared to its SARS-CoV S counterpart.   
The T1359 truncation targeted the sequence in the BCoV S protein that had been 
previously found to play a role intracellular S trafficking as well as a site that is predicted 
by the NetPhos 2.0 software to be phosphorylated (Blom, Gammeltoft, and Brunak, 1999; 
Lontok, Corse, and Machamer, 2004).  The truncation, T1359, had a slight effect on 
protein mediated fusion with a reduction from the wild-type fusion activity of 10% on 
VERO-E6 cells.  Another truncation introduced into the BCoV S protein was designed to 
bring the charged region to a more proximal position to the carboxyl end of the protein.  
This truncation, T1355, showed the biggest reduction of fusion out of all the truncation 
tested for BCoV S (83% of the wild-type fusion for VERO-E6 cells).The corresponding 
SARS-CoV S truncation, T1247, had a very significant impact on the proteins ability to 
cause fusion.  It was speculated that the T1247 truncation exposed an acidic cluster that 
in turn greatly enhanced endocytosis.  This enhancement of endocytosis led to a reduction 
of fusion by 66%.  The charged cluster in the BCoV S is less concentrated than that of the 
SARS-CoV which seems to support the idea that it is exactly this concentration of 
charged residues in the SARS-CoV S protein that is responsible for the substantial 
aberration in fusion levels.  The T1346 truncation for BCoV was designed to truncate as 
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much of the charged region as possible without disturbing the cysteine rich region.  The 
SARS-CoV counterpart truncation targeted the charged region of SARS-CoV S 
glycoprotein.  The T1238 truncation of the SARS-CoV actually increase the size of 
syncytia formation by 40% while the T1346 truncation  made on the BCoV S protein 
caused a reduction in fusion by 15% for VERO-E6 cells.  This increase in fusion may be 
attributed to destabilization of the endodomain by the truncation made.  Stabilization of 
the carboxyl terminus has been shown to decrease the fusion activity of the vesicular 
stomatitis virus G glycoprotein (Waning et al., 2004), therefore, conversely, it is possible 
that destabilization of the carboxyl terminus may cause an increase in fusion. 
The final truncation made in the BCoV and SARS-CoV cleaved off most of the 
protein’s endodomain.  For the SARS-CoV, the 1214T truncation was found to not be 
efficiently expressed on the surface of the cell.  This inability of the protein to be 
expressed on the cell surface may account for its severe reduction (15% when compared 
to the wild-type) in S mediated fusion.  The corresponding BCoV truncation, T1333, 
reduced the size of syncytia formation by 13% in VERO-E6.  This discrepancy in fusion 
levels possibly may only be due to the disruption in glycoprotein transport as it is the case 
with the corresponding mutations of the SARS-CoV S protein.   
No differences in fusion levels were observed between the RBCoV and EBCoV S 
proteins.  It should be noted that between the two strains of BCoV there are seven amino 
acid differences when comparing RBCoV and EBCoV (Fig. 4.1).  Four of these amino 
acid changes occur in the S1 portion of the protein, two of which are in the domain that 
could potentially bind to the receptor on the cell surface.  This change in the potential 
receptor binding domain may account for the differences in virus tropism seen between 
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the two viruses (Chouljenko et al., 2001).  The other three amino acid changes occur in 
the S2 portion which is known to function in fusion since it contains the fusion peptide as 
well as the two heptad repeat regions.  These three amino acids, however, are not located 
in regions known to play a role in membrane fusion.  All amino acid changes in S2 occur 
at locations between the two heptad repeat regions.  This could potentially explain why 
there are no detectable differences in level of fusion caused by the two different proteins. 
A possible explanation for the differences in fusion levels may be due to the lack 
of other viral proteins.  In the case of SARS-CoV, the S protein seems to be the main 
determinance of virus fusion activity; for the BCoV however, the hemagglutinnin-
esterase protein may play a role in virus fusion activity as well as virulence.  Expressing 
the S in the context of the entire virus or at least in the context of other structural proteins 
may augment fusion in order to make quantification more accurate.  Another potential 
cause of the differences noted between the BCoV and SARS-CoV S truncations may be 
due to the fundamental differences in each of the wild-type protein’s ability to cause cell-
to-cell fusion.  The SARS-CoV S, when overlayed with cells expressing the ACE2 
receptor, is able to induce very large syncytia formation; however, the BCoV S is not 
very fusogenic.  Since the BCoV receptor remains unknown, receptor mediated 
enhancement of syncytia formation in is not possible.  Different cell lines were used in 
this study in order to establish a consensus about the levels of fusion caused by each 
truncation.  VERO-E6 cells were more prone to fusion than VERO cells which made 
comparison of fusion levels more accurate than their VERO counterparts; therefore 
VERO-E6 fusion levels were used when comparing the BCoV S and its counterpart 
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truncation.    This low level of fusion activity may hamper further studies on the 
functional domains of the BCoV S glycoprotein.   
MATERIALS AND METHODS 
Cells   
 African green monkey kidney (Vero) cells were obtained from the American Type 
Culture Collection (Rockville, Md.). Cells were propagated and maintained in Dulbecco 
modified Eagle medium (Sigma Chemical Co., St. Louis, Mo.) containing sodium 
bicarbonate and 15 mM HEPES supplemented with 10% heat-inactivated fetal bovine 
serum. 
Plasmids  
 The DNAworks program (Hoover and Lubkowski, 2002) was used to design  
synthetic oligonucleotides used in a PCR-based system in order to generate a codon 
optimized BCoV S glycoprotein for the respiratory strain of the virus.  Since the S 
proteins only differ between the respiratory and enteric strain by seven amino acids, PCR 
overlap extension (Aiyar, Xiang, and Leis, 1996) was used to construct the codon 
optimized enteric strain S glycoprotein.  The BCoV-Lun So 3xF and BCoV-Ent So 3xF 
plasmids were generated by cloning their respective codon-optimized BCoV S gene, 
without the DNA sequence coding for the signal peptide, into the p3XFLAG-CMV-9 
plasmid vector (Sigma).  In order to construct the truncation mutants, primers were 
designed that incorporated a stop codon and an Xba I restriction site at the appropriate 
gene site (Fig 4.2).  Restriction endonuclease sites EcoRV and XbaI were then used to 
clone the gene construct into the BCoV-Lun So 3xF plasmid.   
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Total Protein Immunohistochemistry   
 Vero cell monolayers in six-well plates were transfected with the indicated plasmids 
utilizing the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s 
directions. At 48 h post transfection, the cells were washed with TBS-Ca/Mg and either 
fixed with iced cold methanol. Immunohistochemistry was performed by utilizing the 
Vector Laboratories Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA) 
essentially as described in the manufacturer’s directions. Briefly, cells were washed with 
TBS-Ca/Mg and incubated in TBS supplemented with 5% normal horse serum and 5% 
bovine serum albumin at room temperature for 1 h. After blocking, cells were reacted 
with anti-FLAG antibody (1:500) in TBS blocking buffer for 3 h, washed four times with 
TBS-Ca/Mg, and incubated with biotinylated horse anti-mouse antibody. Excess antibody 
was removed by four washes with TBS-Ca/Mg and subsequently incubated with 
Vectastain Elite ABC reagent for 30 min. Finally, cells were washed three times with 
TBS-Ca/Mg, and reactions were developed with NovaRed substrate (Vector 
Laboratories) according to the manufacturer’s directions. 
Quantitation of the Extent of S-mediated Cell Fusion   
 Vero cell monolayers in six-well plates were transfected in triplicate with the 
indicated plasmids utilizing the Lipofectamine 2000 reagent (Invitrogen) according to the 
manufacturer’s directions. Concurrently, Vero cell monolayers in six-well plates were 
transfected with the plasmid encoding the ACE2 receptor protein utilizing the 
Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s directions.  At 
24 h post transfection, cells containing the mutant plasmids, the ACE2 receptor, and 
normal untransfected cells were washed with TBS-Ca/Mg, trypsinized, and overlayed in 
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a single well of a six-well plate at a ratio of 2 ml (cells transfected with the ACE2 
receptor) : 0.5 ml (cells transfected with the mutant) : 1.5 ml (untransfected cells). All of 
the cells transfected with ACE2 were pooled to ensure that every well had an equal 
amount of cells with receptor expressed on their surface.  After incubation for 24 h, the 
cells were washed with TBS-Ca/Mg and fixed with ice cold methanol. 
Immunohistochemistry was performed by utilizing the Vector Laboratories Vectastain 
Elite ABC kit essentially as described in the manufacturer’s directions. Briefly, cells were 
washed with TBS-Ca/Mg and incubated in TBS blocking buffer supplemented with 
normal horse serum at room temperature for 1 h. After blocking, cells were reacted with 
anti-FLAG antibody (1:500) in TBS blocking buffer for 3 h, washed four times with 
TBS-Ca/Mg, and incubated with biotinylated horse anti-mouse antibody. Excess antibody 
was removed by four washes with TBS-Ca/Mg and subsequently incubated with 
Vectastain Elite ABC reagent for 30 min. Finally, cells were washed three times with 
TBS-Ca/Mg, and reactions were developed with NovaRed substrate (Vector 
Laboratories) according to the manufacturer’s directions. The average size of syncytia for 
each mutant was determined by analyzing the area of approximately 300 syncytia, from 
digital images, using the Image Pro Plus 5.0 software package.  The averages were then 
converted to percentages of the average syncytia size of the wild type SARS-CoV S.  
Error bars shown represent the standard deviations calculated through comparison of the 
data from each of three experiments. 
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CHAPTER V 
CONCLUDING REMARKS 
 
SUMMARY 
The SARS-CoV is a recently discovered coronavirus that is able to produce very 
high mortality rates in subsets of the population (Anand et al., 2003).  A key target for 
analysis of how the SARS-CoV was able to achieve such a high mortality rate is the viral 
spike (S) glycoprotein.  Unfortunately, the ability to transiently express the S protein had 
been hindered by the proteins massive size of 1255 amino acids (Marra et al., 2003) 
along with the predicted high degree of secondary structure of the RNA encoding the 
protein. 
Recently, however, the protein has been codon optimized in order to allow the 
expression of the S protein using a transient system (Li et al., 2003).  This process of 
codon optimization, in which not only are all codons replaced with the specific codon 
most commonly used to encode the amino acid but the secondary structure of the RNA is 
significantly reduced, has allowed the efficient in vitro expression of the protein.  The 
work included in this dissertation has focused on the genetic alteration and manipulation 
of the optimized SARS-CoV S protein in order to elucidate the role of several putative 
functional and conserved domains in SARS-CoV S mediated cell-cell fusion as well as 
intracellular transport.  In addition, we generated an optimized clone of the bovine 
coronavirus (BCoV) S glycoprotein in order to compare similar mutations made in both 
proteins.   
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These investigations have shown that there are several regions that are 
indispensable for the proper functioning and transport of this protein.  The amino 
terminal heptad repeat as well as regions adjacent to the heptad repeat are important 
structural domains for the correct functioning of the protein in S-mediated cell-cell 
fusion.  In order to investigate these regions, mutations designed to collapse the alpha 
helical structure of these domains were introduced into the protein.  These mutations 
produced a severe impact on S-mediated cell-cell fusion but allowed for the appropriate 
synthesis and transport found in the wild-type protein.   
The role of the SARS-CoV endodomain was investigated by the construction of a 
series of carboxyl terminal truncations as well as cluster to alanine mutations targeting 
specific conserved motifs in the endodomain of the protein.  The endodomain of the 
protein is able to affect the function of the proteins commonly thought to be associated 
with the ectodomain (Bagai and Lamb, 1996; Bos et al., 1995; Chang, Sheng, and 
Gombold, 2000; Lontok, Corse, and Machamer, 2004; Schwegmann-Wessels et al., 2004; 
Seth, Vincent, and Compans, 2003; Tong et al., 2002; Waning et al., 2004; Yao and 
Compans, 1995).  Endo-domain truncations of the SARS-CoV S protein specifically 
targeted the acidic cluster and the cysteine rich clusters found within the SARS-CoV S 
endodomain.  The SARS-CoV S protein is divergent from other coronavirus S proteins in 
that the acidic cluster is a separate domain from the cysteine rich domain as opposed to 
the overlapping of these domains as seen in other coronaviruses such as mouse hepatitis 
virus (MHV).  Cluster to alanine mutations were introduced targeting the acidic cluster, 
the cysteine rich domains, and a predicted phosphorylation site in the endodomain.  
Mutations affecting regions of the endodomain led to a wide array of phenotypes.  These 
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phenotypes include a decrease in S-mediated cell-cell fusion, an increase in S-mediated 
cell-cell fusion, altered endocytosis patterns, altered protein recycling, and altered 
intracellular protein transport.  This wide variety of results demonstrate how incredibly 
important the endodomain of type I membrane fusion proteins are in the regulation of 
protein function and transport. 
The bovine coronavirus (BCoV) is able to produce a disease state similar to that 
of the SARS-CoV in cattle (Storz et al., 2000a; Storz et al., 2000b).  Given this 
resemblance to SARS, a comparison study between the two S glycoproteins was 
performed to better understand any homologies shared between the two proteins.  This 
was accomplished by constructing a panel of BCoV S truncations and comparing their 
fusion activity to the activity of a panel of SARS-CoV S truncations.  The absence of 
correlation in impact of protein function between the truncations may point to domains 
that are unique to the SARS-CoV S.  However, there were correlations between some 
SARS-CoV S truncations with similar truncations of the MHV S glycoprotein (Chang, 
Sheng, and Gombold, 2000).  Further studies of the BCoV S glycoprotein are needed in 
order to make any supported claims about the functional domains of the BCoV S 
endodomain.   
In conclusion, this dissertation work has capitalized on the recent development of 
the codon optimization of the SARS-CoV and BCoV S glycoproteins in order to 
introduce targeted mutations and truncations to both of these proteins.  Currently, the 
work produced herein has contributed to the understanding of potent motifs in the S 
endodomain in their functioning in S-mediated cell-cell fusion as well as intracellular 
transport.  
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CURRENT AND FUTURE RESEARCH CHALLENGES 
The high mortality rate for patients infected with the SARS-CoV and the probable 
link between this high mortality with the S glycoprotein make the study of the protein 
tremendously important to the field of viral pathogenesis.  The SARS-CoV is the most 
recently identified human coronavirus whose possible impact on worldwide public health 
has led to an intense research effort in the field.  The elucidation of functional domains 
found in the protein may ultimately lead to new drug development as well as new 
potential vaccine development for the disease. 
These investigations clearly show that the mutations introduced into the predicted 
functional domains of the protein had a significant impact on protein transport and 
function.  One aspect of particular interest would be these mutants impact on viral 
assembly.  Virus like particles have been produced for other coronaviruses using transient 
systems (Corse and Machamer, 2003; de Haan et al., 1998; Huang et al., 2004; Vennema 
et al., 1996).  If a virion like particle assembly system could be established, each of the 
mutants and truncations could be assayed for their ability to be incorporated into the 
virion particles using immunoelectron microscopy.  Through the elucidation of the 
SARS-CoV packaging signal, which is already known for several coronaviruses 
(Cologna and Hogue, 2000; Escors et al., 2003; Fosmire, Hwang, and Makino, 1992; 
Izeta et al., 1999; Woo et al., 1997), a potential virus packaging system could also be 
established.  Once incorporated into the virus like particles, the mutants and truncations 
could also be assayed for their ability of mediating virus entry by using a reporter dye 
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enclosed by the particle or potentially by packaging a reporter gene within the virus like 
particle.  Another use of the particle packaging system could be in vaccine development 
and production.   
The construction of an infectious cDNA clone (Almazan et al., 2000; Gonzalez et 
al., 2002; Yount, Curtis, and Baric, 2000; Yount et al., 2003) may provide a tool to 
observe the constructed mutants and truncations constructed in the research presented in 
this dissertation ability to function in the context of the entire virus.  Specific 
measurements concerning viral entry kinetics, viral replication, virus pathology, and viral 
egress could be ascertained for the entire panel of mutants constructed.  However it 
should be noted that the incorporation of mutations in the cDNA clone could potentially 
be problematic because of the enormous size of the infectious clone.  A potential solution 
for this problem would be to create an infectious cDNA clone without the S glycoprotein 
where the S glycoprotein could be provided in trans.  This would allow the S mutants to 
be made on a separate more manageable plasmid.  This S-null infectious clone would 
also be substantially more safe and easier to handle than a fully infectious clone.  An 
alternate possibility would be to construct an infectious clone using a bacterial artificial 
chromosome (BAC) system in which mutations could be introduced into the BAC using a 
Sac B/Rec A mutagenesis system .  The introduction of the mutations in the context of 
the virus could potentially lead to very significant finding which would significantly 
progress the area of coronavirus research.   
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APPENDIX A 
ADDITIONAL WORK 
 
VIRUS LIKE PARTICLE AND PACKAGING SYSTEM 
 The etiological agent for the recently recognized severe acute respiratory 
syndrome (SARS) was discovered to be the SARS coronavirus (SARS-CoV) (Drosten et 
al., 2003; Ksiazek et al., 2003).  An enveloped positive stranded virus, this coronavirus 
displays a host range divergent from other members of the coronavirus family.  This 
divergence from typical coronavirus may play a role in its dramatically increased 
pathogenicity.  Most coronaviruses can replicate in either respiratory and/or 
gastrointestinal tract (Holmes, 2001; Li et al., 2003), however the SARS-CoV has 
evolved the ability to replicate in both places during the viral infection.   
 Another coronavirus of particular interest is the bovine coronavirus (BCoV). 
BCoV has a significant impact on the cattle industry resulting in serious economic losses.  
Infection by the virus cause epidemics of acute diarrhea in calves and adult cattle (Mebus 
et al., 1973; Saif et al., 1988; Taniguti et al., 1986; Tsunemitsu et al., 1991; Weisberg, 
1975) which results in reduced milk production in dairy cows and/or death (Saif et al., 
1988; Takahashi, Inaba, and Sato, 1980; Taniguti et al., 1986).   
 The typical coronavirus encodes for four structural proteins.  The protein 
responsible for binding and attachment is the spike (S) glycoprotein.  It is the largest 
encoded structural protein found in the coronavirus genome.  It functions as a typical type 
I membrane glycoprotein.  The most abundant protein contained in the virion envelope is 
the matrix (M) glycoprotein.  It is a triple spanning membrane protein that has a long 
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carboxyl terminal cytoplasmic domain inside the virion envelope and a short amino 
terminal domain located outside of the virion (Holmes, 2001; Locker et al., 1992; 
Narayanan et al., 2000).  The other protein that comprises the virion membrane is the 
envelope (E) protein.  This protein is expressed at significantly lower levels than the that 
of the M protein (Godet et al., 1992; Liu and Inglis, 1991; Siddell, 1995b; Yu et al., 
1994).  The final structural protein found in the typical coronavirus is the nucleocapsid 
(N) protein.  The N protein is an internal phosphoprotein that interacts with the genomic 
RNA to form the virion core.  BCoV, as with the SARS-CoV, encoded for these four 
structural proteins that are typically found in coronaviruses.  Unlike the SARS-CoV 
however, the BCoV also has a hemmagglutinin-esterase protein encoded into its genome 
that is only found in a certain subset of coronaviruses.   
 It has been shown that the M and E proteins are instrumental in virion assembly.  
In fact, studies have revealed that expression of the M and E proteins are enough to 
produce noninfectious membrane bound particles of similar size and shape to the normal 
wild-type virion (Corse and Machamer, 2003; de Haan et al., 1998; Huang et al., 2004; 
Vennema et al., 1996).  Expressing S, along with M and E, produced VLPs that were not 
only similar in size and shape but were also infectious.  This indicates that the S protein is 
not required for virion assembly but is required for infectivity.  Similar roles of structural 
proteins have also been elucidated for other coronaviruses including the infectious 
bronchitis virus (IBV) (Corse and Machamer, 2000).  For the SARS-CoV, the expression 
of M and E does not lead to particle formation; however the expression of M and N is 
able to produce VLPs (Huang et al., 2004).     
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 In this study, attempts were made to create virus like particles (VLPs) for BCoV 
and to repeat the study in which VLPs for the SARS-CoV were synthesized.  These 
particles could then be used to create potential vaccines for the viruses that the structural 
proteins were derived from. The definitive goal of this series of experiments was to 
produce BCoV or SARS-CoV particles in which a foreign gene could be packaged.  
Particularly for BCoV, particles created in this packaging system could be loaded with a 
gene that encodes for a cytolytic protein or a protein that is able to elicit a targeted 
immune response.  Since BCoV has a predilection for rectal cells, a BCoV virus like 
particle packaged with a gene encoding a cytolytic protein could be used as treatment 
against rectal (colon) cancer. 
 For the BCoV, the M, E and S proteins were cloned into an expression vector 
under the cytomegalovirus promoter.  Once cloned into the vector, the genes were then 
transfected into cells in order to check for the appropriate protein synthesis.  The M and E 
proteins were able to be efficiently expressed; however, the S glycoprotein was not able 
to be expressed by transient expression.  Several different methods were attempted in 
order to correct the problem of the S protein not able to be expressed.  Among the 
methods employed were cloning the S protein into T7 vaccinia driven expression system, 
cloning the vector into a variety of different vectors under different promoters, and 
separately cloning the S1 and S2 subunits of the S protein into two different vectors and 
transfecting the two subunits into the same cell.  None of these methods were able to 
produce transiently expressed S protein without killing the cells.  It is probable that the S 
protein was so large that the RNA encoding the protein produced from the transfected 
plasmid was unable to get out of the nucleus.  Since coronaviruses are purely 
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cytoplasmic, no mechanism evolved that would allow such a large RNA to be transported 
out of the nucleus.  Another problem is that the RNA encoding S protein has an 
extremely high degree of 2° structure which would further inhibit the RNA from exiting 
the nucleus.   
Recently, the SARS-CoV S protein was able to be transiently expressed through 
the technique of codon optimization (ACE2).  Codon optimization takes advantage of the 
degenerate code used to encode amino acids.  Certain codons are more prevalent for 
encoding the same amino acid than other degenerate codons.  Codon optimization is the 
process of reconstructing the nucleotide sequence in such a way that all of the codons 
used in the optimized gene are the most prevalent used codons.  The optimization 
process, usually done with the assistance of computing software, can also produce a 
sequence that not only uses all of the optimal codons but abolishes most of the 2° 
structure associated with the RNA.  In order to be able to express the BCoV S protein, a 
condon optimized version of the gene was synthesized which allowed transient 
expression of the protein.   
Once all of the proteins were able to be efficiently expressed, different 
combinations of the structural proteins were transfected into a variety of cell lines.  The 
essential combinations transfected for the SARS-CoV were M and N and M, N, and S, 
while for BCoV the most important combinations were M and E and M, E, and S.  Once 
the plasmids were cotransfected, the cells were allowed to incubate for 48 hours before 
processing them for visualization using electron microscopy.  VLPs were not able to be 
visualized using this method.   
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A possible reason that no VLPs were able to be visualized could be that the only 
codon optimized proteins used in the experiment was the S glycoprotein.  In the previous 
study in which SARS-CoV proteins cotransfected were able to produce VLPS, all of the 
structural proteins used were codon optimized.  This codon optimization would lead to 
much higher expression of protein from all of the structural proteins which would also 
lead to higher levels of VLP production.  Our combination of plasmids may not have 
been able to produce enough levels of protein in order to be able to visualize VLP 
formation.  Codon optimization of the BCoV M and E and the SARS-CoV N and M may 
be able to increase expression levels so that enough protein is produced to be able to form 
coronavirus like particles.  Another possible explanation could be the difficulty in 
visualizing the particles themselves.  Coronavirus particles are approximately the same 
size and shape as a wide variety of cellular structures.  This in combination with low 
protein expression or inefficient transfection levels may make it very difficult to visualize 
coronavirus like particles using electron microscopy.  Different transfection reagents in 
combination with the use of cells more susceptible to transfection may be able to alleviate 
this particular problem.    
BOVINE CORONAVIRUS INFECTIOUS CLONE 
 The development of full-length cDNA clones has remarkably advanced the ability 
to perform molecular genetic analysis on the structure and function of RNA viruses.  This 
cDNA clone, once transfected into a permissive cell line, becomes the source of 
infectious RNA transcripts (Ahlquist et al., 1984; Boyer and Haenni, 1994).  These 
infectious clones have been constructed for several viruses including caliciviruses, 
arteriviruses, flaviviruses, picronavirures, and alphaviruses whose positive sensed RNA 
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genomes that range in size from approximately 7-15 kb in length (Agapov et al., 1998; 
Davis et al., 1989; Racaniello and Baltimore, 1981; Rice et al., 1989; Rice et al., 1987; 
Sosnovtsev and Green, 1995; Sumiyoshi, Hoke, and Trent, 1992; van Dinten et al., 1997).  
These clones have made new methods and approaches in studying RNA viruses available 
that have not been previously available before.   
 The family Coronaviridae has the largest RNA viral genomes found in nature 
(Lai and Cavanagh, 1997; Siddell, 1995a).  It is this enormous length of the coronavirus 
genome and stabilization issues with plasmids encoding coronavirus replicase sequences 
have made the construction of  a full-length cDNA clone very cumbersome (Ahlquist et 
al., 1984; Eleouet et al., 1995; Enjuanes and Van der Zaijst, 1995; Lai and Cavanagh, 
1997; Siddell, 1995a).  These problems were overcome when a full-length cDNA clone 
of the transmissible gastroenteritis virus (TGEV) was constructed and stably cloned into a 
bacterial artificial chromosome (BAC) vector (Almazan et al., 2000).   
 In order to be able to take advantage of molecular genetic analysis, a full-length 
cDNA clone of the bovine coronavirus (BCoV) was attempted to be constructed using 
recombinant technology.  Specifically, a cDNA clone could have a dramatic impact on 
studies involving the comparison of two strains of BCoV that were found to have 
different tropisms.  This comparison study was between a respiratory strain of BCoV and 
an enteric strain of BCoV that were isolated from the same animal with fatal shipping 
pneumonia.  It has been suggested that the difference in viral tropism is due to slight 
variation in the S1 subunit of the spike (S) glycoprotein (Chouljenko et al., 1998; Gelinas 
et al., 2001; Hasoksuz et al., 2002; Rekik and Dea, 1994).  There are only 4 amino acids 
in the S1 subunit of the S protein that are different between the respiratory and enteric 
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strains of BCoV.  It is known that the main determinance of tissue tropism is attributed to 
the S1 portion of the S protein.  It is possible that a single amino acid change in the S1 
subunit may shift the BCoV tropism from the respiratory tract to the enteric tract.  Once 
constructed, mutagenesis of the infectious clone could isolate with amino acid(s) that 
plays a role in this difference in tropism.   
 A full-length infectious clone was constructed for both the respiratory and enteric 
strains of BCoV.  This infectious clone was then transfected into a variety of cells 
including HRT-18G, VERO, BHK, and COS-7.  These cells were tested for their ability 
to produce infectious virus after being transfected with the cDNA clone using 
immunohistochemistry, indirect immunofluorensence, and observing the cells for the 
cytopathic effect of the virus.  Once transfected, several rounds of passaging the potential 
virus were made in order to increase virus production to detectable levels.  Also in order 
to prevent false positive results, two silent mutations were introduced into the viral 
genomes so that they could be distinguished from the wild-type virus.  All attempts to 
transfect the cDNA clone and produce infectious virus turned up negative by 
immunohistochemistry, indirect immunofluorensence, and signs of cytopathic effect 
created by the virus.  One method employed to try and augment the efficiency of virus 
production was the use of a T7 in vitro transcription system.  First, several sequences in 
the cDNA clone were mutated because they were know to interfere with T7 transcription.  
The mutations placed in these areas were silent mutations so that the same amino acids 
would be used in translation of the cDNA clone.  Once the infectious clone was free of 
possible interfering sequences, the T7 system was used to transcribe that cDNA into 
RNA that could then be directly transfected into the cell lines.  This was thought to make 
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virus production more efficient since the RNA has already been transcribed.  All attempts 
at isolating infectious virus were unsuccessful. 
 One potential problem in producing infectious virus from both the cDNA and 
RNA transfection system could have been the cell lines used.  The most commonly used 
cell line for BCoV propagation is HRT-18G (Storz et al., 1996).  This cell line, while 
being the best at virus production has very poor transfection efficiency.  HRT-18G cells 
are difficult to transfect under optimal conditions much less when dealing with such a 
large construct.  The enormous size of the genetic material in conjunction with the given 
inability of the cells to be efficiently transfected, make infectious virus recovery virtually 
impossible.  Other cells lines that are able to be efficiently transfected are not very 
hospitable for virus production.  Another problem may be the lack of actual transcription 
or translation of the genetic construct.  Such an enormous RNA would have a very high 
degree of 2° structure which may prevent translation or transcription.  Also, the cDNA 
copy of the virus is unlikely to be efficiently transcribed or translated.  During viral 
replication, viral proteins may play a role in enhancing transcription and/or translation.  
Without the aid of these proteins, expression of the viral genome may not be efficient 
enough to produce an amount of virus that could be isolated.    
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